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BSA Bovine Serum Albumin 
C' Complement 
C'F Complement Fixation 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
EDTA Ethylenediamine tetra-acetic acid 
ELISA Enzyme Linked Immunosorbent Assay 
FCS Foetal Calf Serum 
FITC Fluorescein Isothiocyanate 
GMEM Glasgow Modification of Minimal Essential Medium 
GS Goat Serum 
HAT Hypoxanthine, aminopterin, thymidine 
HT Hypoxanthine, thymidine 
Ig Immunoglobulin 
K Kilo ( 1000) 
MCA Monoclonal Antibody 
NEAA Non-Essential Amino Acids 
NHCP Non-Histone Chromosomal Protein 
PAGE Polyacrylamide Gel Electrophoresis 
PBS Phosphate Buffered Saline 
PEG Polyethylene Glycol 
ppo 2,5-diphenyloxazole 
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SDS Sodium dodecyl sulfate 
SLE Systemic Lupus Erythromatosus 
SRBCs Sheep Red Blood Cells 
TN Tris-Saline 
Tris Tris(hydroxymethyl) methylamine 
Triton-X100 Iso-octyl phenoxy polyethoxy ethanol 
Tween 20 Polyoxyethylene (20) sorbiton monolaurate 
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Summary 
Chromosomal proteins are exceptionally difficult to analyse by 
biochemical techniques because of their complexity, heterogeneity and 
insolubility. An immunological approach is therefore of considerable 
value since it may be employed to identify antigens within the cell by 
immunocytochemistry, to test for the distribution of antigens among 
different cell phenotypes by ELISA and complement fixation and to 
characterise protein antigens by immunoblotting. 
Immunological analysis of the sera from two rabbits and a single 
monoclonal antibody has been undertaken in detail. One serum, from 
rabbit 3.1, was obtained from a rabbit which was immunised with HeLa 
chromatin extracted with 2M NaCl and 5M urea. The antibodies showed a 
moderately strong preference for HeLa chromatin. The major antigens in 
this antiserum required DNA for immunological activity in compelment 
fixation and ELISA. The molecular weights of the major antigens on 
immunoblotting in the absence of DNA were in the range 43,000-45,000. 
In the presence of DNA, faint additional bands at molecular weight 
68,000-70,000 could be detected. The discrepancy between the three 
techniques suggests that the major antigens detected on these assays may 
differ. In particular, the immunoblotting technique may not detect 
complex interactions involving more than one protein antigen in 
combination with DNA. Immunocytochemical analysis suggested that the 
antigen localised in the nuclei and in particular, in the peripheral area 
generally associated with envelope, matrix or lamina proteins. 
Preparations of lamina proteins showed considerable reaction with the 
antiserum so that at least some of the major antigens are in this 
fraction. This does not preclude the presence of these or other major 
antigens in the nuclear matrix or envelope. 
- xix - 
In rabbit 2.1, antiserum to chromatin extracted with only 2M 
NaCl was produced. This gave a totally different spectrum of antigens 
with many of the major antigens having cytoplasmic localisation. 
Antigens detected by immunoblotting included proteins present in 2M NaCl 
extracted chromatin and also present in keratin preparations. the 
reaction with HeLa chromatin was preferential but not specific and 
immunoblotting indicated that the major antigens detected by this 
technique were present in a large number of cell lines. 
The difference in response between the two rabbits could be 
correlated with the fact that they were not syngeneic. However, it is 
more likely that the major antigens in rabbit 2.1 are extracted by the 
additional 5M urea used to prepare the immunising antigen in rabbit 3.1. 
Many of the difficulties associated with the analysis of 
0 
polyclonal serum samples raised to a heterogeneous antigen are removed by 
hybridoma technology. A murine monoclonal antibody, HNo-G7, detected a 
single specific antigen which was not apparent in the analysis of the 
serum of either rabbit. The mouse was immunised with 2M NaCl 5M urea 
extracted chromatin of the type used to immunise rabbit 3.1. This 
monoclonal antibody, localises strongly on the nucleoli of HeLa cells, 
has a preference for epithelial cells and HeLa cells in particular, and 
reacts with chromatin which has been treated with RNase A and DNase I. 
It also does not react with HeLa DNA alone. Sensitive immunoblotting 
showed a molecular weight of 45,000. 
The data emphasise the difference between conventional 
serological analysis and monoclonal antibody technology. Among the most 
important of these is the fact that HNo-G7 is a 
fully stabilised 
monoclonal antibody which can be synthesised in culture 
indefinitely and 
produced from frozen hybridoma cells. It can, 
therefore, be produced in 
whatever quantities are required and 
be utilised in the future to further 
investigate the role of its antigen in processes 





1.1 Chromatin and Chromosome Structure 
1.1.1 Nucleosome Structure 
It is now widely accepted that the nucleosome is the elementary 
repeat subunit of chromatin structure in eukaryotes. The nucleosome 
consists of an internal core of histones surrounded by DNA (for review 
see Felsenfeld, 1978; McGhee & Felsenfeld, 1980; Laskey, 1981; 
Igo-Kemenes et al, 1982). The globular core particle is sealed off by 
another species of histone, Hl, which is usually attached to the 
complex at the entry and exit of DNA (Thoma et al, 1979). 
1.1.1.1 Nucleosome Core Particle 
The first level of chromatin structure organisation is the core 
particle. It has flat cylindrical shape with a diameter of 1l. Onm and a 
height of 5.5 nm (Finch et al, 1977). The core consists of an octamer 
of the basic histone proteins, two molecules of each H2A, H2B, H3 
and H4. This octameric particle is surrounded by 146 base pair (bp) 
of DNA (Lutter, 1979) forming 1.75 turns. This is further extended by 
another 10 bp at each end to form a supercoil of a full two-turns 
comprising 166.0 bp surrounding the particle (Thoma et al, 1979). The 
166 bp particle has been termed "Chromatosome" (Simpson, 1978). The 
nucleosome structure and its involvement in gene transcription and 
initiation has been the subject of intense research interest over the 
last few years (Lohr, 1981,1983; Weisbrod, 1982; Paul, 1982; Oda, 
1983). 
1.1.1.2 Histone H1-Containing Nucleosome 
The next level in the organisation of chromatin structure is the 
"Mononucleosome". The mononucleosome consists of the core particle, the 
linker DNA and one molecule of the lysine-rich histone protein (H1). 
The involvement of H1 in the organisation of the nucleosome has been 
the focus of many research groups (reviewed by McGhee & Felsenfeld, 1980). 
-2- 
From nuclease digestion experiments, it has become clear that 
the globular core particle is well protected. H1 histone is located 
at the entry and exit of the 166.0 bp superhelical DNA (Simpson, 1978; 
Moyne et al, 1981; Thoma et al, 1979). It has been shown that H1 
histone species consists of three distinct domains. The central one is 
a globular protein subunit (Isenberg, 1979) which is in close contact 
with the histone octamer and is able to close two full turns of DNA 
around the core (Allan et al, 1980). 
1.1.1.3 The Linker DNA and Periodicity 
The chromatosomes are linked with each other by "Linker" or 
"Spacer" DNA. The linker length varies from zero bp in lower eukaryotes 
(Noll, 1976; Morris, 1976; Thomas & Furber, 1976) to around 80 bp in 
sea urchin sperm (Spadafora et al, 1976,1978). A considerable amount 
of attention has been paid to the organisation of internucleosomal DNA 
(Lawrence & Goeltz, 1981; Strauss & Prunell, 1982,1983; Karpov et al, 
1982). Data from nuclease digestion experiments have suggested that 
there may be classes of different spacer lengths in different organisms 
and tissues from the same organism (Kornberg, 1977; Chambon, 1978). 
This has been substantiated using different kinds of nucleases as well as 
a combination of nucleases. Using micrococcal nuclease, Karpov et al 
(1982) have reported the presence of 20,30 and 40 bp spacers in 
Drosophila. They have also concluded that lOn bp (n=2,3 and 4) long 
intercore DNA is organised by H3 histone in particular and together 
with the core DNA forms a continuous superhelix. In rat liver 
chromatin, the highly variable lengths of linker DNA within the same 
cell, have been studied extensively by Prunell and Kornberg. They have 
developed a direct method, using a combination of nucleases, by which 
nucleosome dimers are trimmed to 166 bp of the core position retaining 
H1 histone. In rat liver chromatin, the mean value of the 
centre-to-centre distance between nucleosomes has been found to be 
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190 bp by using exonuclease III (Prunell & Kornberg, 1982; Strauss & 
Prunell, 1982). A considerable difference of the helical periodicity of 
DNA on the nucleosome is found in the literature, due to variable 
interpretations of the nuclease digestion data. By electrophoresis of 
nuclease digests in denaturing gels, DNA fragments give rise to a 
characteristic ladder pattern with fragments spaced about 10.0 
nucleotides apart (Noll, 1974). However, Lutter (1979) and Bryan et al 
(1979) have noted a 10.4 nucleotide spacing in DNase-I digestion. 
Simpson and Stafford (1983) have shown recently, by using cloned segments 
of DNA in vitro, that a cutting site spacing of near 10.0 nucleotides 
occurs for a large part of a reconstituted nucleosome. This reflects a 
DNA helical repeat of 10.0 bp in the core particle. Klug and Lutter 
(1981) have concluded that the variation of angle of attack of nucleases 
deduced on the basis of a 10.5 fold screw in the DNA double helix leads 
to steric inaccessibilities, whereas all data are compatible with 
periodicity of 10.0 bp per turn of the helix. An earlier conclusion by 
Finch et al (1977) in what they described as the "Linking-number paradox" 
has suggested that in solution, the helical twist of free DNA corresponds 
to a full turn per 10.5 bp. When coiled around the histone core, the 
helical twist of the DNA corresponds to a full turn per 10.0 bp. 
1.1.2 Supranucleosomal Structure 
It is now well accepted that the first level of DNA condensation 
is provided by nucleosome structure which in low salt concentration gives 
rise to a (nucleosomal) beaded chain (Oudet et al, 1975; McGhee et al, 
1980; Thoma & Koller, 1977; Thoma et al, 1979). At the second level 
of chromatin organisation, the beaded chain (nucleofilament) condenses in 
solution, containing magnesium or a high concentration of monovalent 
cations, to form a thick supercoil or "Solenoidal Structure" of a pitch 
around llnm (Finch & Klug, 1976). The thick 
fibre diameter in high salt 
concentration has been reported to 
be around 25-30nm in nuclease 
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digestion experiments (Finch & Klug, 1976), by electron microscopy (Thoma 
et al, 1979) and by electric dichroism (McGhee et al, 1980). 
Moreover, a radial arrangement for the faces of chromatosomes 
around the fibre axis of 30nm solenoid has been suggested (Finch & Klug, 
1976; McGhee et al, 1980). In this model, six chromatosomes, each of 
llnm in diameter and 5.5nm thick, are arranged per turn of left handed 
solenoid. Evidence for the 6-7 nucleosomes per turn in the solenoid 
fibre has been substantiated by different techniques such as electron 
microscopy, neutron diffraction and x-ray scattering (for review see 
Igo-Kemenes et al, 1982). 
An alternative model to the solenoid is the "Superbead". Renz 
et al (1977), using electron microscopy, have reported the presence, at 
high ionic strength, of a fibre of 20 nm in diameter, composed of 
discrete globular structures that are held by H1 histone. This 
superbead structure has been supported by further work on hen erythrocyte 
chromatin. Chromatin fibre fragments with a length of 500 nm and an 
average diameter of 32 nm have been observed by electron microscopy. 
Each fibre has been found to consist of 13 globular subunits comprising 
a "Superbead". The globular subunits contain a different number of 
nucleosomes at an average of 17 (Meyer & Renz, 1979). Chromatin 
fibres of 33 nm long and 30 nm in diameter have been also reported in a 
variety of different systems (Subirana et al, 1981). Biochemical 
studies supporting the superbead model suffer from the lack of repeated 
periodicity of DNA pattern by nuclease digestion (Igo-Kemenes et al, 
1982). 
1.1.3 Chromosome Structure 
1.1.3.1 Metaphase Chromosome 
There is accumulating evidence that the 25 nm chromatin fibre 
appears to be folded further both 
in interphase nuclei (Benyajati & 
Worcel, 1976; Igo-Kemenes & Zachau, 1978; Adolph, 1980a; Lebkowski & 
Laemmli, 1982), and in metaphase chromosomes 
(Adolph et al, 1977a; Lewis 
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& Laemmli, 1982; Earnshaw & Laemmli, 1983). The fibres in interphase 
and metaphase chromosomes have been found to be arranged in the form of 
loops or domains of 50 -100 Kb of DNA which are constrained by protein 
framework (Paulson & Laemmli, 1977; Igo-Kemenes & Zachau, 1978). 
Stubblefield and Wray (1971) have proposed that mitotic chromosomes 
consist of distinct axial and peripheral chromatin components. 
Recently, Paulson and Laemmli (1977) have shown that, in dehistonised 
chromosome preparations, loops of DNA are seen surrounding a residual 
axial structure. 
A general radial loop model has been suggested in which 
chromatin loops emanate from a central axis formed by a network of 
nonhistone proteins designated as the "scaffolding" that links the bases 
of the loops (Laemmli et al, 1978). Support for such a model comes from 
thin-section electron microscopy of swollen metaphase chromosomes 
(Adolph, 1980b; Hozier et al, 1981) and swollen cells (Adolph, 1981). 
The scaffold structure is composed primarily of two high 
molecular weight proteins (Scl and Sc2) whose interactions are believed 
to be stabilised by metallo-protein interactions (Lewis & Laemmli, 
1982). Further support for the involvement of scaffold proteins, comes 
from nuclease digestion studies of chromosomes after low salt protein 
extraction which reveal a nonhistone protein residual scaffold, visible 
by electron microscopy (Earnshaw & Laemmli, 1983). These residual 
proteins have been found to be fibrous in nature, retaining the 
differentiated regions of the chromosomes derived from the "kinetochores" 
and chromatid axis (Earnshaw & Laemmli, 1983). It has also been noted 
that in the presence of magnesium or at high NaCl concentrations, the 
fibrous network undergoes a lateral aggregation which is reversible. 
-6- 
1.1.3.2 Nucleoids 
Structures resembling the nucleus and retaining its 
morphological features but depleted of protein have been known for many 
years (Cook & Brazell, 1975,1980). These structures which have been 
called "Nucleoids" are released by gently lysing cells in solutions 
containing non-ionic detergent and high concentration of monovalent 
cations. The nucleoids consisted predominantly of superhelical, intact 
DNA, looped during lysis (Cook & Brazell, 1976; Lavin & Davidson, 
1981). The linear nuclear and unbroken DNA has been found to be 
packaged within a cage of RNA and protein in these nucleoids. However, 
they lack any organised membrane structure (McCready et al, 1980). 
A model based on the premise that replication takes place at the 
nuclear cage has also been suggested (McCready et al, 1980) and supported 
by the sequencing of loops of the nuclear DNA coding for the alpha- and 
beta-globin genes (Cook & Brazell, 1980). Recently, it has been 
proposed that regions of the chromosomes involved in replication may be 
preferentially bound to the nuclear matrix (Valenzuela et al, 1983). 
This idea has been supported by electron microscopy of DNA fragments 
showing an enrichment of replicating forks. 
1.1.4 Nuclear Pores 
Electron microscopy of non-membranous ghosts from HeLa cell 
nuclei, has shown the presence of an array of "Rod-like" (250nm long and 
60nm diameter) and "Annular" structures interconnected by thin strands 
(Keller & Riley, 1976). These strands are composed of double stranded 
DNA. The array is believed to be responsible for the spherical shape of 
the interphase nuclei. Candidates for the structural components that 
determine the nuclear shape have been isolated (Keller & Riley, 1976) and 
variously called the "Pore Complex-Lamina" 
(Aarson & Blobel, 1975) or 
"Nuclear Protein Matrix" (Berezney & Coffey, 1974). The major 
components of the ghost 
include annuli with inner and outer diameters 
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43nm and 90nm respectively which are consistent in dimensions with 
nuclear pore structures (Riley & Keller, 1978). It has also been 
proposed that the non-membranous layer could correspond to a structural 
nuclear framework or "Skeleton" which confines and possibly organises 
interphase nuclear chromatin and confers a degree of mechanical rigidity 
on isolated nuclei. These nucleoskeletons have been isolated from cells 
in all stages of the cell cycle except mitosis (Riley & Keller, 1978). 
Recently, it has been found that digestion of the thin connecting strands 
by DNases results in the destruction of the gross morphology of the 
nucleoskeleton and the release of thick rod- and pore-like structures 
(Detke & Keller, 1982). This has led to the conclusion that DNA is 
required to maintain the structural integrity of the nucleoskeleton. In 
addition, it has been shown that the major nucleoskeletal proteins are 
also present as major components of the chromosome scaffold. At least 
two of the nucleoskeletal proteins appear to be modified during the 
transition into mitosis suggesting that nuclear dissolution associated 
with open mitosis is accompanied by gross rearrangement of the 
nucleoskeletal elements to form components of metaphase chromosomes 
(Detke & Keller, 1982). 
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1.2 Control of Gene Expression 
The control of gene expression has been a major focus of 
research over the past decade. The experimental results have provided 
the solution to a number of structural questions, but little has been 
achieved with respect to the actual mechanism. Many candidates have 
been suggested to play a part in this process including RNA, nonhistone 
chromosomal proteins and ribonucleoproteins. Research on the control of 
gene expression at the level of RNA processing and DNA modification has 
been particularly intensive and has shown considerable progress. 
1.2.1 Control of Initiation of RNA Synthesis 
Eukaryotic mRNAs are synthesised in the nucleus of a cell as a 
part of a long transcriptional precursor unit referred to as 
heterogeneous nuclear RNA (hnRNA). 
The development of new techniques in DNA and RNA sequencing has 
led to the identification of sequences in and near many structural genes 
which have common features (reviewed by Paul, 1982). The isolation of 
RNA polymerases has helped in understanding part of the mechanism of 
transcription. In addition, other mechanisms involved in processing and 
maturation of the genetic message in nuclei, and its transportation to 
the cytoplasm has become clearer. It is now widely accepted that many 
eukaryotic gene sequences on the DNA are discontinuous. The primary RNA 
transcripts (hnRNAs) which are derived from these DNA segments contain 
coding sequences (exons) and non-coding sequences (introns or intervening 
sequences) (Abelson, 1979). 
The formation of mature eukaryotic mRNA in nuclei involves a 
complex series of reactions, including capping, methylation, 
polyadenylation and splicing, before being exported to the cytoplasm. A 
possible control mechanism of expression has been suggested at each level 
(Shatkin, 1976; Banerjee, 1980; Breathnach & Chambon, 1981; Busch et 
al, 1982; Knowler, 1982). 
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A simple schematic diagram which represents some important 
events in mRNA maturation is shown in figure 1. 
1.2.1.1 Modulator and Enhancer 
The fact that some sequences located upstream of the appropriate 
genes are associated with a certain level of control of gene expression 
has attracted much interest. Sequences comparable to the promoter in 
prokaryotes have been reported in the sea urchin H2A histone gene 
(Grosschedl & Birnstiel, 1980a) and in cloned mutants of SV40 (Benoist & 
Chambon, 1980,1981). 
Recent interest has been focu sed on other sequences situated 
upstream of the initiation site of transcription. Grosschedl & 
Birnstiel (1980b) working on sea urchin H2A histone gene, have shown 
the presence of three functional DNA segments located upstream of the 
gene, given the names, "Modulator Selector & Initiator" elements. The 
modulator has been shown to control the rate at which the specificity 
elements operate. Dierks et al (1981) have reported a 10 bp sequence 
located before the cap site and also found preceding rabbit beta-globin 
genes and many other genes at a similar location. This sequence may be 
involved in modulating the efficiency of transcription. 
Sequences called "Enhancers" with analogous characteristics to 
the modulator described earlier, have also been reported in the 
eukaryotic viral gene of SV40. Banerji et al (1981) have found a 72 
base sequence which greatly enhances transcription of genes located 
upstream of the initiation site of the gene. 
1.2.1.2 Initiators and Selectors 
Transcriptional initiation is one level of the control of 
eukaryotic gene expression. The specificity for the location and the 
frequency of transcription initiation resides in the upstream 
5'-sequences for genes transcribed by RNA polymerase II (Breathnach & 
Chambon, 1981) and probably by RNA polymerase I (Grummt, 1981). 
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Figure 1 Diagramatic representation of the processing of the transcript 
of a gene containing a single intron 
Intron 
DNA 
---I 1--- -1 
Exon I Exon II 
Transcription 
hnRNA 5' ---- --- --131 
Terminal processing 
(m) 




ap poly (A) 
Ligation of coding sequences 
" (m) Cap poly (A) 
Transport across nuclear membrane 
Cytoplasmic mRNA 
(Adapted from Knowler, 1982) 
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Sequences situated upstream from the initiation site of specific genes 
have been reported to be responsible for transcription initiation. A 
possible consensus sequence for such initiation is called the "Chambon 
box" (Benoist et al, 1980; Struhl, 1981). This sequence resides 
approximately 80 bp upstream. 
Another consensus sequence commonly centred about 25-30 bp 
upstream from the cap site has also been reported in most of the genes 
sequenced so far. This (AT) rich sequence which is known as "TATA" box 
was first noted by Goldberg and Hogness (see e. g. Breathnach & Chambon, 
1981). It is believed that this sequence is necessary for accurate 
initiation, since in its absence multiple initiation points have been 
reported (Benoist & Chambon, 1981; Grosveld et al, 1982). It is also 
reported that upon deleting this sequence, a lower rate of initiation has 
been noted in other genes (Paul, 1982). Other workers, using mutants 
lacking the sequence upstream from position-29, have shown that specific 
transcription is not promoted in the absence of such consensus sequence 
(Corden et al, 1980). Recently, Davison et al (1983) have found that 
the TATA box region is involved in the stable binding of transcription 
factor(s). 
In any case, since the TATA box is absent from some genes 
(Breathnach & Chambon, 1981), Grosschedl and Birnstiel (1980a, 1980b) 
have proposed that the TATA box acts as a "selector". 
1.2.2 Control at the Level of RNA post-transcriptional Modifications 
1.2.2.1 Polyadenylation 
Two important modifications commonly occur to hnRNA before it is 
processed further to yield mRNA. These modifications are 
polyadenylation at the 3'-end and capping at the 5'-end. 
Evidence for the occurrence of poly(A) sequences in cytoplasmic 
mRNA was first reported by Edmonds and 
Caramela (1969). It has been 
shown that poly(A) is absent in nucleolar 
RNA (rRNA) but is present in 
the RNAs of both cytoplasm and nucleoplasm 
(Edmonds et al, 1971). 
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An important hexanucleotide sequence (AAUAAA) has been found to 
signal the post-transcriptional addition of polyadenylic acid. This 
hexaucleotide is located at about 25-30 nucleotides from the 3'-end of 
mRNA (Proudfoot & Brownlee, 1976), and it has been observed in all 
eukaryotic mRNAs studied so far. This sequence has also been found in 
the late gene of eukaryotic virus SV40 (Fitzgerald & Shenk, 1981). 
However, other components or structural features may also be involved. 
It is worth noting that in a number of genes, the hexanucleotide sequence 
is found in internal positions and does not induce polyadenylation. 
Moreover, several cases are known where transcription units contain more 
than one polyadenylation site (for review see Knowler, 1982). 
The nature of the mRNA product from a transcript could be 
post-transcriptionally controlled by differential selection of 
polyadenylation sites (Nevins & Darnell, 1978). However, some evidence 
supports a role for the 3'-end poly(A) tail in extending the stability of 
mRNA and in the selection of the 3'-end mRNA chains during their 
biogenesis (Browerman, 1981). It has also been suggested that the 
polyadenylate may modulate mRNA transport across the nuclear membrane. 
However, histone mRNA which lacks a poly (A) tail, has been found to 
leave the nucleus much faster than the polyadenylated sequence (Andesnik 
& Darnell, 1972; Greenberg & Perry, 1972). Another possible role for 
the poly(A) sequence is its involvement in the splicing mechanism (Bina 
et al, 1981). This has been contradicted by Zeevi et al (1981) who have 
shown that splicing can occur in the absence of polyadenylation. 
1.2.2.2 Capping 
5'-Terminal capping is one of the important post-transcriptional 
processes to which an hnRNA is subjected before maturation to yield 
mRNA. The unique 5'-cap was first shown by Reddy et al 
(1974). The 
5'-end of the gene transcript is capped by the addition of a 
7-methyl 
guanosine (Cap-O) through a pyrophosphate 
bond (Zimmern, 1975; Dubin & 
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Stollar, 1975). The cap may then be modified further by the 
2'-0-methylation of the ribose moieties of the first or the first two 
nucleotides of the transcripts (Cap-1 and Cap-2 respectively) (Moyer & 
Banerjee, 1976; Rose, 1975; Sommer et al, 1976). The cap protects the 
mRNA against attack by phosphatases and other nucleases at its 
terminus. In addition, it promotes the mRNA's functional role at the 
level of initiation of translation (Rottman et al, 1974). 
The 5'-termini of both mature mRNA and its precursors are 
identical and map at the same point on the gene sequence (Weaver & 
Weismann, 1979). This suggests that transcription is likely to be 
initiated at or very close to the 5'-end of the mRNA and little, if any, 
5'-trimming occurs. 
A number of eukaryotic genes have a tetranucleotide (CTCA) 
sequence immediately preceding the encoding sequence of mRNA which may 
represent a capping signal (Vankatesan et al, 1980). 
Yamaguchi et al (1982) have observed another sequence which is 
complementary to the 3'-terminal of 18S rRNA, but situated in the 
5'-noncoding region of eukaryotic mRNA. This sequence together with the 
5'-cap structure enhance the rate of initiation of the complex formation 
in protein synthesis. 
1.2.3 Control by Differential Gene Splicing 
One of the major alterations which occur to the primary RNA 
transcript (hnRNA) is cutting various sequences (introns) and joining the 
remaining sequences (exons) in a process called "Splicing". This 
process produces a mature mRNA ready to cross the nuclear membrane to the 
cytoplasm. Splicing has attracted a considerable amount of attention 
in 
recent times as potential control mechanism (reviewed recently 
by Mount, 
1982). The sites of splicing points at the exon-intron 
junctions has 
been the focus of interest. Mount (1982) has collected a catalogue 
containing the sequences of splicing sites 
from a large number of nuclear 
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as well as viral gene encoding proteins. These are called the consensus 
sequences. The catalogue has also confirmed the presence of GT/AG rule 
originally described by Breathnach et al (1978). The GT is present at 
the beginning of the intron and AG is at the end. This rule has been 
obeyed in the majority of the collected intron/exon sequences except for 
few cases like the 
-X immunoglobulin gene of MOPC-315 plasmacytoma 
(Bothwell et al, 1981) and in alpha-crystallin eye lens gene (King & 
Piatigorsky, 1983). However, splicing is not a simple mechanism and 
many nuclear proteins and poly-ribonucleotide (such as the small nuclear 
RNAs-snRNA) components are thought to be involved (Rogers & Wall, 1980; 
Lerner & Steitz, 1979; Lerner et al, 1980). 
It is now well known that eukaryotic genes are subjected to 
various degrees of regulation at the transcriptional and 
post-transcriptional levels. Two categories of transcriptional units 
can be identified. A "simple" transcription unit which encodes single 
protein genes such as the histone genes (Hentschel & Birnstiel, 1981) and 
alpha- and beta-globin transcription units (Nishioka & Leder, 1979). On 
the other hand, the "complex" transcription units are those whose primary 
transcript can produce more than one mRNA encoding more than one 
protein. These transcripts contain two or more poly(A) sites, and two 
or more variations of post-transcriptional gene expression (Darnell, 
1982). Two important systems of this type are the viral and 
immunoglobulin systems. 
1.2.3.1 The Viral System 
Viral systems have been widely employed in the study of some of 
the mechanisms involved in gene structure and gene expression. 
Studies 
on the control of gene expression by differential transcript processing 
or splicing in viruses, have produced much 
information relating to the 
complex mechanism of mRNA maturation. 
analysed in SV40 (Fiers et al, 1978; 
This process has been extensively 
Shermann & Weisman, 1980), Polyoma 
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(Soeda et al, 1980), adenovirus and other viruses (Darnell, 1982; Logan 
& Shenk, 1982) and more recently in influenza virus (Lamb & Lai, 1982). 
In practical terms, RNA splicing is believed to be a control 
mechanism and/or a regulatory event. The adenovirus system provides a 
good model for this-theory. The study of the formation of adenovirus 
mRNA has provided many of the details of eukaryotic mRNA biogenesis. 
Multiple steps are required to produce a functional mRNA including steps 
where alternative pathways are possible. In adenovirus, at early stages 
after infection, at least six transcription units are expressed. All of 
these units encode families of messenger ribonucleic acids whose members 
are differentially processed by splicing and as a result encode different 
polypeptides. At late (L) time after infection, new families of mRNAs 
are made and most of these are produced from a single transcription unit. 
At early (E) time after infection, E1A gene region encodes two 
mRNAs which are produced by differential splicing. The E1A specific 
gene product facilitates expression of other mRNAs, E1B, E2, E3, E4 and 
L1 (Jones & Shenk, 1979). It is also likely that a variety of 
non-adenovirus genes are regulated by similar mechanisms. In addition, 
E1A not only acts at the level of initiation of transcription but may 
modulate certain cellular genes (Logan & Shenk, 1982). 
Recently, analysis of the product of adenovirus L1 mRNA during 
early and late infection has provided evidence for the control of gene 
expression through an alternative splicing pathway (Chow et al, 1979). 
Evidence for the expression of a particular region of a genome which can 
be controlled through alternative splicing of the primary RNA transcripts 
has been found not only in viruses but also in cellular genes (Amara et 
al, 1982; King & Piatigorsky, 1983). 
More recently, Mariman et al (1983), using mapping 
data from Sl 
nuclease digestion have shown that there are alternative splicing 
pathways for the excision of the 
first and second introns from RNAs that 
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are derived from the major late transcription unit in adenovirus. It is 
interesting to note that the first cleavages are introduced in the 
nascent RNA before the RNA polymerase has progressed more than 2000 
nucleotides beyond the cleavage sites. It is also shown that intron (1) 
is preferentially removed before intron (2), however. alternative pathways 
have also been found. Similarly, Sherman and Weissman (1980) have 
indicated that in SV40 virus, splicing is not strictly sequential. 
Moreover, the expression of a transcription unit such as 
adenovirus unit, could also be controlled through differential poly(A) 
site selection at the post-transcriptional stem (Darnell, 1982). the 
same is true of the immunoglobulin heavy chain gene (see section 
1.2.3.2). However, nuclear RNA splicing in adenovirus-2 mRNA formation 
has also been noted in the absence of poly(A) sites (Zeevi et al, 1981). 
1.2.3.2 The Immunoglobulin System 
{t. J6 
Antibodies are composed of two identical heavy- and, 
4 
light-chain 
polypeptides. Each heavy (H) and light (L) chain contains an amino 
terminal, variable (V) region and a carboxyl end, constant (C) region. 
The variable regions are encoded by several hundred germ-line genes, 
while a very limited number of genes encode the (C) region. The various 
classes of immunoglobulins with different functions (IgM, IgD, IgG, IgE 
and IgA) are distinguished by different heavy chains defined by their 
constant regions. The mouse CH gene locus consists of eight genes 
(p, 6, Y3 . 12a, 12b, 
Y1., e ,d) (Marcu, 1982) . 
Vertebrate immune systems are able to respond specifically to an 
almost unlimited number of different foreign molecules (antigens). The 
production of immunoglobulins that bind specifically to the antigen 
comprises the major component of this response. The genes encoding 
immunoglobulins display several complex features associated with the need 
to generate such a large repertoire of specificities. 
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There are three unlinked immunoglobulin gene families: the 
light chain (k) and ()) gene families and a single gene family encodes 
heavy chains (Tonegawa, 1983). Variable regions show the most 
diversity; this is due to the role of the variable region to recognise 
vast varieties of immunogens (antigens). To create variable region 
diversity, at least one specific genetic mechanism exists; the process 
of DNA joining. Light chain variable regions are encoded by two gene 
segments, variable (V) and joining (J), which are separated in germ line 
DNA. The heavy chain variable regions are encoded by three such gene 
segments, (V), diversity (D) and (J) (Early et al, 1982, Marcu, 1982; 
Höchtl & Zachau, 1983; Alt & Baltimore, 1982). 
It has been found that during B-lymphocyte development and 
immunoglobulin synthesis, the (p) heavy chain is first inserted as an 
integral protein in the plasma membrane. However, a similar (p) chain 
has been detected as part of secreted immunoglobulins (Alt et al, 
1980). It has also been observed that the mRNA isolated from 
B-lymphocyte tumour cell lines directs the synthesis of two forms of 
heavy chains, 67,000 and 64,000 in molecular weight. Rogers et al 
(1980) using cDNA clones of mouse B-lymphocyte tumours have noted the 
presence of two mRNAs which differ in their 3'-termini. One 3'-terminus 
has been found to dictate amino acid sequences appropriate for 
membrane-binding and the other is involved in secretion. This work has 
been substantiated by further analysis of the data obtained from the 
cloning experiments. Early et al (1980) in their analysis of the 
genomic cloned DNA data have revealed the presence of two poly(A) sites 
in the same transcription unit and the primary transcript. It has also 
been shown that depending on the choice of poly(A) site, two heavy chain 
mRNAs can be formed. These two xRNAs produce two different products; 
the pmembrane (m) chain and the p secreted (S) one. Both Nm and Ps 
mRNAs are produced from transcripts of a single gene. The mapping 
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analysis data have also suggested that developmental control of the site, 
at which poly(A) is added to the transcripts of the Ngene, determines the 
relative levels of pm or ps chain synthesis. Meanwhile, Singer et al 
(1980) working on human lymphoma cells have arrived at a similar finding 
regarding the presence of two kinds of mRNA coding for receptor and 
secretory forms of IgM N-chains. They have proposed that the 
synthetic pathways for these immunoglobulins diverge at the post 
transcriptional level, possibly by differential RNA splicing. 
Moreover, murine cell lines producing IgG have also been found 
to produce two mRNA species for immunoglobulin "(-chains (Rogers et al, 
1981). Membrane-bound or secreted antibody is thought to be expressed 
first by regulation of the site of transcriptional termination or poly(A) 
addition and then by site specific RNA splicing (Rogers et al, 1981). 
Recently, Knapp et al (1982) have noted a simultaneous 
expression of immunoglobulin N- and 5-chains from a cloned B-cell 
lymphoma, where a single copy of VH gene is shared by two adjacent Cp 
and CS genes. They argue that dual expression of P- and S-heavy 
chains using a single VH gene is accomplished by alternate RNA splicing 
mechanism. Similar suggestion by Moore et al (1981) have also been 
reported earlier, using clones from mouse sperm DNA. They have also 
compared their results with that of rat myeloma DNA whose Cp gene has 
been deleted. They have concluded that two alternative mechanisms may 
be used in the expression of IgD molecules; RNA splicing in B-cells and 
DNA rearrangement in plasma cells. Other workers have also reported RNA 
splicing as a control mechaiism (Maki et al, 1981) in immunoglobulin 
synthesis. They have also suggested that the same five exonic regions 
common to both N chains also appear in 
9 chains. 
The molecular basis of the presumed differential choices of 
poly(A) and splice sites is not fully known and it remains possible that 
other components or template changes may dictate a post-transcriptional 
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outcome. It is still possible that a selective protein that binds to 
the DNA at one or the other poly(A) site might instead trigger the choice 
of poly(A) site during transcription (Darnell, 1982). 
1.2.4 Translational control 
The initiation of polypeptide chain synthesis in eukaryotes 
involves a complex series of events, including a number of nonribosomal 
initiation factors (eIF) (for review see Thomas et al, 1981) 
The primary event in the initiation of protein synthesis is the 
A 
formation of a ternary complex (80S. Met-tRNA. mRNA) and the first 
important step in the formation of this complex is the association of 
eukaryotic initiation factor (2) (eIF-2), which consists of three 
subunits (0c, A , &1(), with met-tRNA and GTP molecules (Gupta et al, 
1973). Factor eIF-2 as well as having a crucial role in this 
association is subjected to regulation by phosphorylation (Clemens et al, 
1982; Pain & Clemens, 1983). A summary of the initiation of protein 
synthesis is shown in Figure (2). 
Figure 2 Initiation of protein synthesis (adapted from Thomas et 
al, 1981) 
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Gene expression in eukaryotes often involves the selective 
translation of certain mRNA templates over the others. This type of 
regulation is used frequently in virus-infected cells and in cell 
differentiation. Most animal viruses are able to adopt the protein 
synthesising machinery and make it translate the viral mRNA and shut-off 
the translation of the host mRNA. This mRNA discrimination is thought 
to occur mainly at the initiation step which involves the recognition of 
mRNA and binding of the ribosome. 
It has been observed that Mengovirus RNA competes thirty five 
times more effectively than globin mRNA, in the reticulocyte lysate 
system, for a critical component in translation (Rosen et al, 1982). 
The competition is relieved by the addition of eIF-2. This suggests 
that the virus RNA competes directly or indirectly with the globin mRNA 
for eIF-2. In another experiment Walden et al *(1981), using reovirus 
infected SC-1 cells, have found that viral and host mRNAs must compete 
for a_message-discriminatory component prior to their binding to the 40S 
ribosomal complex. However, they also found that the host mRNAs in 
general have greater affinities than reovirus mRNA. 
Among the other possible control mechanisms for gene expression 
at the translational level in eukaryotes, is the sequestering of mRNA 
into inactive particles (mRNPs) unassociated with ribosomes (Heywood & 
Kennedy, 1976; Havaranis & Heywood, 1981). In addition, Bester et al 
(1975) have suggested that a small RNA named translational-control RNA 
(tcRNA) is involved in maintaining the mRNA in an inactive state. It 
has been reported recently that small RNAs are associated with stored 
mRNPs in a variety of cell systems (Vincent et al, 1980; O'Loughlin & 
Gross, 1981). Indeed a myosin heavy chain (MHC) mRNA has been purified 
and shown to contain a number of low molecular weight RNAs 
(Havaranis & 
Heywood, 1981). Recently, three low molecular weight RNAs molecules 
including tcRNA have been found in chick embryonic skeletal muscle. The 
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tcRNA (102 nucleotides) has been shown to inhibit the translation of 
mRNAs with which it is associated (McCarthy et al, 1983). Interactions 
of mRNA-tcRNA 102 alter the secondary structure of mRNA. Some kind of 
specificity is involved in this RNA-RNA interaction because tcRNA has 
shown no tendency to associate with ribosomal RNA or globin mRNA 
(McCarthy et al, 1983). This may suggest a certain degree of control at 
the translational level. 
1.2.5 Control at the Level of DNA Methylation 
Modified purine and pyrimidine bases in DNA have been observed 
for more than three decades (reviewed by Razin & Riggs, 1980; Adams & 
Burdon, 1982). The most significant of these modifications is the 
methylation of cytosine at position number five (m5C) and to a lesser 
extent 6-methylaminopurine (m6 A). 
The methyl group in 5-methylcytosine is located in the major 
groove of DNA helix and does not change the base pairing characteristics 
of cytosine (Razin & Riggs, 1980). The methylated base m5C has been 
found in 2-7% of mammalian DNA (Vanyushin et al, 1970). Methylation 
occurs enzymatically after DNA synthesis by methyl transfer from 
S-adenosylmethionine (Burdon & Adams, 1969). 
The studies on methylated sites have become intensified since 
the discovery of the inverse relationship between the sites of digestion 
of many bacterial endonucleases and the methylated sites of the genome 
(Razin & Riggs, 1980). Many bacterial restriction enzymes have shown a 
strong affinity for unmethylated restriction sites but they have low 
affinity and no activity on methylated sites (Smith, 1979; Roberts, 
1978). 
The location of the methylated cytosine is non-random. About 
90% of m5C residues in eukaryotic DNA are found in the dinucleotide 
sequence CpG. Several restriction enzymes include CpG in their 
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recognition sequence (Roberts, 1978) and most of these enzymes do not 
digest the DNA if the CpG sequence is methylated (Van der Ploeg & 
Flavell, 1980). 
The preliminary indication that gene activity was associated 
with undermethylation was reported by Christman et al in 1977. This 
finding has been supported later by the work of Jones and Taylor (1980). 
However, Rogers and Wall (1981) working on immunoglobulin heavy 
chain genes in relation to methylation and class switching, have noted 
that the p, Yi, and 8 genes are allJ2methylated when they are expressed. 
Numerous reports correlating hypo- and hyper-methylation with 
the state of gene activation have been published recently. The 
restriction sites of digestion of some endonucleases are similar but can 
differentiate between the methylated and unmethylated CG sequence (Jones 
et al, 1981; Piekarwicz, 1982). In assessing the relationship between 
the state of methylation and gene activation, some groups have concluded 
that in mammalian sperm, RBCs, and early embryog , the DNA is highly 
methylated and undermethylation is associated with gene activity 
(Waalwijk & Flavell, 1978; Mandel & Chambon, 1979; Jones et al, 1981; 
Bird et al, 1981) while in contrast, unmethylation at the HpaII sites in 
a variety of tissues including sperm has been noted (Bower et al, 
1983). However, co-existance of methylated and unmethylated sequences 
in the same genome has been observed in a wide range of eukaryotes. In 
addition, the presence of unmethylated sequences in the otherwise heavily 
methylated genomes of vertebrates suggests that methylation compartments 
are a general feature of eukaryotic genomes (Cooper et al, 1983). 
Naveh-Many & Cedar (1981) have suggested that transcribed 
sequences in the chicken are undermethylated compared to those in the 
genomic DNA. However, analysis of individual chicken genes has shown a 
rather complex picture with methylation patterns that vary for different 
genes. Moreover, Weintraub's group has shown a correlation between the 
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DNase-I sensitivity, the presence of HMG-14 and -17 and acetylated 
histones, a deficiency of 
m5C at certain sites and the expression of 
globin genes during the development of the chick (Groudine & Weintraub, 
1981; Weintraub et al, 1981). Weintraub et al (1981) have analysed the 
chromosome structures and expression of cc-gene cluster in developing 
chicken embryos and have shown that adjacent regions at both 5'- and 3'- 
sides of the active a-genes are methylated and relatively insensitive to 
DNase-I. As a general conclusion a correlation between regions of the 
chromosomes that are undermethylated and regions that are expressed seems 
to be favoured. 
1.2.6 Control at the Level of Chromatin Structure 
It is now widely accepted that active genes are packaged into an 
altered nucleosome structure. The chromatin structure of the 
transcribed genes is different from that of the bulk of DNA. The 
difference reflects an essential feature in explaining some aspects of 
gene expression, especially with respect to nuclease digestion. Other 
variations which may dictate special function in gene activity stems from 
the role of some non-histone proteins and variant histone components. 
1.2.6.1 Nuclease Sensitivity 
The use of DNases has helped a great deal in understanding and 
differentiating the areas of actively transcribed gene from the inactive 
ones. Weintraub & Groudine (1976), studying transcribed and 
non-transcribed genes have demonstrated that the globin gene in chick 
erythrocyte nuclei is preferentially sensitive to digestion by pancreatic 
DNAse-I. They have also shown that the gene is resistant to micrococcal 
nuclease which suggests that it is packaged into nucleosome-like 
particles that are different from most other nucleosomes. TheDNase-I 
sensitivity has been found to be tissue specific (Weintraub & Groudine, 
1976; Garel & Axel, 1976). DNase-I sensitivity of actively transcribed 
genes seems to be a general phenomenon (Garel & Axel, 1976; Flint & 
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Weintraub, 1977; Groudine et al, 1978; Storb et al, 1981). However, 
the micrococcal nuclease sensitive fraction of calf thymus nucleosomes 
have also been found to be enriched in transcriptionally*active DNA 
(Davie & Saunder, 1981). In a similar fractionation technique and using 
micrococcal nuclease, it has been possible to separate actively 
transcribed genes and genes which are transcribed at different rates. 
Results obtained by this method have been difficult to substantiate 
(Weisbrod, 1982). 
Recently, Nicolas et al (1983) have demonstrated that higher 
order chromatin structures might be responsible for nuclease sensitivity 
of active genes. Gottschling et al (1983) have reported that the 
transcribed region of rRNA genes in Tetrahymena has a shorter nucleosome 
repeat compared with the non-transcribed central spacer of bulk 
chromatin. However, the transcribed region has been found to display an 
increased sensitivity to micrococcal nuclease in rapidly growing cells 
which suggests an altered chromatin structure during transcription. In 
an extension to the previous finding, Palen and Cech (1983) have 
concluded that transcriptional activation is accompanied by major changes 
in the structure of the ribosomal gene chromatin and that the extent 
and/or type of structural alteration differs in each functionally defined 
region of the rDNA. 
DNase-I sensitivity as a property of active gene regions has 
been correlated with under-methylation of DNA (Razin & Riggs, 1980). 
This correlation has been noted in the chicken globin gene (Weintraub et 
al, 1981), ovalbumin (Kuo et al, 1979) and in other systems (for review 
see Adams & Burdon, 1982). 
DNase-I hypersensitive regions have also been observed. These 
are located in specific positions of the genome. In Drosophila, they 
are located in the vicinity of the heat shock genes (Wu, 1980) adjacent 
to the 5'-ends of the coding regions. Similarly, DNase-I hypersensitive 
- 25 - 
sites have been found in other systems (Stadler et al, 1980; Weintraub 
et al, 1981), also situated adjacent to the coding sequences of the 
genes. Tissue specificity of DNase-I hypersensitivity has been found in 
rat preproinsulin-II gene system, predominant in insulinoma and absent in 
nonexpressing tissues such as kidney, spleen and brain (Wu & Gilbert, 
1981). The structural basis and the functional significance of DNase-I 
hypersensitivity are not well understood (see Igo-Kemenes et al, 1982). 
1.2.6.2 Histone H1 
Chromatin is usually undergoing extensive transient alterations 
in structure during the cell cycle. During (S) phase, the DNA must be 
made accessible in such a way to be presented to DNA-polymerases. Later 
during mitosis, the DNA is folded and compacted to form the mitotic 
chromosomes. Several structural and functional protein changes must 
accompany this sequential organisation. H1 histone is believed to 
play a role in the higher order structure of chromatin (see section 
1.1.1.2). The occurrence of precisely timed stage-specific changes in 
histone subtypes during development suggests that they are important in 
differentiation (Cohen et al, 1979). Direct evidence for the specific 
exchange of one histone subtype for another has been demonstrated in 
fertilised sea urchin eggs (Poccia et al, 1981). The switch in histone 
Hl occurs almost immediately while the core histones are replaced at 
specific intervals. 
Post-synthetic histone modification by phosphorylation, 
acetylation, methylation and poly ADP ribosylation is a well studied 
feature of chromatin structure and metabolism. Attempts have been made 
to link these modifications to transcriptional activation. Correlations 
between an increase in histone acetylation and increased RNA synthesis 
have been observed (Weisbrod, 1982). Special attention has been 
focu sed on linking the enrichment of histone-acetylation to 
transcriptionally active chromatin (Weisbrod & Weintraub, 1981). 
- 26 - 
Phosphorylation of H1 histone has been implicated in gene activation. 
H1 is generally present in 2-5 subtypes differing from one another in 
the N-terminal region of the molecules (for review see Cartwright et al, 
1982). H1 histone undergoes cell cycle related phosphorylation at 
several sites, principally during (S) phase and mitosis (Hohmann et al, 
1976; Ajiro et al, 1981a, 1981b). These observations have suggested 
that Hl phosphorylation plays a part in some of the conformational 
alterations of chromatin during the cell cycle. It has also been shown 
that within a single cell type there are differences between H1 
subtypes with respect to the extent of phosphorylation during the cell 
cycle (Hohmann et al, 1976; Ajiro et al, 1981a, 1981b). However, H1 
subtypes differ from each other functionally (Lennox et al, 1982). It 
has also been demonstrated that there are qualitative differences between 
the H1 complement of undifferentiated embryonal carcinoma cells and 
differentiated endodermal cells, raising the possibility that such 
changes may play a role in the process of jell differentiation (Lennox et 
al, 1982). 
1.2.6.3 High Mobility Group (HMG) Proteins 
High mobility group proteins are low molecular weight 
non-histone chromosomal components. They have been found to possess 
common features in a number of chromatin preparations of various origins 
(Goodwin et al, 1973; Alfageme et al, 1976; Spiker et al, 1978). The 
most important proteins of this group are HMG-1, -2, -14 and -17. Their 
importance stems from the possible structural and functional roles of 
these proteins. Analysis of nucleosome preparations has shown that 
HMG-17 and -14 are found in association with mononucleosomes 
(Mathew et 
al, 1979), in particular binding DNA sequences between 
145-160 bp as well 
as within the 145 bp core particle (Goodwin et al, 1979). However, 
Sandeen et al (1980) have shown that major sites of HMG-14 and -17 
binding are located near the termini of the core particle 
DNA. It has 
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also been reported that HMG-14 and -17 bind to a well defined nucleosomal 
structure rather than to DNA (Weisbrod et al, 1980). 
Chromatin fractionation and nuclear digestion have been used to 
differentiate between proteins associated with active and inactive 
genes. Rapidly released and/or soluble nucleosomes are generally 
reported to be enriched in transcribed DNA sequences and in HMG-14 and 
HMG-17 (Levy-Wilson & Dixon, 1978; Mathew et al, 1979), and small 
amounts of HMG-1 and HMG-2 are also found (Jackson & Rill, 1981; Goodwin 
et al, 1979; Nicolas et al, 1983). However, several reports have 
correlated the association of HMG proteins with the maintenance of 
actively transcribing regions in chromatin (Levy-Wilson et al, 1977; 
Vidali et al, 1977). 
The functional connection between HMG-14 and -17 and the active 
genes has been well demonstrated by the experiment of Weisbrod and 
Weintraub (1979). In this experiment it has been shown that DNase-I 
sensitivity of globin genes in erythrocyte chromatin was lost on the 
removal of HMG proteins with 0.35M NaCl. Similar findings have been 
reported by Nicolas et al (1983) working on chick embryonic red blood 
cells. The sensitivity to DNase-I has been restored by reconstitution 
with HMG-17 and HMG-14 (Weisbrod & Weintraub, 1979; Gazit et al, 1980; 
Nicolas et al, 1983). Weisbrod et al (1980) have studied the 
interaction of HMG-14 and -17 with actively transcribed genes by 
monitoring the sensitivity of specific genes to DNase-I after 
reconstitution of HMG-depleted chromatin with HMG-14 and HMG-17. They 
have observed that the most actively transcribed genes become sensitised 
to DNase-I by HMG-14 and HMG-17. Both HMGs have activity which can be 
reconstituted onto isolated nucleosome core particles. Furthermore, 
HMG-14 and HMG-17 have been found to bind equally well to genes 
transcribing large amounts of mRNA and to genes that are transcribed 
rarely. 
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Further evidence supporting the correlation of the presence of 
HMG-14 and HMG-17 with gene activity, stems from the altered rate of 
phosphorylation at different stages of cell cycle. Bhorjee (1981), has 
demonstrated a seven fold increase in 
32P incorporation into HMG-14 in 
(G2) phase of the cell cycle compared with (Gl), and a two fold increase 
in incorporation into HMG-17 in early (S) phase. This report has also 
concluded that the differential phosphorylation of HMG-14 and -17 at 
specific stages of the cell cycle suggests that they may well play a role 
in tissue-specific maintenance of the altered chromatin structure 
characteristic of potentially active or actively transcribed chromatin 
domains. 
In another significant finding, the stage-specific 
phosphorylation of HMG-14 has been found to be parallel to that of 
histone H1, and this adds weight to the theory that HMG-14 and HMG-17 
substitute for H1 in active regions of chromatin (Weisbrod, 1982). 
1.3 Nonhistone Chromosomal Proteins 
The nonhistone chromosomal (NHC) proteins are a class of highly 
heterogeneous proteins in eukaryotic nuclei. Some of them are assumed 
to play a crucial role in the mechanism of gene activity. They can be 
divided into three groups, based on their affinity for DNA, the low, 
intermediate and high-affinity proteins. The high mobility group (HMG) 
proteins fall within the DNA-low affinity group. The comparatively 
straight forward methodology of their isolation and purification, coupled 
with their abundance has led to fairly detailed characterisation of the 
principal members of this group and tentative structural and functional 
roles have been suggested. In contrast, the high-affinity proteins have 
proved difficult to isolate and characterise and therefore little is 
known regarding their roles. However, attempts have been made to 
determine the role of some isolated proteins which have 
intermediate-affinity for DNA. Amongst these proteins are enzymes and a 
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number of cofactors. In addition, a number of chromosomal proteins with 
no known enzymatic or enzyme-associated activity have been identified and 
resolved from the bulk of chromosomal proteins by electrophoresis. The 
lack of known enzymatic functions and the large amounts of each present 
in a given cell, suggest that these proteins are involved in structural 
organisation. Another group of proteins are found to be species-, 
tissue- and cell-specific. Quantitative variation of a number of these 
has been associated with genetic activity in some cells. These groups 
of proteins are analysed in greater detail in the following sections. 
1.3.1 Enzymes and Co-factors 
A number of enzymes essential for the metabolism of nucleic 
acids and protein modification have been localised in the nonhistone 
fraction of chromosomal proteins. These include enzymes involved in 
DNA, RNA, histone and nonhistone protein metabolism and modifications. 
Examples of the different components with their assigned functions are 
summarised in Table (1). 
Initial attempts to examine the role of NHCPsin the regulation 
of transcription were made by assessing the effects of these proteins on 
DNA-dependent RNA synthesis. Results from several laboratories indicate 
that NHCPs added directly to histone-DNA complexes of various chromatin 
preparations, increase the availability of DNA as a template for RNA 
transcription (Kaniyam & Wang, 1971; Spelsberg & Hnilica, 1971a & b). 
A protein co-factor which stimulates RNA polymerase I has been found to 
be crucial for transcription of native calf thymus DNA (Goldberg et al, 
1977). Le Graverend and Glazer (1980) have characterised a nonhistone 
chromosomal protein from rat liver nuclei which stimulates RNA synthesis 
in vitro. 
In addition, isolation of RNA polymerase II stimulatory factors 
from calf thymus chromatin (Benson et al, 1978), lamb thymus (Revie & 
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(Seifart et al, 1973) and mouse myeloma cells (Lentfer & Lezius, 1972) 
has also been reported. Recently, an NHCP-fraction has been 
chromatographically isolated and found to contain a large amount of 
nascent RNA chains (Ferraro et al, 1982). 
Three factors associated with RNA polymerase III have been 
purified from human KB cells (Segall et al, 1980), and Xenopus (Pelham & 
Brown, 1980). Factors from KB cells have also been found to stimulate 
accurate initiation of transcription at the major late promoter of 
Adenovirus-2 (Matsui et al, 1980). 
1.3.2 Structural Proteins 
HMG proteins -14 and -17 have been found to bind to the core 
nucleosome and have a major effect on nucleosome structure (Mathew et al, 
1979). Reconstitution experiments have indicated that both HMG-14 and 
-17 bind readily to the 145-base pair core particle at a stoichiometry of 
1 and 2 molecules per core, respectively, in a manner that does not 
exclude binding of H1 (Albright et al, 1980). Another protein of this 
group is HMG-20 (Ubiquitin) (Schlesinger et al, 1975) which has been 
suggested to reside on linker DNA, between the core particles, in the 
transcriptionally active chromatin (Watson et al, 1978). Ubiquitin, 
however, is found as a constituent of the conjugate protein A24 which 
consists of H2A histone and HMG-20 (Goldknopf & Busch, 1977). HMG-20 
is covalently linked via a glycyl-glycine peptide at its C-terminal end 
to the amino group of lysine -119 in histone H2A. The absence of 
ubiquitin in mitotic chromatin, has led to the suggestion that it plays a 
structural role within the chromatin components preventing condensation 
to higher-order structures in metaphase (Matsui et al, 1979). Recently, 
A24 has been found to be associated with mononucleosomes containing 
transcriptionally inactive sequences (Levinger et al, 1981). 
Detke and Keller (1982), in their comparison between the 
interphase nucleoskeleton and metaphase chromosome scaffolds in HeLa 
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cells, have found that the major proteins of both preparations are 
similar. They have also distinguished the nucleoskeletal proteins from 
the major nuclear laminar proteins. Although the nucleoskeletal 
components comprise only a small subset of the total nuclear proteins, it 
has been suggested that they are responsible, at least in part, for the 
gross morphology of the nucleus (Riley et al, 1975). 
Another group of proteins which may play a part in the 
structural interconversions of chromatin as well as in the regulation of 
cell proliferation are the contractile proteins (LeStourgeon et al, 
1975). These proteins have been found in the NHCP-fraction, and 
suggested to be involved in intranuclear contractile functions. 
The structure of metaphase chromosomes is stabilised by another 
class of NHC-proteins, the tightly-bound scaffold proteins (Adolph et al, 
1977 a& b). Accumulated evidence suggests that both metaphase 
chromosomes and nuclei contain a residual skeleton or scaffold which 
maintains the DNA in a compact, looped arrangement (Laemmli et al, 
1978). Two types of scaffold protein fractions have been characterised, 
based on their method of preparation (Lebkowski & Laemmli, 1982). The 
type-I structure has been shown to be stabilised by the Ca++ ion. 
This stabilisation can be altered by the addition of 2-mercaptoethanol 
which disrupts the metalloprotein interaction to give a type-II 
structure. The metalloprotein interaction involved is suggested to be 
important for DNA folding. DNA binding studies have revealed that 
twelve proteins of type-I and four of type-II scaffolds bind DNA in vitro 
(Lebkowski & Laemmli, 1982). However, it has been shown that following 
treatment with cupric ion, the scaffold residue shows a simple protein 
composition comprising two high molecular weight (135K & 170K) 
proteins. They are designated as scaffold 1 and 2 (Scl & Sc2) 
respectively (Lewis & Laemmli, 1982). More recently, Earnshaw and 
Laemmli (1983) have visualised a nonhistone protein residual scaffold by 
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electron microscopy. This protein scaffold has been obtained from 
nuclease digested chromosomes under conditions of low salt protein 
extraction. It is suggested that the extremely. simple composition of 
the residual scaffold proteins, is fibrous in nature and determines the 
dimensions of the chromosomes. Evidence has been presented to 
demonstrate that the scaffolding network plays a dynamic role in 
chromosome condensation at mitosis (Earnshaw & Laemmli, 1983). 
1.3.3 Tissue and Cell Specific Proteins 
Several attempts have been made to correlate the presence of 
nonhistone chromosomal proteins with certain specific tissues or cell 
types. Comparison between the chromosomal proteins of a number of 
tissues and cells has been performed by immunological criteria or 
electrophoretic profiles. A fraction of nonhistone proteins has been 
found necessary for the in vitro transcription of tissue-specific RNA 
species (Spelsberg et al, 1971). A dehistonised chromatin fraction from 
Novikoff hepatoma has been shown, by immunological criteria, to be tissue 
specific (Chytil & Spelsberg, 1971), and to require and recognise only 
homologous DNA (Wakabayashi & Hnilica, 1973) for its immunoactivity. In 
comparison between tumour and normal tissues, Fujitani et al (1978), have 
localised a protein antigen (45K - 60K) to the chromatins of embryonic 
liver and several transplantable tumours but not of normal tissues. 
Further immunological studies on the Novikoff hepatoma antigens have 
revealed the presence of two proteins (P39 &P 49) specific for Novikoff 
hepatoma. These antigens have been localised in chromatin as well as in 
the cytoplasm (Schmidt et al, 1981). A similar approach has been used 
on the nonhistone chromosomal protein fraction from HeLa cells. The 
HeLa antigens have been identified in the DNA-tightly-bound proteins 
in 
the scaffold area (Campbell et al, 1979). This group of antigens 
has 
been found by immunological criteria to be cell specific (Briggs et al, 
1979) and species specific (Dunn et al, 
1980). However, a different 
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110K nonhistone phosphoprotein purified from the 0.35M NaCl nuclear 
extract has also been found common to four cell lines including Novikoff 
hepatoma and HeLa cells but failed to be traced in normal tissues (Durban 
et al, 1981). 
Electrophoresis has been used to demonstrate and characterise 
specific proteins in different chromatin preparations. Yaneva et al 
(1980) have shown, by electrophoretic comparison, the presence of at 
least one unique band in each tissue examined. Quantitative and 
qualitative differences in the electrophoretic profiles have also been 
noted. Two dimensional gel electrophoresis has been used by Wu et al 
(1981) to demonstrate differences in the pattern of proteins of several 
human tumours and normal cells. Two proteins (140K & 54K) have been 
found in four types of tumour cell but not in the four normal cell types 
examined, whereas another two proteins, of 56K but different isoelectric 
points, have been shown to occur only in the normal cells and not in the 
tumour cells. Qualitative and/or quantitative differences in the two 
dimensional gel patterns of NHCPs have also been observed in closely 
related mouse cell lines (Plasmacytomas) which were known to differ in 
their ability to express known genes (Lincoln & Stott, 1983). These 
differences were correlated with gene expression. 
1.4 Characterisation of Nuclear and Nucleolar Components by 
Immunological Approaches 
1.4.1 Antibodies to Nucleic Acids 
Antibodies to purified nucleic acids are obtained with great 
difficulty. Several reports have described successful immunisation with 
RNA preparations. Antisera obtained from rabbits immunised with yeast 
RNA have shown reactivity towards yeast, human, rabbit and rat RNA (Lamon 
& Bennett, 1970). Hernandez et al (1968) have shown that after 
immunisation of four rabbits with tRNA, believed to be free from protein 
carriers, and twenty nine rabbits with oligonucleotides prepared by 
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partial enzymatic digestion of RNA, almost all antisera obtained from 
both types react in the complement fixation assay with RNA of high 
molecular weight as well as with oligonucleotides prepared from tRNA. 
However, one antiserum out of 33 reacts specifically with tRNA itself. 
On the other hand, antisera obtained after immunisation with free tRNA 
have failed to react with tRNA (Bonavida et al, 1970). 
Despite the difficulties experienced by immunisation of 
experimental animals, anti-RNA antibodies are commonly detected in 
autoimmune diseases in man and animals. Anti snRNA antibodies have been 
detected in sera from patients with SLE (Lerner et al, 1980,1981). 
Successful hybridomas with reactivity against rRNA have been produced 
from autoimmune mice (Eilat et al, 1980). One of these monoclonal 
antibodies derived from NZB/NZW (F1) mouse lymphocytes fused with the 
myeloma cell line MPC-11, has shown specific binding to rRNA and failed 
to bind significantly to DNA, tRNA and synthetic single- and 
double-stranded polynucleotides. Similarly, monoclonal antibodies 
derived from MRL mice have shown specific reactivity towards rRNA (Lerner 
et al, 1981). Eilat et al (1982) produced a sequence specific anti-RNA 
monoclonal antibody which recognise a G/C-rich ribonucleotide. 
Antibodies to DNA have been proved difficult to raise in 
laboratory animals. Antisera from animals immunised with purified DNA 
from calf thymus, salmon sperm, E. coli and rat liver have also failed to 
show immunoreactivity towards DNA (Levine & Stollar, 1968; Barnett & 
Vaughan, 1966; Yachin, 1962). This led Stollar (1973) to conclude that 
native DNA is not immunogenic. 
However, spontaneous antibodies reacting with native DNA have 
been reported in almost all patients with Systemic Lupus Erythromatosus 
(Tan et al, 1966). Evidence for the presence of antisera which react 
with ss-DNA in patients with SLE and other autoimmune 
diseases has been 
presented (Koffler et al, 1973,1974). Specific antisera which react 
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only with double-stranded DNA and others that bind both ds- and ss-DNA 
have also been demonstrated in SLE patients (Gilliam et al, 1980). 
Antisera which react with ds-poly d(AT) have been shown to bind well to 
ss-DNA (Gilliam et al, 1980). Peripheral blood lymphocytes from 
patients with no autoimmune disease show no production of anti-DNA 
antibodies but after EBV transformation (Epstein-Barr Virus), anti-DNA 
antibodies producing cells have been detected (Hoch et al, 1983). In 
addition, it has also been shown that normal mice can produce anti-DNA 
antibodies if their B-lymphocytes undergo mitogen-stimulated polyclonal 
activation (Fish & Ziff, 1982; Dziarski, 1982). Moreover, production 
of autoantibodies by human-human hybridomas has been reported from many 
laboratories. Shoenfeld et al (1982) using the ELISA technique have 
demonstrated the feasibility of producing anti-ss-DNA monoclonal 
antibodies using peripheral blood cells from a number of patients with 
autoimmune diseases such as SLE and Atopic Allergy. Recently, Shoenfeld 
et al (1983) have managed to fuse a human lymphoblastoid cell line 
derived from patient with multiple myeloma with lymphocytes from an SLE 
patient. Among the thirty monolconal antibodies produced against 
denatured DNA, eighteen of them react with additional polynucleotide such 
as native DNA, left handed double helical DNA (Z-DNA), poly(I) and 
poly(dT). Ten of these monoclonal antibodies showed reactivity towards 
nucleic acids and cardiolipin phosphlipid. Accordingly, this report 
suggests that DNA itself need not be the immunogenic stimulus for 
autoantibody formation in this type of disease. 
Laboratory animals such as NZB/NZW mice have also been found to 
make antibodies to DNA (Stollar, 1973). Lee et al (1981) 
have produced 
six hybridomas which secrete extremely specific monoclonal antibodies to 
deoxyribonucleic acids from NZB/NZW mice. It has been shown that 
various RNAs failed to react with these monoclonal antibodies. In 
addition, the ss-DNAS tested showed 
higher reactivity than ds-DNA. Some 
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of these monoclonal antibodies exhibit sequence preferences which make 
them a powerful tool for distinguishing between similar nucleic acids. 
Other groups have succeeded in producing a number of hybridomas that 
secrete monoclonal anti-DNA autoantibodies from NZB/NZW (Hahn et al, 
1980; Jacobs & Tron, 1982) or MRL mice (Lerner et al, 1981). Hahn et 
al (1980) in their studies using murine anti-DNA monoclonals have shown 
that these antibodies exhibit specificity towards ds-DNA and ss-DNA but 
not ss-RNA or poly(I-C). Jacobs and Tron (1982) and Andrzejewski et al 
(1981) produced 10 anti-DNA monoclonal antibodies with identical 
specificity to a conformational determinant of the B-helical form of 
ds-DNA. Other anti-nucleic acid monoclonal antibodies have recently 
been reported (Kioke et al, 1982). These monoclonals were produced from 
hybrids of (MRL 1) X NZB-NZW (F1) mouse lymphocyte fused with 653 
myeloma cell line. Twelve clones have shown specific reactivity with 
ss-DNA only while another two react with both ss- and ds-DNAs. Studies 
with mouse anti-DNA monoclonal autoantibodies have revealed that a single 
antibody can bind to multiple nucleic acid antigens of different base 
composition (Andrzejewski, 1981; Pisetsky, 1982; Kioke et al, 1982). 
Structural differences in polynucleotide backbones can explain individual 
variations in binding specificities among the monoclonal antibodies. In 
addition, phosphodiester-containing epitopes also account for the ability 
of some monoclonal anti-DNA autoantibodies to bind to certain 
phosphlipids such as cardiolipin (Lafer et al, 1981c). Immunisation of 
normal rabbits (Guarnieri & Eisner, 1974) or mice (Rauch et al, 
unpublished data) with cardiolipin has been found to stimulate the 
production of both anti-cardiolipin and anti-DNA antibodies. Moreover, 
MCAs derived from these cardiolipin-immunised mice, bind to cardiolipin, 
DNA, poly(I) and poly(dT). The polyspecificities of some 
MCAs signify 
that it is not possible to imply the origin of spontaneously produced 
autoantibodies from serum analyses only. 
- 
In contrast to most other nucleic acids, left-handed-DNA (Z-DNA) 
is a strong immunogen which elicits Ab production in both mouse and 
rabbit. The anti-left handed-DNA Abs react with only Z-DNA and show no 
reactivity with native B-DNA (Lafer et al, 1981a). However, nuclei of 
many rat cells exhibit Z-DNA immunoactivity with anti-Z-DNA which 
suggests that Z-DNA may exist naturally in mammalian chromatin (Morgenegg 
et al, 1983). In Drosophila, fluorescent staining with these Abs has 
shown specific binding to polytene chromosomes especially in the 
interband regions (Lafer et al, 1981b). Monoclonal antibodies to Z-DNA 
have also been produced recently and shown to exhibit high specificity 
(Pohl et al, 1982). 
1.4.2 Antibodies to Histones 
Most of the amino acids sequences of histone proteins are 
similar in different species reflecting the conserved primary structures 
of these proteins. As a result of this fact, these proteins are in 
general weak antigens. 
Antisera raised against total rat liver chromatin have shown no 
reactivity towards pure histone fractions, while antisera to purified 
histones failed to interfere with the reaction between antibodies to 
chromatin and chromatin itself as judged by C'F assay (Goldblatt & 
Bustin, 1975). Antisera raised against calf thymus H2 A, H2B and 
H4 histones have failed to distinguish between these histones and those 
obtained from chicken erythrocytes, frog liver and human spleen (Stollar 
& Ward, 1970). Pothier et al (1975) managed to raise antisera against 
the major histones of calf thymus. These antisera have been used to 
localise the distribution, by immunofluorescence of various proteins 
during the cell cycle, and also to follow their reactivity on chromosomes 
of different cells. Cross reactivity is common among all but Hl 
histone. Antibodies elicited against Hl and H2B histones of 
Drosophila have also been used coupled to fluorescent labels in order to 
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localise their positions on polytene chromosome (Alfageme et al, 1976). 
Both H1 and H2B have been found in most chromosomal regions. 
In contrast to antibodies to the four other histones, those 
elicited against unfractionated H1 derived from calf thymus (Bustin & 
Stollar, 1972) or rat tissues (Hekman & Sluyser, 1973) have shown both 
species and organ specificity in this histone class. Similarly, 
specific antisera against H1-subfractions have been used to detect 
species- and tissue-specificity (Sluyser & Bustin, 1974) as well as 
changes in conformational determinants and changes due to chemical 
modifications (Bustin & Stollar, 1973). 
High levels of antibodies to histones have been found in many 
patients with autoimmune diseases. This makes the specific antisera a 
potentially useful diagnostic tool in such diseases. Anti-histone 
antibodies from sera of patients with various rheumatic diseases have 
been shown to react predominantly with histone complex H3-H4 (Rubin 
et al, 1982). 
1.4.3 Antibodies to Nonhistone Chromosomal Proteins 
NHC proteins are the most heterogeneous group of nuclear 
proteins. The DNA-low affinity proteins are relatively easy to 
fractionate. A wide variety of antisera specific to components of this 
group has been reported. These have in general been used to locate the 
corresponding antigen in different subtractions or cell types. Bustin 
and Neihart (1979) have raised a rabbit antiserum to calf thymus HMG-1 
and shown that it reacts with both the chromatin 
itself and also 
cytoplasmic components of Chinese hamster V-79, rat 
liver TR-12 and 
bovine trachea EBTr-NBL-4 cells. Another antiserum raised against chick 
oviduct HMG-1 has been used in a limited study of 
the effect of oestrogen 
stimulation on HMG-1 distribution 
in cells (Teng & Teng, 1981). 
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Antibodies to HMG-1 and HMG-2 proteins have also been detected 
by ELISA in antisera from patients with SLE and other autoimmune diseases 
(Bustin et al, 1982). However, the immune response to HMG-14 and HMG-17 
proteins appears to be stronger. 
The distribution of nonhistone proteins of a variety of 
molecular weights in polytene chromosomes of Drosophila salivary glands 
was visualised some years ago by the use of antisera raised to 
chromosomal antigens eluted from SDS-PAGE (Stumph et al, 1974). More 
detailed information on the location of a particular NHCP in the same 
polytene chromosome was later obtained using antiserum raised against 
purified Dl nonhistone protein (Alfageme et al, 1976). Similarly, 
antisera raised against other purified individual NHCP from Drosophila 
have been used to assess the selectivity of distribution patterns, and 
two of these have shown that the corresponding protein distribution is 
limited on the polytene chromosome (Silver & Elgin, 1978). On the other 
hand, an antiserum raised against a 21K protein has shown prominent 
immunofluorescent staining at dense chromomeres and the chromocentre in a 
pattern mimicking DNA distribution (Silver & Elgin, 1978). 
The high affinity NHC protein group has proved more difficult to 
fractionate. This, together with the unknown function of most of these 
proteins, makes the isolation and identification of individual proteins 
more difficult. However, antiserum to a chromosomal protein fraction 
specific for HeLa cells has been elicited in rabbit. Although this 
antiserum has not been shown to react with a single protein, it has been 
useful to localise the immunoactivity to the transcriptionally 
inactive 
region of log phase chromatin (Campbell et al, 1979). Further studies 
have suggested that some of the antigenic proteins in the scaffold area 
are both tight binding and cell-specific. It 
has been shown that the 
specific antigens, of this chromatin fraction, are a complex of 
human or 
HeLa DNA only and the tightly bound NHC proteins. In addition, 
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immunochemical tests have revealed that the antigens are continuously 
present throughout the cell cycle (Briggs et al, 1979). 
Another DNA: NHCP complex immunogen has been detected in Novikoff 
hepatoma (Wakabayashi & Hnilica, 1973). This immunogen has been shown 
to have species- and tissue-specificity (Fujitani et al, 1978). 
However, more recently antisera against three partially purified Novikoff 
hepatoma antigens from the same group have been used to localise their 
distribution in various subcellular fractions by immunoblotting 
techniques (Schmidt et al, 1981). These proteins, of 39K, 49K and 56K 
molecular weights have been found in cytoplasmic fractions as well as in 
isolated chromatin. 
In an early approach, Chytil and Spelsberg (1971) showed that 
the antigeneity of NHCPs of chick oviduct chromatin was associated with 
DNA and was species-specific. In addition, the differential 
distribution of this antigen complex in different tissues indicated a 
tissue-specificity. 
Species-specificity of another NHCP: DNA complex from chick 
reticulocytes have also been investigated by immunological criteria 
(Krajewska et al, 1979). Further immunological evidence for tissue-, 
species- and cell-specificity of this NHCP group have emerged from more 
recent studies. Erythroid cell-specific antisera detecting the 
tightly-bound DNA: NHCP complex from dehistonised chicken reticulocyte 
chromatin have shown no cross reactivity with chromatin of thrombocytes 
(Krajewska & Klyszejko-Stefanowics, 1982) although thrombocytes are 
closely related to erythroid cells. In addition, antisera to the 
tightly bound NHCP: DNA complex of thrombocytes have shown no 
immunological similarity with those raised against erythrocyte 
DNA-tightly bound chromatin. More recent studies have confirmed that 
antisera raised in mice to chromatin from different tissues of the 
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chicken reacted preferentially with the chromatin type that was used for 
immunisation (Vanderbilt & Anderson, 1983). 
Antisera against a single NHCP of predefined function have also. 
been used to determine the presence of such protein in different 
subcellular preparations. Watson and Moudrianakis (1982) have elicited 
an antiserum to an NHC protease. Antiserum against a nonhistone 
chromosomal phosphoprotein (B2) that is specifically associated with the 
nucleosome structure has also been reported (Zhao & Liew, 1982). 
Monoclonal antibodies to NHCPs will be discussed in section 
(1.5.3). 
1.4.4 Antibodies to Nucleolar Antigens 
The nucleolus is the site of synthesis of 28S, 18S and 5.8S 
ribosomal RNAS (Wellauer & Dawid, 1973). In addition to ribosomal RNA 
precursors, the nucleolus contains a small species of RNA, U3 (for 
review see Ro-Choi & Busch, 1974). This species of RNA is of interest 
because of its unique and specific localisation in the nucleoli 
(Prestayko et al, 1971) and its hydrogen bonding to nucleolar 35S and 28S 
RNA (»restayko et al, 1970). Other small RNAs can also be detected in 
nucleoli (reviewed by Busch et al, 1982). The assembly of ribosomes 
begins in the nucleolus. Therefore, it is likely that many of the 
molecular associations found in cytoplasmic ribosomes may also be present 
in nucleolar precursors. 
Nucleolar immunofluorescent staining has been found in some SLE 
patients whose antisera contain antibodies against cytoplasmic antigen 
with rRNA characteristics (Miyachi & Tan, 1979). On the other hand, 
Homberg et al (1974) have described another type of distinctive 
immunofluorescent pattern found in some antisera of patients with SLE and 
other collagenous diseases. These sera which are of anti-ribosomal 
character have failed to react with nucleolar ribosomes (Bianchi et al, 
1974). 
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In general, anti-nucleolar antibodies are more common in 
Scleroderma than in other SLE and Rheumatic diseases. Although earlier 
reports showed an 11-21% incidence of anti-nucleolar antibodies in 
Scleroderma patients (Fennell et al, 1962; Beck et al, 1963; Burnham et 
al, 1966), a higher percentage has been described in a later report 
(Ritchie, 1969). Anti-nucleolar antibodies have also been detected in 
Sjögren's Syndrome (Tan & Lerner, 1972) as well as in response to 
malignant melanoma (McBride et al, 1972). 
Nucleolar specific antibodies have been raised in rabbits 
immunised with whole nucleoli from Novikoff hepatoma ascites cells or 
from normal rat liver. Of the fourteen antigens detected, ten reacted 
with both kinds of antisera (Davis et al, 1978). In addition, 
comparison of the nucleolar antigens of human liver and HeLa cells has 
shown a 54K immunogen in HeLa but not in normal liver cells (Chan et all 
1980). However, in a more detailed comparison, antisera raised against 
a nuclear 0.01M tris-HC1 (pH 8) extract or nucleolar preparation of HeLa 
S3 cells, have shown a wide range of nucle olar immunofluorescence in 61 
out of 63 human adenocarcinomas, squamous cell carcinomas, sarcomas, 
haematological neoplasms and other malignant tumours (Busch et al, 
1979). With these antibodies, nucleolar immunofluorescence has not been 
visualised in 23 normal tissue specimens. In similar studies, Davis et 
al (1979) have also described the presence of a nucleolar antigen which 
was found in several human tumours but not in non-tumour tissues. These 
reports suggest that such specific antisera may be a useful tool for 
differentiating malignant from normal tissues. 
1.5 Monoclonal Antibodies 
1.5.1 History and Background 
In 1975, Köhler and Milstein showed that somatic cell 
hybridisation could be induced in culture between antibody-producing 
B-lymphocytes which are mortal in tissue culture and myeloma cells which 
- 44 - 
continue to grow in appropriate conditions. The hybrid cell which 
results from such fusion has the ability to grow continuously and produce 
the B-lymphocyte specified antibody in selective culture media. 
The two pathways of nucleotide biosynthesis in eukaryotic cells 
are the "De Novo" synthesis and the "Salvage" pathways. The De Novo 
synthesis of purines and pyrimidines can be blocked by the folic acid 
antagonist; Aminopterin. However, the cell can still synthesise DNA 
via the so called Salvage pathways, if it possesses the required enzymes, 
Thymidine Kinase (TK) for the pyrimidines, and Hypoxanthine Guanosine 
Phosphoribosyl Transferase (HGPRT) for the purines. When the De Novo 
synthesis of DNA is blocked, the cells which contain these enzymes can 
survive if exogenous hypoxanthine and thymidine are provided in the 
culture media (Littlefield, 1964). After the fusion event, three kinds 
of cells are mixed in the selective media, HAT media. The spleen cells 
which have the ability to synthesise the antibodies die in culture after 
a few days, while the myeloma cells which are usually either producer of 
irrelevant antibodies or non-producers, lack the enzyme HGPRT and thus 
cannot survive in aminopterin-supplemented media. Only the hybrid cells 
have the ability to survive in HAT medium since they have acquired the 
ability to make HGPRT from the spleen cells. The antibody produced by 
such a hybrid cell clone is monoclonal (see Figure 3). 
Since the beginning of monoclonal antibody technology in 1975, 
several modifications have been introduced aiming at optimising the 
product of this useful technique. The first attempt by Köhler and 
Milstein utilised Sendai virus as the fusing agent (Fusogen). 
Polyethylene glycol (PEG) has been introduced as a good and conventient 
fusogen of mammalian cells (Pontecorvo, 1975). Galfre et al (1977) have 
successfully used PEG to produce mouse hybrids secreting monoclonal 
antibodies of choice. The addition of dimethyl sulfoxide (DMSO) to PEG 
solution was shown to enhance the PEG-mediated cell fusion (Norwood et 
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al, 1976). A large number of chemicals as well as different grades of 
PEG have been tried to promote fusion events, but low molecular weight 
PEG (1000-4000) proved to be superior in producing high number of growing 
somatic cell hybrids (Klebe & Mancuso, 1981). 
Pardue et al (1983) have reported a successful in vitro 
immunisation of spleen cells using recently developed technqiues (Luben & 
Mohler, 1980; Reading, 1982). Mouse spleen cells from an unimmunised 
animal have been incubated in thymocyte culture conditioned medium with 
the required antigen. Five days later, these spleen cells have been 
fused with myeloma cells using PEG solution. This technique is 
specially useful in situations where very small amounts (nanograms) of 
antigen are available. 
Another useful development has been the introduction of 
non-secretary myeloma cells. After fusion with these cells, the hybrids 
secrete only the antibody from B-lymphocytes. The desired monoclonal 
antibody secretion seems to be amplified (Köhler et al, 1977; Schulman 
et al, 1978; Kearney et al, 1979). 
In addition to mouse-mouse fusions, many attempts have been made 
to produce hybridomas by rat-rat fusions (Galfre et al, 1979), 
human-human fusions (Cote et al, 1983; Olsson & Kaplan, 1980; Croce It 
al, 1980) and mouse-human fusions (Levy & Dilley, 1978; Schlom et al, 
1980; Cote et al, 1983). However, permanent cultures of 
antibody-producing human B-lymphocytes have also been obtained by 
transformation with Epstein Barr (EBV) virus (Steinitz et al, 1977; 
Crawford et al, 1983 a& b). 
Other developments such as the use of reliable and quick 
screening assays, including Solid-Phase Radioimmunoassay, ELISA, 
Fluorescence Microscopy and Fluorescence-Activated Cell Sorting (FACS) 
techniques have led to the stream lining of monoclonal antibody 
technology (for more detailed information regarding the use of these 
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assays, see Current Topics in Microbiology & Immunology (1978) vol. 81, 
ed. Melchers, Potter & Warner). 
1.5.2 Properties and Limitations of Monoclonal Antibodies 
The main advantages of monoclonal antibodies over conventional 
sera lie in the fact that antibodies of chosen specificity and affinity 
may be produced indefinitely in large and standard amounts. This has 
major implications for diagnostic, therapeutic and preparative applied 
research and also makes them a powerful tool in basic research. 
1) Diagnostic Applications 
Undoubtedly the main advantage of MCAs in diagnosis lies in the 
fact that large amounts of antibody of the chosen specificity may be 
produced indefinitely. Many clinical assays have in the past relied on 
rabbit sera which are variable in titre, specificity, bleed and animal. 
Standardisation of any particular assay is now possible. 
The high specificity gives the advantage of fine diagnosis 
between two similar strains of the same virus or bacterium or two similar 
polypeptide hormones. The antibodies may also be used to find tumour 
associated antigens and to dissect out the aberrant immune response in 
autoimmune diseases. 
2) Therapeutic Applications 
Monoclonal antibodies have considerable potential in the field 
of tumour therapy and have already been used for this purpose. Their 
high specificity makes it possible, in principle, for antibodies to 
tumour-associated antigens to be targetted to tumour cells leaving normal 
tissues unaffected. The antibody can either be used by 
itself, with 
reliance on the complement system to potentiate 
the immune response, or 
associated with drugs or toxins. 
While MCAs may also have potential in the treatment of 
autoimmune disease via anti-idiotype 
therapy or specific suppression of 
the immune response, this field is at an early stage of 
development. 
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3) Preparative Applications 
The most successful preparative use to date of MCAs has been in 
the purification of alpha-interferon (Secher & Burke, 1980). The major 
advantages of monoclonal antibodies in this area lie in that the material 
used for immunisation need not be pure, though the assay must be 
specific. It is possible, at least in theory, to isolate a pure 
component from a very heterogeneous mixture. In practice the response 
is dominated by major Ags and some degree of prepurification is highly 
desirable. 
The ability to select affinity of Ab is also occasionally an 
advantage in preparative techniques. Thus it is possible to select an 
antibody of comparatively low affinity (Mason & Williams, 1980) for 
affinity purification of a readily denatured antigen. 
4) Applications in Basic Research 
The ability of MCAs to react with a single epitope has extensive 
implications in many fields of basic research. It is, at least in 
theory, possible to contemplate a detailed analysis of the distribution 
within and among cell types of any chosen Ag, to investigate its detailed 
function by inhibition with Abs directed to different epitopes, to purify 
it in substantial quantities for detailed structural analysis and 
potentially to isolate the genes coding for its production. In this 
last point it has been suggested that the DNA coding for the antibody may 
even be altered so that an Ab of chosen specificity unobtainable from 
eukaryotic systems may be produced in bacteria. 
The work described in this thesis was directed towards some 
aspects of these basic applications with chromosomal proteins. 
While in theory MCAs have the potential to perform many of the 
functions outlined above, they have limitations relating to their 
monoclonal nature. Amongst these limitiations are firstly, their 
over-specificity, for example they may not always react with all strains 
- 49 - 
of virus. Secondly they may also exhibit under-specificity due to their 
reaction with single and possibly common epitope such as a carbohydrate 
moiety. A third disadvantage may be that it has not yet proved possible 
in practice to emplsy monoclonal antibodies to dissect a complex array of 
antigen. Fourthly, functions dependent on the binding of two Abs in 
close proximity like C'F may not always perform. More detailed accounts 
of the properties and limitations of monoclonal antibodies are given in 
recent reviews (Edwards, 1981; Goding, 1980; Staines & Lew, 1980, 
Yelton & Scharff, 1981; Fazekas de St. Groth & Scheidegger, 1980). 
1.5.3 Monoclonal Antibodies to Chromosomal Proteins 
There is considerable interest in the specific association of 
certain nonhistone chromosomal proteins with actively transcribed DNA and 
the possible role of these proteins in chromosome structure and gene 
expression. The complex and heterogeneous nature of this group means 
that MCAs have great potential to play a major role in dissecting and 
characterising such proteins. The use of immunofluorescent methods has 
helped to locate some such antigens on chromosomes. Saumweber et al 
(1980) have used the indirect immunofluoresc2nce technique to demonstrate 
that amongst a number of MCAs raised against the total nuclear fraction 
from Kc cells of D. melanogaster, fifty eight have shown a highly 
selective staining pattern on polytene chromsomes of the salivary 
glands. Three distinct staining patterns have been recognised. 
Staining, of the transcriptionally active regions, of the phase dark 
bands and of most interbands, have been noted clearly. The molecular 
weights of the individual proteins that react with the monoclonal 
antibodies have been determined. These antibodies 
have shown reactions 
with wide range of proteins of different molecular weights. 
In another 
work, Howard et al (1981) have produced a monoclonal antibody 
that 
recognises a single nonhistone protein of 
62K molecular weight in 
Drosophila. The antibody preferentially stains the 
induced heat shock 
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loci. This study demonstrates that MCAs can be used successfully to 
verify the hypothesis that specific individual NHC proteins are 
preferentially associated with the set of loci that includes both active 
sites and those scheduled to be active at some time during development. 
Among other MCAs produced by Saumweber et al (1980), one has been used in 
further investigation. HUgle et al (1982) have applied this antibody 
(T7), which is known to react with transcriptionally active regions, to 
stain HeLa and PTK2 cells. Using T7; positive immunofluorescent 
staining on interphase nuclei of HeLa and PTK2 cells has been noted. In 
an attempt to localise the antigen for this MCA, three polypeptides of 
molecular weights (44K, 63K and 70K) have been identified. It has been 
concluded that these polypeptides are probably components of two 
different RNP structures. One of these structures is sensitive and the 
other is resistant to RNAse treatment. Also among the monoclonal 
antibodies reported by Saumweber et al (1980), are many whose antigens 
have been found associated with pulse labelled-RNA (Risau et al, 1982). 
The distribution pattern of these antigens has been determined in 
comparison with that of RNA polymerase B by double labelling 
immunofluorescence using as a reference a MCA directed towards subunit 
one of Drosophila RNA polymerase B. The results have indicated the 
existence of two types of RNA-associated particles (Kabisch & Boutz, 
1983). This Ab can prove very useful in locating those NHC proteins 
which have been suggested to play an important role in gene activation 
and are associated with RNA forming particles (Yang et Al, 1981). 
Another group of MCAs directed against a nuclear protein of 53K 
(P53) have been reported. MCAs to (P53) produced by Crawford et al 
(1981) have shown selective reactivity with human cell lines derived from 
spontaneous tumours or transformed in vitro with simian virus 40. In 
contrast, this phosphoprotein has not been detected in normal human 
cells. Othek groups of workers have also described the production of 
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MCA against a 53K transformation-related nuclear protein (De Leo et al, 
1979; Dippold et al, 1981). Dippold et al (1981) have noted that 
expression of (P53) in human cells correlates with the growth level. 
High levels of P53 have been found associated with rapid cell 
proliferation. However, recently Bosslet et al (1983) have described 
another murine MCA reactive with cell nuclei which is not exclusively 
against DNA nor P53 in transformed cells but towards a nucleo-protein 
complex. 
Another group of MCAs have been produced against avian red cell 
nuclear proteins (Kane et al, 1982). Although some of them have shown 
cross-reactivity with a number of polypeptides which may reflect a common 
protein domain, the others provided an interesting specificity for the 
identification and isolation of tissue- and species-specific nuclear 
components. In more recent studies, Vanderbilt and Anderson (1983) have 
been able to produce MCAs from mice immunised with erythrocyte 
chromatin. Tissue specificity has been noted in the immunoreactivity of 
a number of these Abs. Three protein antigens have been localised as 
nuclear while another three proteins are found in the cytoplasm. On the 
other hand another group of MCAs derived from mice injected with 
chromatin from hen oviduct, react strongly with hen oviduct chromatin 
(Vanderbilt & Anderson, 1982). All of these Abs react with chromosomal 
proteins in the absence of nuclear DNA while a large fraction of them 
reacts specifically with oviduct chromatin but not with other tissues. 
Another MCA against NHC protein has been reported recently (Kuo et al, 
1982). 
Teng et al (1982) have raised a highly specific anti HMG-17 
MCA. No cross-reactivity with even the closely related HMG proteins 
(-1, -2 and -14) has been detected. Turner 
(1981) has successfully 
produced another group of MCAs to chromatin-associated proteins from 
human liver, rat liver and a human lymphoblastoid cell line. The 
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subcellular location of target antigens has been examined by 
immunofluorescence. Three of these Abs have given staining patterns 
consistent with the in vivo association of the target Ag with chromatin 
recognising, respectively, the interphase nucleus and metaphase 
chromsomes, the nuclear per'phery, and the mitotic spindle and other 
microtubule-containing structures. Moreover, another four MCAs have 
recognised Ags associated with the intermediate filament network possibly 
due to cytoplasmic contamination. 
.' 
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Concluding Remarks and Aim of the Project 
As is outlined in the introduc(ion, gene expression is a very 
complex process which involves the participation of many components, 
including nucleic acids and various types of nuclear protein. Many of 
these components are present in very small amounts which makes their 
characterisation and purification, as well as the assignment of any 
specific role for each one of them, an extremely difficult task with the 
limited capacity of the available biochemical techniques. Moreover, 
understanding of the structural assembly of chromosomes in metaphase or 
interphase nuclei, and the forces responsible for bringing about the 
fundamental changes in these structures during the cell cycle is limited. 
Many nonhistone nuclear proteins which are involved in different 
aspects of metabolism are still unpurified and uncharacterised. In 
addition, proteins involved in the control of gene expression of cells 
are still largely unidentified. Consequently, highly specific 
antibodies may be a useful tool in the characterisation of individual 
chromosomal components. 
Specific antibodies could be employed in the following ways: 
(1) In basic research, specific antibodies to minor proteins or 
proteins that share common biochemical features which make them 
inseparable or very difficult to purify, could be used to 
characterise and purify them. 
(2) While cell surface antigens are more commonly used as markers to 
classify and type cells in culture there are many situations in 
which the cell surface antigens are not readily resolved. 
Chromosomal antigens may provide better antigenic resolution in 
such cases. 
(3) Monospecific antibodies to proteins associated with the control 
of gene expression could obviously be of great value 
in the 
elucidation of this complex process. 
- 54 - 
(4) Highly specific antibodies against tumour or other 
disease-associated antigens could play a valuable role in 
diagnosis and possibly in treatment. 
Consequently, the research undertaken and presented in this 
thesis is aimed at producing specific antisera and monoclonal antibodies 
to chromosomal components at the basic level of research but with the 
anticipation of possible long term clinical significance. 
Materials & Standard Solutions 
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2. Materials and Standard Solutions 
2.1 Materials 
The materials used during the course of this project are listed 
below with their suppliers names and addresses. 
2.1.1 Cell Culture Materials 
Aminopterin ) 
RPMI-1640 medium ) 
Foetal Calf Serum (FCS) ) 
Penicillin/Streptomycin 
Flow Laboratories, Irvine, 
Scotland 
Glaxo Pharmaceutical, London 
Gentamycin ) Sigma Chemical Co., Dorset 
Hypoxathine ) England 
Thymidine 
Non Essential amino acids (NEAA) ) Gibco Europe, Paisley, 
Fungizone ) Scotland 
GMEM medium 
2.1.2 Disposable Plasticware 
(1) All tissue culture plasticware and disposable plastic bottles 
were supplied by Sterilin, Teddington, England 
(2) Costar plates (24-well and 96-well) were supplied by 
Costar-Inc., Northumbria Biological Ltd., England 
(3) ELISA plates were obtained from Dynatech Laboratories Ltd., 
Sussex, England 
(4) Flexible microtitre plates for radioimmunoassay were supplied by 
Flow Laboratories, Scotland 
2: 1.3 Radiochemicals 
L-[ 
35S]Methionine, 
specific activity 5000i/mmoleand 
125 125 [ I]iodine (carrier-free Na I), 1.9-2.6Ci/mmole were supplied by 
the Radiochemical Centre, Amersham, England. 
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2.1.4 X-ray and Photographic Materials 
X-ray films (Kodak X-Omat S) were supplied by Kodak-Pathe-France 
400ASA Photographic films (Kodak) were purchased from a 
photographic retailer, Glasgow, Scotland. 
2.1.5 Enzymes 
Staphylococcal nuclease (EC 3.1.4.7) was purchased from BCL, 
Bell Lane, Lewes, East Sussex, England. 
Ribonuclease A (EC 3.1.4.22); Bovine Pancrease, and DNAse I (EC 
3.1.21.1) were obtained from Sigma Chemical Co., Dorset, England. 
Trypsin 1: 250 (EC 3.4.21.4); Difco, was supplied by Difco 
Laboratories, PO Box 14B, Central Av., East Molesey, Surrey. 
2.1.6 Chemicals 
The following chemicals were supplied by Sigma Chemical Co., 
England. 
O'-phenyldiamine (OPD), 8-azaguanine (AG), digitonin, 
deoxycholic acid, polyoxyethylene sorbiton monopalmitate 20 (Tween 20), 
N, N, N'N'-tetramethylene diamine (TEMED), tris (hydroxymethyl) aminoethane 
(Trizma Base), N-desacetyl-N-methyl colchicine (Democolcine), 
O'-dianisidine, spermine, spermidine, N-2-hydroxyethylpiperazine 
N'-2-ethane sulfonic acid (HEPES), Coomassie Blue (G-250). 
Other chemicals were supplied as listed below: 
dimethyl sulfoxide (DMSO) 
2-mercaptoethanol ) Koch Light Laboratories, 
dithiothreitol (DTT) ) Bucks, England 
NaCl and KC1 
2,5-diphenyloxazole (PPO) 
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PMSF (phenyl methyl sulfonyl 
fluoride) 
Rohm & Haas, Tyne & Wear, 
Eng land. 
Aldrich Chemical Co. Ltd., 
Gillingham, Dorset, England 
Boehringer, West Germany 
All other reagents were "Analar" grade and were supplied by 
British Drug House (BDH), Dorset, England. 
2.1.7 Cell Lines 
2.1.7.1 Human Cell Lines 
The sources and characteristics of human cell lines which were 
used during the course of this research are listed in Table 2a. 
2.1.7.2 Animal Cell Lines 
The sources and characters of mouse and other nonhuman cell 
lines used during the course of this research are shown in Table 2b. 
2.1.8 Animals 
2.1.8.1 Mice 
BALB/c mice were obtained from the University of Glasgow Colony, 
Animal House, Department of Biochemistry. Mice were propagated by 
sibling mating and entered the study at 2-4 months of age. Both sexes 
were used. 
2.1.8.2 Rabbits 
White Albino, English, Dutch F3X-F2Y and Half Lop rabbits of 
both sexes entered the study at approximately 8-10 months of age. 
2.1.9 Serological Materials 
Commercial rabbit anti-class specific (mouse) immunoglobulin 
antisera were obtained from Bionetics Laboratory Products, supplied by 
Uniscience, Ltd., Cambridge, England. 
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Peroxidase conjugated goat anti-rabbit and rabbit anti-mouse 
were from Miles Laboratories Ltd., Slough, England. 
Affinity purified sheep anti-rabbit IgG and anti-mouse IgG were 
supplied by Dynatech Laboratories, Sussex, England. 
Sheep anti-mouse (anti-Y), donkey anti-sheep and other normal 
sera (rabbit, sheep and goat) were obtained from Scottish Antibody 
Production Unit (SAPU), Wishaw, Scotland. 
Rabbit haemolysin was purchased from Flow Laboratories, Irvine, 
Scotland. 
Guinea pig complement was obtained from Wellcome Diagnostics, 
Dartford, England. 
2.1.10 Sheep Red Blood Cells (SRBCs) 
SRBCs were supplied by Professor Douglas of the Veterinary 
School, University of Glasgow. 
2.1.11 Miscellaneous 
Ficoll, polyvinylpyrolidone (PVP), bovine serum albumin (BSA), 
Protein A and NP-40 were supplied by Sigma Chemical Co., England. 
Nitrocellulose papers were purchased from Schleicher & Schüll, 
West Germany. 
Low molecular weight marker proteins and Sephadex G25 were 
obtained from Pharmacia Fine Chemicals, Uppsala, Sweden. 
Eppendorf tubes (1.5m1 capacity) were obtained from Eppendorf 
Gerätebau, Hamburg, West Germany. 
2.2 Standard Solution and Buffers 
2.2.1 Fusion and Cell Culture Media 
2.2.1.1 RPMI-1640 medituyr 
This was supplied by Flow Laboratories as a dry powder. The 
content of the bottle was dissolved in distilled water as 
instructed by 
the supplier and to it 2g/L of Sodium bicarbonate was added. The pH was 
adjusted to pH 7.0-7.1 with concentrated HC1 and water added up to the 
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required volume. The medium was sterilised by filteration and then 
aliquoted and stored at 4°C. 
The composition of RPMI medium is shown in Table 3. 
Immediately before use, fungizone, penicillin-streptomycin and/or 
gentamycin and the required amount of heat-inactivated FCS were added. 
2.2.1.2 Heat-Inactivation of Foetal Calf Serum (FCS) 
Foetal calf serum was inactivated at 56°C for 45-60 minutes, 
then aliquoted in sterile bottles and stored at -20°C. 
2.2.1.3 HT and HAT media 
The concentration of HT and HAT in medium is as described by 
Littlefield (1964). Hundred fold concentrated HT stock was prepared by 
dissolving hypoxanthine, thymidine and glycine in distilled water. 
Solubilisation of hypoxathine was assisted by stirring the mixture at 
45-50°C for 60 minutes and the warm solution was sterilised by 
filteration aliquoted, and stored at -20°C. 
HT medium was made up by diluting 1. Oml of the sterilised stock 
with 100ml of complete FCS-RPMI medium to give a concentration of 
3x10 
5M, 
lx10-3M and 1.6x10-4M for glycine, hypoxanthine and 
thymidine respectively. 
HAT medium was prepared from HT complete medium with the 
addition, to each 100m1 of this medium, 0.4m1 of 0.1mM stock aminopterin 
supplied by Flow Laboratories to give a final concentration of 4x10-7M. 
2.2.1.4 GMEM medium 
Glasgow modified Eagle's minimum essential medium (GMEM) was 
supplied by Flow Laboratories. It was made up as IOX concentrated 
solution and stored at 4°C. This was diluted and supplemented with 
penicillin/streptomycin, sodium bicarbonate and calf serum (CS) or foetal 
calf serum (FCS) prior to its use. 
The composition of GMEM is given in Table 4. 
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Table 4 Composition of Glasgow modified Eagle's Medium (GMEM) 
Amino acids mg/litre 
L-Arginine HC1 42.12 
L-Cystine disodium salt 28.42 
L-Glutamine 584.6 
L-Histidine HC1 H2O 21.00 
L-Isoleucine 52.46 
L-Leucine 52.46 








D-Ca pantothenate 2.00 
Choline chloride 2.00 
Folic acid 2.00 
i-Inositol 4.00 
Nicotinamide 2.00 
Pyridaxal HC1 2.00 
Riboflavin 0.20 
Thiamine HC1 2.00 
Inorganic salts 
CaC12.2H20 264.9 








Sodium phenol red 17.00 
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2.2.1.5 Polyethylene glycol (PEG) Solution 
2. Og of polyethylene glycol 1500 (PEG 1500) was autoclaved at 15 
lb/sq. in. for 15 minutes, then cooled down to 45-50°C and added to it 
2m1 of filter-sterilised 0.15M-HEPES (N-2-hydroxyethyl piperazine 
N'-2-ethane sulfonic acid) buffer pH 7.5 to give 50% w/v sterile PEG 
solution. 
2.2.1.6 Antibiotics 
Penicillin 105 I. U. /L and streptomycin 100mg/L were used in 
routine culture media from a 100X stock. 
For hybridoma production and cloning media, gentamycin (50pg/ml) 
was used as well as penicillin and streptomycin. Fungizone, 2.51g/ml in 
final concentration, was also added. 
2.2.1.7 Trypan Blue Dye Solution 
This solution was made up by mixing one part of 1% (w/v) trypan 
blue dye and four parts of 1% NaCl (w/v). The mixture was diluted with 
saline, to give 0.1% solution, immediately before use for the Trypan Blue 
Exclusion Test. 
2.2.2 Chromatin and Dehistonised Chromatin Buffers and Solutions 
All solutions and buffers were prepared then stored at 
-20°C. PMSF was added immediately before use from X100 stock in DMSO. 
2.2.2.1 Solution (1) 
0.34M Sucrose 
10.0mM tris-HC1 pH 7.5 
1.0mM EDTA 
1.0mM PMSF 
0.1% Triton X-100 
2.2.2.2 Solution (2) 
80.0mM NaCl 
20.0mM EDTA 
l. 0mM PMSF 
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2.2.2.3 Solution (3) 
0.34M NaCl 
2.2.2.4 Solution (4) 
7.5M Urea 
3. OM NaCl 
1.0mM MgCl2 
0.15M phosphate buffer pH 6.0 
2.2.2.5 2M Salt buffer 
2. OM NaCl 
10.0mM tris-HC1 pH 6.0 
1.5mM MgC12 
1.0mM PMSF 
0.1% Nonidet-P-40 (NP-40) 
2.2.2.6 Sucrose buffer 
1. OM Sucrose 
2. OM NaCl 
10.0mM tris-HC1 pH 6.0 
1.5mM MgC1 2 
1.0mM PMSF 
0.1% Triton X-100 
2.2.2.7 SSC buffer 
150.0mM NaCl 
15.0mM Sodium citrate buffer pH 5.5 
2.3 Immunoassay Buffers 
2.3.1 ELISA Buffers 
2.3.1.1 Carbonate/EDTA Buffer (Antigen Coating Buffer) 
1.41mM Na2CO3 
1.79mM NaHCO3 ) pH 9.6 
1.00mM EDTA 
0.02% NaN3 
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2.3.1.2 Citrate-phosphate Buffer 
113.8mM Na2HPO4 
46.45mM Citric acid ) pH 5.5 
2.3.2 Complement Fixation Assay Buffers 




0.10M tris base 
approximately 6.6m1 of concentrated HCl added to give a final pH 
7.4 in a total volume of 1L 
2.3.2.2 Working diluent (W. D. ) 
100ml Stock diluent 
1. Og BSA 
Distilled water up to 1 litre 
2.3.3 Saline Buffers 
2.3.3.1 Tris-saline (TN) 
50.0mM 
150.0mM 










KH 2PO 4 pH 7.3 
Methods 
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3. METHODS 
3.1 Preparation of Nuclei and Chromatin 
3.1.1 Preparation of Nuclei 
3.1.1.1 The method of Chauveau et al 
This was completed after the procedure of Chauveau et al (1956) 
as modified in "Methods in Enzymology" (1967). 
Nuclei were prepared from human cell lines. All steps were 
done at 40C. 
Cells were washed in PBS and then homogenised in 0.33M sucrose - 
4mM CaC12. The homogenate was centrifuged at 600xg for 10 minutes to 
pellet the nuclei which were resuspended in (0.25M-sucrose, 3mM-CaC12), 
homogenised and spun at 1500xg for 5 minutes. The pellet was suspended 
in nine volumes of (2.4M-sucrose, 3mM-CaC12) and homogenised in a tight 
fitted Teflon pestle in a mechanical homogeniser, then centrifuged at 
45,000xg for lh. The pellet was collected, resuspended in 0.25M sucrose 
- 3mM CaC12, centrifuged at 600xg for 10 min. The nuclei were 
collected as a pellet and washed with PBS. 
3.1.1.2 Polyamine method 
Nuclei were prepared following the method of Blumenthal et al 
(1979), as modified by Lewis and Laemmli (1982). 
Solution (I) 












Cells were collected, washed once and soaked at room temperature 
for 15 min in 100mM-tris-HC1 pH 
7.4 containing 100mM-NaC1 and 
-6B- 
5. OmM-MgC12. The mixture was centrifuged at 1400xg for 5 min. The 
pellet was collected, washed three times at 25°C in 15. Oml of solution 
(I). The cells were collected after each wash by centrifugation at 
1400xg or 5 min. Swollen cells (pellet) were resuspended at 4°C and 
vortexed for 15 sec in 10.0 ml of twice concentrated solution (I) 
containing 0.1% digitonin and lOpg/ml of RNAase A. All subsequent steps 
were carried out at 4°C. The cells were lysed by gentle (5 strokes) 
and vigorous (5 strokes) homogenisation in a tight fitting pestle. The 
homogenate was centrifuged at low speed (180xg) for 5 min and the 
supernatant was collected, layered gently onto 37. Oml of a 15-60% (w/v) 
sucrose gradient in solution (II) and centrifuged at 4000xg for 5 min 
then at 1100xg for 30 min. 
Cytoskeletal materials remained on top and nuclei were collected 
as a pellet. 
3.1.2 Chromatin Preparation 
This was carried out after the procedure of Briggs et al (1979) 
with minor modifications. The solutions used are described in 2.2.2 and 
all steps were performed at 4°C. 
Cells were washed with solution (1) and lysed by gentle 
homogenisation (1-2 strokes) in 5 volumes of the same solution. The 
homogenate was spun at 5000xg for 5 minutes. The supernatant referred 
to as cytoplasmic fraction was stored at -20°C. The pellet was 
collected, suspended in 3 volumes of solution (2) and homogenised with a 
Teflon tight-fitting pestle until the nuclei appeared to be broken when 
examined under the microscope. The mixture was spun at 8000xg for 10 
minutes and the pellet was collected, resuspended in 3 volumes of 
solution (2) lacking PMSF and homogenised again for few strokes. The 
homogenate was centrifuged at 36,000xg for 15 min. The pellet was 
extracted by homogenisation in solution (3) and centrifuged at 36,000xg 
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for 15 minutes. The chromatin was collected as a pellet, resuspended in 
one volume of 100-fold diluted SSC buffer and pelleted by centrifugation 
at 36,000xg for 15 minuts. 
3.1.3 Dehistonised Chromatin 
3.1.3.1 2M Salt extracted chromatin 
The chromatin prepared in 3.1.2 or nuclei in 3.1.1 were further 
extracted by 2M-salt buffer. 
The pellet from 3.1.1 and 3.1.2 was resuspended in 3 volumes of 
2M-salt buffer described above in 2.2.2.5 and homogenised for several 
strokes with a tight fitting pestle. Each 2.5m1 of the homogenate was 
layered gently on the top of 2.5m1 of sucrose buffer (2.2.2.6) in 5m1 
capacity cellulose nitrate centrifuge tube. The tubes were spun at 
140,000xg in SW50.1 rotor for 90 minutes. The supernatant was decanted 
gently and the pellet washed twice with double distilled water. 
3.1.3.2 2M Salt - 5M urea extracted chromatin 
Chromatin preparations as described above in Sections 3.1.2 and 
3.1.3.1 were further extracted by 2M salt - 5M urea following the 
procedure of Briggs et al (1979) with minor modifications. 
Chromatin or 2M salt extracted chromatin was suspended in 
2mM-tris-HC1 pH 7.5, and the concentration of DNA was adjusted to give 
0.5mg/ml. Two volumes of solution (4) (2.2.2.4) were added and the 
solution was stirred for 2h at 4°C then spun at 100,000xg for 24-36h. 
The supernatant was decanted carefully and the sides of the tubes were 
rinsed three times with double-distilled water containing 0. lmM-PMSF. 
The pellet was resuspended in 2mM-tris-HC1 pH 7.5, homogenised then 
stirred at 4°C overnight. The suspension was centrifuged at 1400xg 
for 5 minutes and the dehistonised chromatin was collected as supernatant. 
- 70 - 
3.1.4 Bhorjee and Pederson's Method of Preparation of Nucleoli and 
Nonhistone Chromosomal Proteins 
This was completed after the procedure of Bhorjee and Pederson 
(1973). The experiment was performed at 0-40C. 
The cells were washed once with PBS buffer and centrifuged at 
500xg for 5 minutes. The pellet was suspended in TNM hypotonic buffer 
(lOmM-tris-HC1 pH 7.0, lOmM-NaCl and 1.5mM-MgC12). The suspension was 
allowed to stand for 10 minutes then homogenised by a tight-fitting 
Teflon homogeniser (10 strokes). The nuclei were collected by 
centrifugation at 1000xg for 3 minutes and washed three times in 10 
volumes of TNM buffer. The clean nuclei were resuspended at 4x107 per 
ml in TNM buffer containing lmM-PMSF and disrupted by brief sonication 
(4x15 seconds at a current of 1.5A1 The sonicate was then layered on 
top of equal volume of 30% sucrose bed in TNM buffer and centrifuged at 
4500xg for 15 minutes. The nucleoli were collected as a pellet. 
The material which remained on top of 30% (w/v) sucrose bed was 
collected and aliquoted into 10ml portions. Each aliquot was then 
layered gently on the top of 27m1 of 60% sucrose solution (w/v) in 
TN-EDTA buffer (2.5mM-tris-HC1 pH 7.2, lOmM-NaCl & 25mM-EDTA) and 
centrifuged at 131,000xg for 90 minutes in SW27 Beckman rotor. The 
pellet was suspended in 0.5-lml of TNM buffer, and dialysed overnight 
against several changes of TNM buffer. Histones were extracted from the 
dialysed chromatin by adding H2SO4 to a concentration of 0.2M and 
allowing the sample to stand at 4°C for 30 min. The extract was then 
centrifuged at 37,000xg for 15 minutes. The pellet was re-extracted 
again with 0.2M-H2SO4 and centrifuged. The nonhistone fraction was 
pelleted and resuspended in (2.5mM-tris-HC1 pH 7.2 and lOmM-NaC1), 
dialysed against the same buffer overnight. 
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3.2 Animal Procedures 
3.2.1 Preparation of immunogen in complete Freund's Adjuvent (CFA) 
Dehistonised chromatin obtained by procedure 3.1.3 was suspended 
in PBS. The required amount of immunogen in 50-100Nl was then mixed 
with equal volume of CFA. The mixture was vortexed to make an emulsion 
which was passed through narrow gauge (G21-G23) needle. 
3.2.2. Injection of Mice 
Individuals were immunised i. p. with 100-150pl of immunogen 
(measured as 100pg of DNA) as an emulsion in CFA prepared as reported in 
3.2.1. The immunisation was repeated twice in CFA with 10-14 days 
interval in between. A booster of 100pg immunogen in PBS was given i. p. 
14-18 days after the second injection. The animals were sacrificed 
under anaesthetic (ether) 4-5 days after the booster and spleens were 
collected. 
3.2.3 Injection Protocol of Rabbits 
Individual rabbits were given (70-150Ng) of immunogen, (measured 
as DNA content) emulsified in CFA, subcutaneously (S. C. ) in the back of 
the animal on 2-3 sites. Two S. C. injections were given in CFA two 
weeks apart, followed by a booster of 100pg of immunogen in PBS 14-20 
days after the second injection. The booster was injected i. v. in the 
ear. 
3.2.4 Fluid Withdrawal 
3.2.4.1 From Mice 
3.2.4.1a Blood withdrawal 
Blood from mice was withdrawn from the tail 3-4 days after 
booster. The end of the tail was cut (2mm) by sterile scalpel blade 
while the animal was under anaesthesia. A few drops of blood could be 
collected by massaging the tail gently. 
3.2.4.1b Ascitic Fluid withdrawal 
Ascitic fluids were withdrawn from the intraperitoneal cavity of 
mice by a syringe attached to 21G gauge needle. The anaesthesised mouse 
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was laid on the back and carefully a small incission was made through the 
skin without cutting the peritoneal membrane. A sterile needle (G21) 
was then inserted and the fluid was withdrawn slowly making sure that the 
needle did not touch the viscera. 
3.2.4.2 From Rabbits 
Rabbits were bled from the marginal vein on the ear. The area 
was cleaned and shaved, then a small cut was made in the vein by a 
sterile scalpel blade. The blood was drained by massaging and pressing 
on the vein to stop the return blood flow. 
3.3 Lymp hocyte H ybridoma Production and Tissue Culture 
3.3.1 Pre paration of Myeloma Cells 
Myeloma cells 653 (X63-Ag-653) reported by Kearney et al (1978) 
were obtained from Flow Laboratories, Scotland. 
The cells were grown in RPMI 1640 medium supplemented with 10% 
FCS, 20pg 8-azaguanine, fungizone, penicillin and strptomycin, at 37°C 
c 
in humidified 5% C02 incubator. Cells for fusion were collected from 
culture medium and examined for at least 95% viability. 
3.3.2 Preparation of Spleen Cells 
Spleen cells as feeder layer and for fusion from immunised 
BALB/c mice were prepared by the same method. Mice were washed with 
alcohol and dissected by sterile equipment. Spleens were collected from 
the mice, washed twice with sterile serum-free RPMI medium containing 
fungizone and gentamycin as described in 2.2.1.6. The spleen cells were 
released by teasing the spleen with several injections of RPMI medium. 
The cells were then washed 3-4 times with RPMI. 
3.3.3 Assessment of Cell Viability and Counting 
Cell viability was examined by Trypan Blue exclusion test. An 
aliquot of cell suspension was mixed with an equal volume of trypan blue 
dye solution (2.2.1.7). The number of live and dead cells were counted 
in a Neubauer Haemocytometer. 
Routine cell counting was also done in a haemocytometer. 
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3.3.4 Feeder Layer 
Spleen feeder cells were prepared as described in 3.3.2. A 
known number of cells were suspended in 20% FCS-supplemented RPMI medium 
(with or without HT supplements as described in 3.3.5 and 3.3.6) and 
dispensed at a concentration of 106 cells per ml. 0.5 ml of this cell 
suspension was placed in each well of 2 ml capacity (or 0. lml in 0.25m1 
capacity well) 24 hr before fusion or cloning. 
3.3.5 Fusion Protocol 
This was carried out by the procedure of Pontecorvo (1975) with 
minor modifications, using HEPES buffer as described by Klebe and Mancuso 
(1981). 
Spleen cells (lxlO8) were mixed with (1x107) myeloma cells 
in serum-free RPMI medium, washed and centrifuged at 500xg for 5 min. 
The supernatant was carefully and fully aspirated, and the pellet was 
tapped gently. To the pellet, lml of sterile and pre-warmed (37°) 50% 
(w/v) PEG solution (2.2.1.5) was added slowly over a period of 60 seconds 
with very gentle shaking. The mixture was incubated at 37°C for 60 
sec and then diluted slowly with 5ml of warm RPMI medium over a period of 
3-5 min with gentle shaking. The mixture was again incubated at 37°C, 
and left for 5 min, after which 5ml of warm RPMI medium was added and the 
suspension was spun at 500xg for 5 min. 
The cells were then gently resuspended in RPMI 1640 medium 
containing 20% (v/v) FCS, hypoxanthine, thymidine and glycine (HT 
medium). Half a millilitre of this suspension was added to each well of 
24-well costar plate (2ml capacity) prelayered with a spleen cell feeder 
layer 5xl05 cells per well as described in 3.3.4, and the plates were 
incubated at 37°C in humidified CO2 incubator at a density of 5x105 
myeloma cells/ml. After 6-18 h incubation in HT medium, 0.5m1 of HT 
medium containing three times concentrated aminopterin was added to each 
well, and the plate was again 
incubated in the Co2 
incubator for one 
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week. The cells were fed on days 8 and 11 by removing lml of the medium 
without disturbing the cells, and then lml of fresh HAT medium (2.2.1.3) 
was added slowly. 
3.3.6 Cloning by Limited Dilution 
Screening for positive wells by ELISA was carried out between 
day 15 and 18 after fusion as described in 3.4.2. Cells in the wells of 
interest were cloned (first cloning) by limited dilution in HT medium in 
a 96-well costar plate prelayered with spleen feeder cells (106 
cells/well). The limiting dilution was performed at 1 cell per well or 
less. The plates were examined under the microscope after 5-7 days. 
Wells containing single foci were marked and tested on day 15-20 after 
cloning. The positive clones were recloned again (second cloning). 
The positive clones from the second cloning again either expanded or 
recloned for 3rd or 4th cycle. 
Positive single clones at this stage were considered monoclonal 
and propagated in FCS-supplemented RPMI. 
3.3.7 Freezing of Cells 
Cells were suspended in 1.0ml aliquots containing 2x106 cells 
per ml in RPMI-1640 supplemented with 10% (v/v) FCS, 10% (v/v) DMSO in 
1.5m1 capacity sterile bottles. The aliquots were frozen at -70° 
overnight, then transferred to Gas-phase liquid nitrogen freezer. 
3.3.8 Thawing of cells 
Frozen cells were quickly thawed in a 37°C water bath and then 
layered onto the top of 5. Oml of 50% (v/v) FCS in RPMI in a sterile 
bottle. The bottle was centrifuged at 300xg for 5 min, and the cells 
were collected and grown in 30-40% (v/v) FCS-RPMI. Half the medium was 
changed after 24-48 hr with 20% (v/v) FCS-RPMI and then 
the cells were 
fed with 10% (v/v) FCS-RPMI as necessary. 
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3.3.9 Propagation of Monoclonal Antibodies 
3.3.9.1 In Vivo 
In order to establish the monoclonal hybridoma cell lines as 
tumours in BALB/c mice, the animals were given a primary injection of 
0.4m1 of Pristane (2,6,10,14-tetramethyl pentadecane) per mouse 
intra-peritoneally (i. p. ) at least seven days before the cells were 
injected. 
_ 
106-107 Myeloma cells were suspended in 50-100pl of PBS 
and injected intra-peritoneally (i. p. ) into each mouse. ' The animals 
were examined daily after 14 days for the development of Ascites 
tumour. Ascitic fluid was drained as described in Section 3.2.4.1b 
3.3.9.2 In vitro 
Hybridoma (or Myeloma) cells were grown in complete RPMI-10% 
(v/v) FCS medium in sterile flasks at 370C in a humidified 
C02 incubator and were subcultured when required before fully 
confluent. Supernatant (MCA) was collected and stored at -20°C. 
3.3.10 Routine Culture 
Other cell lines were grown in large scale cultures in 2.5L 
sterile roller bottles. The bottles containing the cultures were gassed 
to give 5-7% (v/v) CO20 sealed and placed on a mechanical rolling 
device in a 37°C hot room. 
The appropriate culture media for each cell line is shown in 
Table 2. 
3.4 Assays of Monoclonal Antibodies and Other Antisera 
3 . 4.1 Radioimmunoassay 125 
Affinity purified sheep antiglobulins were labelled with 1 
using the chloramine T method as described in 3.5.3. Flexible 
microtitre plates were used and the procedure was carried out in 
duplicate. Protocol: 
1) l00N1 (100pg/ml) of chromatin in carbonate-EDTA buffer 
(2.3.1.1), was placed in each well and left overnight at 4°C. The 
plate was then washed twice with 
TN buffer. 
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2) 150pl of 5% (v/v) goat serum plus 3% (v/v) BSA in TN buffer 
(GS-BSA-TN) was added to each well to saturate any remaining non-specific 
binding sites and the plate was left at room temperature for lh, then 
washed with TN buffer, 
3) 80pl of culture fluid (supernatant) or the required dilution of 
antisera or ascitic fluid in (GS-BSA-TN) was added to each well. The 
plates were incubated at 4°C overnight (o. n. ), washed 3-4 times with TN 
buffer. 
4) 70pl of 
1251-anti-gamma-globulin 
(106 c. p. m. /ml) in 
GS-BSA-TN buffer was added to each well and the plate was incubated at 
room temperature for two hours (or overnight at 4°C), wash 4-5 times in 
TN buffer. The wells then dried, cut, and counted in an LKB minigamma 
counter. 
5) Controls: Antigen, antibody and blank (GS-BSA-TN) controls were 
run simultaneously on the same plate. 
3.4.2. Enzyme Linked Immunosorbent Assay (ELISA) 
The ELISA technique which was first outlined by Engvall and 
Perlman (1971) and then modified for the optimal conditions as described 
by Engvall (1980) was adopted. The reaction was performed in a 
specially coated ELISA plate (Dynatech). 
The protocol was as described for radioimmunoassay in Section 
3.4.1, except after step three; 70p1 of peroxidase linked anti-mouse IgG 
in GS-BSA-TN buffer (1/500) was added and the plate was incubated for 2h 
at 4°C (or lh at room temperature) and washed 4-5 times with TN 
buffer. To the wells, 5Opl of o-phenyl-diamine (OPD), as a substrate 
(0.4mg/ml) in citrate-phosphate buffer (2.3.1.2) containing 0.01% fresh 
H2O21 was added and the plate was kept in the dark for 10-20 minutes 
or till the colour developed in the wells. The reaction was terminated 
by the addition of 100pl of 4M H 2SO4 and the A492 of the solution 
was read in a Multiskan 
(Flow) microtitre reader. Controls as described 
in 3.4.1 were also prepared on the same plate. 
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3.4.3 Complement Fixation Assay (C'F Assay) 
This was completed following the method of Wasserman and Levine 
(1961) with minor modifications. 
3.4.3.1 Preparation of complement (C') 
Guinea pig Lyophilised complement (Wellcome) was used. The 
contents of each bottle were dissolved, as recommended by the supplier in 
5m1 of chilled distilled water at 0°C, then aliquoted in cold (0°C) 
Eppendorf tubes and stored at -700 for a maximum period of three months. 
When needed, the aliquots were thawed at 0°C and diluted with 
chilled working diluent (2.3.2.2) and kept at 0°C for up to lh. The 
dilution required was estimated by incubating the dilute complement 
(0.6m1) with 0.2ml of activated SRBCs (3.4.3.3. ) at 37°C with 
shaking. The maximum dilution of complement which gave full cell lysis 
within 15-20 mins was selected. The maximum dilution was routinely 
found 1/500. 
3.4.3.2 Preparation of Antibody-Antigen-Complement Mixture (Ab-Ag-C') 
All steps were carried out at 0-4°C. 
Plastic tubes contained serial dilution of antisera (O. lml each) 
in working diluent were set up in a duplicate samples. Chromatin 
samples as prepared in 3.1.2 were suspended in working diluent to give 
100pg of DNA per ml and O. lml of this suspension was added to each 
tube. To this mixture, 0.6ml of 1/500 dilution of complement was added 
and the mixture was incubated at 4°C for 18-20h. 
Antibody control for each dilution, chromatin controls (Ag), 
working diluent, and complement controls were prepared and incubated at 
the same time. 
3.4.3.3 Activation of Sheep Red Blood Cells (SRBCs) 
Fresh sheep red blood cells (supplied routinely every 28 days) 
were washed 2-3 times with working diluent, centrifuged at 300g for 5 
mins. The cells were then suspended 
in working diluent (approximately 
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1/100) so that 0.2m1 of this suspension when lysed with 0.8m1 of water 
gave an A413 of 0.9-1.1. 
To this cell suspension rabbit antisheep haemolysin was added to 
t 
a concentration of ipl/ml of suspension. The mixture was incubated at 
37°C for 30 min with occasional shaking, then cooled and used the same 
day. 
3.4.3.4 Determination of the percentage of complement fixed by the 
Antibody-Antigen Complex 
After 18-20h, the tubes in 3.4.3.2 were put on ice and 0.2m1 of 
activated SRBCs was added to each one. The tubes were incubated in a 
shaking water bath at 37°C and watched for complete cell lysis in 
complement control tubes. 
The incubation was then extended for another 2-3 min, and 
terminated by placing the tubes on ice-bath. The tubes were spun at 
500g for 5 mins at 4°C. The supernatants were collected and read at 
A413. 
The percentage of Complement Fixation (% C'F) is calculated as 
follows: 
A413 Complement Control Complete Lysis - A413 test sample 
CIF x 100 
A413 Complete Lysis 
3.4.4 Determination of the pH Effect on Monoclonal Antibody in ELISA 
This was completed as described in 3.4.2, except that serial 
dilutions of Ab were added in different pH ranges. A range of pH 3 to 
pH 12 was selected using the Universal Buffer described by Britton and 
Welford (1937) added to it NaCl to give saline concentration. 
The universal buffer was made 0.02857M with respect to boric 
acid, citric acid, 5,5'-diethyl barbituric acid, potassium dihydrogen 
phosphate, buffered with NaOH. To this buffer NaCl was added to give a 
concentration of 0.14M. 
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3.4.5 Competition Assay 
The competition assay was carried out to allow two (or more) 
different or homologous antigens to compete with each other for the 
antibody binding site. 
In small volumes (150pl) of TN buffer containing 0.2% BSA, 
serial dilution of different concentrations of antigen (Agl) were 
incubated with fixed amounts of antiserum or monoclonal antibody in small 
glass tubes at 4°C for 18-24h. The tubes were centrifuged briefly at 
500xg for 3 min. The unabsorbed antibody (supernatant) was then 
collected gently and 50pl from each tube was added to the wells of ELISA 
plate. The plate was precoated 10. ONg of HeLa chromatin (Ag2) and 
blocked with GS-BSA-TN buffer as described in Section 3.4.2. The 
procedure was continued as in Section 3.4.2. 
3.4.6 Enzyme Treatment of HeLa Chromatin Reacting with Monoclonal 
Antibody 
The procedure of Turner (1981) was adopted with minor 
modifications. On an ELISA plate, different concentrations of HeLa 
chromatin were immobilised as described under Section 3.4.2. The plate 
was then washed with TN buffer. Enzymes (50pl) were added to the wells 
in the appropriate concentrations and buffer systems. The wells were 
incubated at 25°C for 60 min (except for RNAase-A which was incubated 
at 370C) in a humid atmosphere. The wells were then washed 5 times 
with TN buffer and blocked with BSA-GS-TN buffer for lh at room 
temperature. The plate was washed twice with TN buffer and a fixed 
amount of monoclonal antibody was added to each well. The procedure was 
continued as described under Section 3.4.2. 
Enzyme-untreated control was also run simultaneously. 
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The enzyme concentrations and the appropriate buffers are shown 
below: 
1) DNase-I (EC 3.1.2.1.1) 
500pg per ml in: 
50mM acetate buffer (pH 5.0) 
4.2mM MgCl 2 
1.0mM PMSF 
2) RNase-A (EC 3.1.4.22) 
200pg per ml in: 
10. OmM tris-HC1 (pH 7.5) 
Boiled for 10 min and cooled down immediately before use. 
3) Trypsin (EC 3.4.21.4) 
200pg per ml in: 
10.0mM tris-HC1 (pH7.6) 
3.5 Immunological and Immunochemical Methods 
3.5.1 Chemical Fractionation of Antibodies 
Ammonium sulphate precipitation was carried out using the method 
outlined in the EMBO Laboratory Manual (1979). 
Saturated ammonium sulphate solution was prepared by mixing 75g 
of solid on a total volume of 100ml of distilled water. The mixture was 
stirred for 1-2h at room temperature then stored at 4°C. 
Culture supernatants (or a known volume of ascitic fluid or 
antiserum, diluted 4 times with PBS) were placed on ice for 10 min. an 
equal volume of saturated ammonium sulphate was added dropwise with 
constant stirring at 0-40C over a period of several minutes. The 
mixture was left on ice for 30-60 min and then centrifuged at 5000xg for 
10 min. The pellet was collected in a small volume of buffer A 
(10mM 
tris-HC1 pH 7.8 - 40mM NaCl), and transferred 
into deionised dialysis- 
tubing. Dialysis was carried out agäinst 100 volumes of buffer B(20mM 
tris-HC1 pH 7.8 - 20mM NaCl). The 
buffer was changed every 3h and a 
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total dialysis of at least 9h was allowed, after which the sample was 
collected and spun at 15000x9 for 10 min. The supernatant was collected 
and its A280 measured. 
3.5.2 Analysis of Biosynthetically Radiolabelled Immunoglobulin 
3.5.2.1 Radiolabelling 
Cells for labelling were healthy with a viability range of 
95-100%. Hybrid cells 1.5x106 per millilitre were suspended in 
methionine free-RPMI medium supplemented with 10% dialysed 
heat-inactivated FCS. [ 35 S]-methionine solution was evaporated to 
dryness using a stream of nitrogen in a fume hood or under vacuum. The 
dry amino acid was redissolved in 10-20N1 of methionine-free RPMI and 
added to the cell suspension to give a final concentration of 150NCi/ml. 
The cells were grown in CO-humid incubator at 37°C. Complete 
RPMI-10% FCS (50pl) was added to the cell suspension 5h after the start 
of incubation which was continued for a further 11-19h. The cell 
suspension was then centrifuged at 500xg for 5 min. The pellet was 
collected for the analysis of the internally labelled-Ig. The 
supernatant was either frozen at (-70°C) or used for 
immunoprecipitation. 
Foetal calf serum was dialysed against several changes of PBS at 
4°C for 18h. 
3.5.2.2 Cell Lysis and Immunoprecipitation 
3.5.2.2a Cell lysis 
The cell pellet was suspended in 0.4ml of cold TKM (100mM 
tris-HC1 pH 8.0,100mM KC1 and 5mM MgC12) buffer. Triton X-100 (10% 
in TKM), 50N1, was then added and the mixture was left at 
0-40C (with 
occasional gentle shaking for 10 min 
to allow cytoplasmic lysis to 
occur. The lysate was then centrifuged at 
500xg for 10 min to pellet 
nuclei and debris. To the collected 
supernatant, 5011 of 10% 
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deoxycholate, 5% SDS in TKM was added. The cell lysate was used 
immediately for immunoprecipitation. 
3.5.2.2b Immunoprecipitation 
Supernantant (250pl) from 3.5.2.1 was added to 250x1 of TKM 
buffer containing 2% triton X-100,2% deoxycholate and 1% SDS. To 90N1 
of this mixture (or cell lysate mixture in 3.5.2.2a), 1-2p1 of rabbit 
anti-mouse antiserum was added. The mixture was incubated at 40C for 
30-60 min, then 10pl of goat anti-rabbit antiserum was added and the 
mixture was incubated overnight at 4°C. Control samples containing 
normal rabbit serum were also run simultaneously. 
After the overnight incubation, 50N1 of 0.75M sucrose in TKM 
containing 1% triton X-100,1% deoxycholate and 0.5% SDS (TKMD) was added 
and the mixture was layered gently on top of a 0.6m1 of two step sucrose 
gradient (1M - 0.5M) in TKMD. The gradient was centrifuged at 4000xg 
for 10 min at 4°C, and the top layer was then aspirated gently leaving 
the pellet which was washed with TKM and collected again. 
3.5.2.3 Polyacrylamide Gel Electrophoresis Analysis 
The pellet collected from 3.5.2.2b was dissolved in the 
appropriate volume of sample buffer described in 3.6.1, boiled for 5 min 
then cooled and applied to 10% gel. The gel contains 0.8: 30 acrylamide 
mixture and was run at constant current of l5mA, stained and destained as 
described in Section 3.6.2. 
3.5.2.4 Fluorography 
This was carried out after the procedure of Bonner and Laskey 
(1974) with minor modifications. 
The destained gel which contains the radiolabelled proteins was 
soaked in DMSO (5 times the volume of the gel) for 30 min with gentle 
rocking. This was repeated 3 times with fresh DMSO. The gel was then 
impregnated (with gentle rocking) in four volumes of scintillation 
solution of 20% w/w 2,5-diphenyloxazole 
(PPO) in DMSO for 45-60 min. 
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After this immersion in scintillator, the gel was washed with several 
changes (10 volumes) of deionised (or distilled) water over a period of 
lh. The gel was then dried under vacuum in a gel dryer (Bio-Rad). 
In a dark room, X-ray film (X-Ornat) was placed in contact with 
the dry gel and exposed at -700C for 4-18h in a dark wrap. The film 
was developed and fixed in the dark according to the instruction of the 
developer supplier. 
3.5.3 Antibody Radiolabelling 
The methods of Greenwood et al (1963) were adopted with minor 
modifications. 
Affinity purified sheep anti 
'y-globulin (Dynatech) was diluted 
in 0.5M phosphate buffer pH 7.5 to give a concentration of 200Ng IgG per 
200p1. Sodium iodide (125I), lmCi (carrier-free) was added followed 
immediately by 100Ng/100Nl of freshly prepared chloramine T in 0.5M 
phosphate buffer. The mixture was shaken frequently over a period of 60 
sec. The reaction was stopped by the addition of 125pg of sodium 
metabisulphite in 100p1 of 0.05M phosphate buffer pH 7.5 and the mixture 
again left for 60 sec with shaking. Potassium iodide 2mg in 200pl of 
0.05M phosphate buffer was added as a carrier for 
125I 
ions followed by 
400111 of 0.2% BSA in 0.05M phosphate buffer. The mixture was then 
passed through 1.5xlOcm pre-equilibrated sephadex G25 column and the 
sample was eluted. 
Pre-equilibration and elution were performed by passing 0.1% BSA 
in 0.05M phosphate buffer through the column. Fractions of 0.5 - 0.7m1 
were collected. 
PMSF was added to the phosphate buffer immediately before use to 
give a final concentration of 0.1mM. 
A typical elution profile is shown in Figure 4. 
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3.5.4 Immunoblotting 
3.5.4.1 ELISA Technique 
Antigens (proteins) transferred to nitrocellulose paper (3.6.3) 
were detected by Enzyme Linked Immunoassay (ELISA) as described by Towbin 
et al (1979). 
Nitrocellulose paper after blotting was washed with TN buffer, 
and the paper was then incubated with 3% BSA - 5% GS in TN buffer 
(GS-BSA-TN) for lh at room temperature to block the nonspecific sites. 
The paper was washed with TN buffer and incubated with the first antibody 
(antiserum, ascitic fluid or culture medium) diluted in GS-BSA-TN buffer 
at 40C overnight. The paper was then washed 3 times with TN buffer 
and incubated for 2h at room temperature with peroxidase conjugated 
second antibody (anti-gamma-globulin) diluted 1/500 - 1/700 in GS-BSA-TN 
buffer and washed 4-5 times with TN buffer. To visualise the antibody 
reaction the nitrocellulose paper was incubated in the dark with 
o-dianisidine 0.0025% w/v ( as a substrate) in TN buffer containing 0.01% 
H202. The colour developed within 10-20 min and the reaction was 
stopped by washing the paper in a large volume of TN buffer or deionised 
water. 
3.5.4.2 Immunoblotting by Radiolabelled Antibody 
The practical principle was essentially the same as that 
described in 3.5.4.1 except that the second Ab was 
125I-labelled 
affinity purified antiglobulin (3.5.3). 
The nitrocellulose paper was incubated with the second antibody 
at 106c. p. m. 
125I 
per ml of GS-BSA-TN for 2h at20C. The paper was 
then washed 4-5 times with TN buffer, dried by blotting between filter 
papers and then autoradiographed using Kodak X-ray (X-Omat S) film. 
3.5.4.3 Immunoblotting by 
125I-Protein A Method 
This was performed after the procedure of Battiger et al (1982) 
using Tween 20 as blocking agent as modified 
in our laboratory 
(A. M. Campbell, personal communication). 
-86- 
The nitrocellulose paper after protein transfer was washed 
several times in (20mM tris-HC1 pH7.2,0.15M NaCl, 0.5mg/ml NaN3,0.5% 
Tween 20) for 30-60 min to block non-specific sites. The blot was then 
incubated (at 4°C overnight) with first antibody (the mouse monoclonal) 
diluted in the same buffer. The paper was washed 5 times (for 30 min) 
with the blocking buffer and then incubated (for 4h/at room temperature) 
again with second antibody (anti-mouse IgM H+L) diluted 1/100 in the same 
buffer. The nitrocellulose paper was washed again 5 times as described 
above and then allowed to react with 
125I-protein A (2x107 cpm/ml) 
for lh, washed (5-10 times over 30-60 min in the blocking buffer), dried 
by blotting between filter papers then autoradiographed using Kodak X-ray 
(X-Omat S) film. 
3.6 Gel Electrophoresis and Protein Blotting 
3.6.1 Slab Gel Electrophoresis 





Separating gel buffer 
Stacking gel buffer 
Running (Reservoir) buffer 
3M tris-HC1 pH 8.8 
0.5M tris-HC1 pH 6.8 
4) Sample buffer 
(0.025M tris base) 
(0.192M Glycine 
(0.1% SDS ) 
pH 8.3 
(0.0625M tris-HC1 pH 6.8 
2% SDS 
( 10% glycerol ) 
5% 2-mercapto-ethanol) 
(0.001% bromophenol blue ) 
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5) 30% Acrylamide mixture 
a) 0.8: 30 (the ratio of bisacrylamide to the total) 
29.2g acrylamide 
0.8g bisacrylamide 
Upto 100m1 of distilled water 
The mixture was filtered then stored at 4°C and used only 
as indicated in the text. 
b) 1.2: 30 
28.8g acrylamide 
1.2g bisacrylamide 
Upto 100ml of distilled water 
This mixture was used routinely unless otherwise stated in 
the text. 
6) 10% Separating gel mixture lOml 30% acrylamide mixture 
3.75m1 separating gel buffer 
1.50m1 1% ammonium persulfate 
1.67m1 9M urea 
15N1 TEMED 
upto 30m1 Water 
This 10% gel mixture was used routinely unless otherwise stated. 
7) 3% Stacking gel mixture 2. Oml acrylamide mixture 
S. Oml stacking gel buffer 
0.5m1 ammonium persulfate 
1.13 ml 9M urea 
10 N1 TEMED 
upto 20m1 distilled water 
The separating gel mixture was poured between two glass plates 
(22x30cm) held apart by 1.2mm diameter silicone tubing in addition to 
1.1mm-thick spacers on each side. The glass plates were held vertically 
and the gel allowed to polymerise. 
The stacking gel was then poured on 
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the top of the separating gel with a Teflon "comb" in place to provide 
sample slots. After polymerisation, the sample slots were washed 
thoroughly with the reservoir buffer to remove the unpolymerised gel 
solution. 
Before loading the samples, the gel was pre-run for 30-60 min at 
200V. Samples (15-30pg proteins per 20-50pl of sample buffer) were 
dissolved in sample buffer, boiled for 3-5 min, cooled and loaded in the 
sample slots. The gels were normally run at 200V till the dye entered 
the separating gel, then the run was carried out at constant current of 
14-15mA overnight. 
The run was terminated when the dye front reached 2cm from the 
bottom of the gel. 
3.6.2 Staining and Destaining of Gels 
Slab gels were stained with 0.25% w/v coomassie blue R250 
(Sigma) in 45: 10: 45 methanol: acetic acid: water overnight at room 
temperature or for lh at 37°C. 
Gels were destained in several changes of 45: 10: 45 methanol: 
acetic acid: water. The percentage of methanol was decreased gradually 
up to 20%. 
3.6.3 Protein Blotting 
3.6.3.1 Electroblotting 
This was completed after the method of Towbin et al (1979). 
The assembly of the gel and nitrocellulose paper is illustrated below. 
Basically, a plastic grid followed by foam pad (Scotch-Brite pad) and 
then wet filterpaper 3mm (Whatman) were laid 
flat underneath the slab 
gel. On the top of the gel, buffer-soaked nitrocelluose paper was 
laid 
carefully excluding any air bubble which might 
be formed between the gel 
and paper. The paper was followed 
by wet filter paper and another foam 
pad and plastic grid. The assembly was 
tied tightly by rubber bands and 
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then immersed vertically in an electrophoretic destainer tank containing 
20% methanol in 24mM tris-192mM glycine pH 8.3. The nitrocellulose 
paper was placed facing towards the anode (+ve) and the gel facing the 
cathode (-ve). The electrophoretic run was at 300mA for 2.5-3h. 
The plastic grids contained many holes to allow the current to 
flow freely. 
000000000000000000 
plastic grid A^ AA AAA AA AAA AA nitrocellulose paper 
foam ..... gel ....... .......... 
filter paper---ý---- AAAAAAAAAAAA^A^ filter paper 
0000000000000000000 
plastic grid foam 
3.6.3.2 Blotting by Diffusion 




0.1mM DTT (fresh) 
10.0mM tris-HC1 pH 7.0 
Urea Pretransfer Buffer 
4M urea in transfer buffer 
Before blotting, the gels were immersed in urea pretransfer 
buffer and agitated for 3h. The assembly of gel for blotting was 
basically as described in 3.6.3.1 except that nitrocellulose papers were 
put on each side of the gel and the transfer was performed by immersing 
the whole assembly in transfer buffer for 36-48h. 
3.6.3.3 Staining of Blots 
Protein on nitrocellulose paper was stained by 0.1% freshly 
prepared amidoblack (Naphthalene - blue black - Sigma), made up in 
45: 10: 45 methanol: acetic acid: water, for 10 min. 
3.6.3.4 Destaining of Blots 
Nitrocellulose papers were destained immmediately after staining 
by several changes of 90: 2: 8 methanol: acetic acid: water. 
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3.6.3.5 DNA Binding on the Blot 
The method of Bowen et al (1980) was employed: 
( 10.0mM tris-HC1 pH 7.0 
( 1.0mM EDTA 
( 0.02% BSA 
DNA-binding buffer ( 0.02% Ficoll 
0.02% polyvinyl pyrollidone 
(PVP) 
( 50.0mM NaCl 
To determine whether the antigenic determinants of the proteins 
transferred on nitrocellulose paper are DNA-dependent or not, the 
proteins on the paper were reconstituted with DNA. After blotting, the 
paper was washed with DNA binding buffer and incubated with 100rg/ml DNA 
in the same buffer at 37-40°C for 2h with continuous shaking. The 
paper was washed with TN buffer and treated as described in 3.5.4. 
3.7 Immunofluorescence 
3.7.1 Preparation of Monolayer Cells 
Round glass coverslips were washed with dilute chloros solution, 
rinsed with distilled water then dried and sterilised in a hot air oven 
at 400 
°C. The coverslips were cooled down and 4-5 of them were placed 
in a sterile 60mm plastic petridish. Cells at 105/5011 were placed on 
the top of coverslips and grown for 48h in the appropriate medium in a 
CO2 incubator. 
3.7.2 Preparation of Mitotic Cells 
Metaphase cells were prepared exactly as described in 3.7.1. 
except that the medium was supplemented with 0.5pg/ml 
final concentration 
of Democolcine (N-desacetyl-N-methyl colchicine) 
845h before collecting 
the cells. 
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3.7.3. Lysis and Fixation of Cells to Preserve Keratins 
Hypotonic buffer Fluorescence Buffer (F) 
5.0mM MgC12 130 mM KC1 
2.0mM EGTA 5.0mM NaCl 
1.0mM DTT 1.0mM NaN3 
5.0mM NaN3 5.0mM MgCl2 
0.5mM PMSF 1.0mM EGTA 
5. omM tris-HC1 pH 7.5 20.0mM potassium phosphate 
buffer pH 7.5 
Cells were lysed on coverslips according to the procedure of 
Granger and Lazarides (1982) with minor modifications. 
Cells attached to coverslips were washed with PBS and lysed by 
immersion in several changes of cold hypotonic buffer at 0-4°C for 10 
min. The coverslips then were held face-up position in the bottom of a 
beaker filled with hypotonic buffer up to a height of 3-4cm. The cells 
were further disrupted by sonication. The sonicator probe tip was 
positioned 3-4cm overhead and sonication was at 1.5 - 1.7V for 15-20 sec 
using 6.0mm diameter Ti probe. Disrupted cells on coverslips were then 
fixed with 3% gluteraldehyde (Electron Microscopy Grade) in buffer (F) 
for 30-60 min at room temperature. 
After fixation, the cells were made permeable by immersion in 
cold acetone (-10°C) for 10 min. 
3.7.4 Cells Preparation on Coverslips for General Immunofluorescence 
Staining 
The procedure of Stenman et al (1975) was adopted. The cells 
were grown on coverslips as described in section 3.7.1, washed once with 
cold PBS and treated with ice-cold hypotonic medium (10mM tris-HC1 pH 
7.4,40mM glycerol, 20mM NaCl, 5mM KC1,1mM CaC12 and 0.5mM MgC12) 
for 10 min. The excess of buffer on coverslips was blotted gently and 
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the coverslips were air-dried. The cells were fixed in ethanol: acetone 
(1: 1) at -20°C for 10 min, airdried and then treated with antibodies as 
described under Section 3.7.5 except that the dilutions of antisera were 
performed in 0.2% BSA in PBS. 
3.7.5 Treatment of cells with Antibodies 
Acetone treated cells were washed with PBS and incubated for 
30-45 min at room temperature with first antibody (antisera or MCA) 
diluted in TN buffer. The coverslips were washed 3 times with PBS then 
incubated for 20 min at room temperature with second antibody (goat anti 
mouse - or rabbit - IgG H+L) coupled to FITC (Miles) diluted lA0-1/30 in 
PBS. The coverslips were washed 3-4 times with PBS and mounted with-90% 
glycerol in (85mM NaHCO3 and 15mM Na2CO3 pH 8.9) and viewed by 
"Leitz" fluorescent microscope. 
3.7.6 Chromosome Spread Preparation 
Healthy cells were grown in plastic tissue culture bottles for 
48h in the appropriate medium. Democolocine (N-desacetyl-N-methyl 
colchicine) was added to a final concentration of 5pg/ml and the cells 
were incubated for 45-60 min. The mitotic cells were then harvested by 
gentle rocking of the plastic bottle and the cells were washed with PBS 
and centrifuged at 500xg for 5 min. The cells were resuspended in 
0.075M KC1 and allowed to stand for 10-12 min then centrifuged at 500xg 
for 5 min. All the KC1 solution was sucked off except 0.25-0.5m1. The 
cells were resuspended very gently in the remainder of KC1 solution and 
then fixed in cold 3: 1 methanol: acetic acid fixative mixture by pouring 
5ml slowly dropwise and another 5m1 quickly. The cells were 
left in the 
fixative mixture for at least 30 min (up to 24h) then centrifuged at 
500xg for 5 min. The pellet was resuspended in 10ml of 
fixative mixture 
and centrifuged again. The collected pellet was resuspended 
in 1-2ml of 
fixative mixture. From this suspension 
5-6 drops were dropped from a 
height of 100cm onto a slide (prewashed with chromic acid 
for at least 2h 
then dried). 
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3.7.7 Chromosome Staining 
Chromosomes which were spread on a slide as described in Section 
3.7.6 were either treated with antibodies as in 3.7.4 for 
immunofluorescent staining or stained with Giemsa stain as follows. 
The chromosomes fixed on the slides were stained with Giemsa 
stain (10%) in Gurr's buffer (BDH) pH 6.8. The staining was performed 
for 30 min at room temperature and the slides were washed thoroughly 
under tap water and dried. 
3.7.8 Photography 
Cells or chromosomes were viewed in Fluorescence Microscope 
(Leitz) using different magnifications or an oil immersion lens with 
magnification of X2000. Photographs were taken using 400ASA film 
(Kodak) attached to an Orthomat camera. 
3.8 Miscellaneous 
3.8.1 DNA Preparation 
The procedure of Flint et al (1976) was adopted with minor 
modifications. 
Cells were washed in solution (1) (2.2.2.1), vortexed and 
homogenised gently (one stroke), then spun at 500xg for 5 min. The 
pellet was collected, resuspended in hypotonic buffer (10.0mM tris-HC1, 
1.0mM EDTA, 0.5% SDS pH 7.9) and vortexed. The suspension was extracted 
twice with phenol saturated with hypotonic buffer lacking SDS. The 
aqueous layer was collected each time and then extracted further with 
isoamylalcohol: chloroform 1: 24 and the aqueous phase collected. Sodium 
acetate 3M (1/10th volume) was then added to give a 
final concentration 
of 0.3M. Cold ethanol (2 volumes) was then added and nucleic acids were 
precipitated at -200 overnight. 
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The precipitate was collected, added to 20-25m1 of tris-HC1 pH 
7.9 and incubated with 50Ng/ml of ribonuclease A (boiled for 10 min and 
cooled on ice immediately before use) at 370C for 60 min. The mixture 
was then extracted twice with saturated phenol and once with 
isoamylalcohol-chloroform. Two volumes of cold ethanol was added to the 
aqueous layer to precipitate DNA at -200C. 
3.8.2 DNA Digestion 
Chromatin or dehistonised chromatin was suspended in digestion 
buffer (10mM tris-HC1,40mM NaCl, 1.0mM CaC12,1mM PMSF pH 7.5) at a 
concentration of 0.60mg DNA/mi. Staphyloccocal nuclease (Boehringer) 
15,000U in lml of digestion buffer was then added and the mixture was 
vortexed and incubated at 37° for 90-120 min in a shaking water bath. 
The reaction was terminated by the addition of EDTA to a final 
concentration of 2.0mM. 
3.8.3. DNA Reconstitution 
The nuclease digested chromatin was reconstituted in the 
following manner. 
The digested chromatin (100Ng) was dialysed against 500m1 of (5M 
urea, 2mM EDTA, 2.5M NaCl and 50mM tris-HC1 pH 7.5) at 4°C for 18h. 
The dialysing buffer was changed four times over a period of 36-48h 
bringing the concentration of NaCl down to 40mM then urea was dialysed 
out (3-4 changes) against (40mM NaCl, 1mM EDTA and 50mM tris-HC1 pH 7.5) 
overnight at 4°C. 
If the digested chromatin was prepared for C'F assay, further 
dialysis (2 changes) against working diluent was necessary. To 
reconstitute native DNA with the digested chromatin, the required amount 
of DNA (homologous or heterologous) was added to the chromatin before the 
last change of dialysis. 
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3.8.4 DNA Estimation 
The procedure of Burton (1956) was used with minor modification. 
A duplicate series of test tubes were prepared containing 20, 
40,60 and 100Ng per 10011 of standard calf DNA solution (from a stock 
lmg/ml distilled water). HC1O4 0.5M solution (0.5m1) was added to 
each tube and the mixtures were incubated at 700C for 30 min, cooled to 
room temperature and centrifuged at 600xg for 10 min. The supernatant 
was collected, 2. Oml of diphenylamine reagent was added to each 
supernatant and the solutions were kept in the dark-at room temperature 
for 20-24h. The A600 of the solution was read and plotted on graph 
paper. A typical straight line was obtained within the range of 
concentrations used as shown in Figure S. Any unknown DNA sample was 
treated in the same way and its concentration was obtained from the 
standard curve. 
Diphenylamine (DPA) reagent was prepared by dissolving 1.5g of 
DPA in 100ml of glacial acetic acid added to 1.5m1 of concentrated 
sulphuric acid and the reagent was stored in the dark at room 
temperature. Before this reagent was used, a 20m1 aliquot was withdrawn 
and O. lml of aqueous acetaldehyde (16mg/ml) added to it. For routine 
measurement of DNA concentration, 1 A260 unit was found to be 
equivalent to 50Ng/ml. 
3.8.5 Protein Estimation 
The procedure of Bradford (1976) was adopted. 
A duplicate series of test tubes containing 10,20,30,40 and 
50pg/O. lml of standard BSA solution (from a lmg/ml stock) were prepared 
in 150mM NaCl. The volume in the test tubes was kept constant at 
0. lml. Bradford's reagent (3. Oml) was then added and the tubes were 
vortexed and left to stand for 10 min to complete 
the reaction. The 
A595 
of the coloured solution obtained was read and a standard curve 
was drawn. 
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To estimate an unknown protein sample concentration, the protein 
was treated exactly in the same way as for the standard and its 
concentration was obtained from the standard curve. The standard curve 
is shown in Figure 6. 
Bradford's reagent was freshly prepared by dissolving 100mg of 
Coomassie Brilliant Blue G-250 (Sigma) in 50m1 of 95% ethanol. This 
solution was mixed with 100ml of 85% w/v phosphoric acid, diluted with 
distilled water to a volume of 1L, and filtered. 
3.8.6 Intermediate Filaments Preparation (IF) 
This was completed after the procedure of Schmidt et al (1982) 
with minor modification. 
The cells (1-2g) were lysed by homogenisation (15 strokes) in a 
tight-fitting pestle in lysis buffer (0.3M KC1,0.15M potassium phosphate 
buffer pH 6.5). The homogenate was stirred gently for 20 min at 40C 
and homogenised again, diluted with 4 volumes of cold distilled water, 
centrifuged at 800xg for 10 min. The pellet was then suspended in 4 
voluems of 0.4% NaHCO3 at 4°C, stirred gently for 10 min, centrifuged 
at very low (180xg) speed for 3 min. The pellet was collected, 
resuspended in 0.05M NaHCO3 - 0.05M Na2CO3 (1g pellet/ml), stirred 
for 10 min, diluted with 10 volumes of 0.5mM CaCl 2 and centrifuged at 
800xg for 10 min. 
To make acetone powder of IF, the pellet was added to three 
volumes of acetone, mixed and spun at 180xg for 5 min. The residue was 
collected, mixed with one volume of acetone containing 0.5mM Na2CO3 
and air dried. 
3.8.7 Nuclear Lamina Protein-Matrix Preparation 
The method of McKeon et al. (1983) was followed with minor 
modifications. 
-98__ 







Jig Of Standard BSA 
10 20 30 40 50 
- 99 - 
HeLa cells (20x106) were washed and extracted by four strokes 
in a tight-fitting pestle (Teflon) in 2. Oml of PBS (section 2.3.3.2) 
lacking KC1 but containing 0.1% Nonidet P-40,15.0mM 2-mercaptoethanol 
and 1.0mM PMSF. The mixture was then centrifuged at 1000xg for 10 min 
and the pellet was resuspended in 2. Oml of the same buffer containing 
5.0mM CaCl 2 and exposed to 
10 units/ml of micrococcal nuclease for 10 
min at 220C. The reaction was stopped by the addition of EDTA to a 
concentration of 3.0mM and the mixture was centrifuged at 1000xg for 10 
min. The pellet was extracted by 1.0ml of 3M NaCl (4 strokes in glass 
homogeniser) in a buffer containing 80mM KC1,5mM EDTA, 0.1% triton X-100 
and 15.0mM Pipes (1,4-piperazinediethane sulfonic acid, pH7.4). The 
homogenate was then centrifuged at 2000xg/10 min and the pellet was 
collected. 
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4. Results and Discussion 
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4.1 Results Obtained Using R3.1 Antiserum 
Results 
R3.1 is a polyclonal antiserum obtained after immunising a (Half 
Lop) rabbit with two subcutaneous injections of histone-depleted HeLa 
chromatin (150Jg of DNA) extracted with 2M salt and 5M urea, prepared as 
described in Section 3.1.3.2. A booster injection of the antigen (150pg) 
was given intravenously six days before bleeding of the animal. 
The antiserum shows a high titre of immunoreactivity towards 
HeLa chromatin even at a dilution of 1/1200. This has been shown by C'F 
assay and ELISA (Figures 4.1.1,4.1.11 & 4.1.12). 
Using ELISA, the antiserum (R3.1) reacted in a similar pattern, 
when between 2-18pg of HeLa chromatin was layered in each well of the 
ELISA plate (Figure 4.1.1). If the amount of chromatin plated in each 
well was reduced to lpg/well or less, the immunoreactivity of R3.1 fell 
drastically. This gives an indication of the limited amount of antigen 
which could be immobilised in each well of the ELISA plate. 
The target antigen requires the presence of DNA for its 
immunoreactivity with R3.1 antiserum. This is demonstrated by the great 
loss of activity on micrococcal nuclease digestion as seen in ELISA 
(Figure 4.1.2) and C'F assay ( Figure 4.1.3). Since micrococcal 
nuclease digests both DNA and RNA, it is possible that the complex 
antigen may require RNA to determine the configuration of the antigenic 
determinants and to make them accessible for the antibody recognition. 
The immunoactivity of the complexed antigen was almost completely 
restored upon reconstituting the nuclease-digested chromatin with HeLa 
DNA alone (Figures 4.1.2 & 4.1.3). As the HeLa DNA was prepared in a 
way which eliminates the presence of RNA by digestion with large amounts 
of RNAase A, as described in Section 3.8.1, DNA rather than RNA is 
therefore required for the immunoreactivity of R3.1 antiserum with HeLa 
chromatin. In order to demonstrate whether the immunoreactivity of the 
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Figure 4.1.1 ELISA of R3.1 Antiserum with HeLa chromatin 
Enzyme linked immunosorbent assay of different 
concentrations of R3.1 antiserum reacted with various 
amounts of HeLa chromatin layered in the wells of ELISA 
plate. (Antibody and antigen controls were subtracted) 
0 18pg chromatin 
p 2pg chromatin 
p lpg chromatin 
X lOng chromatin 
The highest antibody control was 0.07 A492 unit at 1/150 dilution while the 
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Figure 4.1.2 ELISA of R3.1 Antiserum with HeLa Digested- and 
Undigested-chromatins 
Enzyme linked immunosorbent assay of R3.1 antiserum 
(1/250) allowed to react with different concentrations 
of HeLa antigen immobilised on an ELISA plate. The 
Chromatins measured as total protein content and the 
DNA values estimated as total DNA applied on the ELISA 
plate. (Antibody and antigen controls have been 
subtracted). 
O Undigested HeLa chromatin 
0 Micrococcal nuclease-digested HeLa chromatin 
reconstituted with HeLa DNA 
0 Micrococcal nuclease-digested HeLa chromatin 
V HeLa DNA alone 
Antibody control was found to be 0.04 A492 unit, while antigen controls were 
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Figure 4.1.3 C'F Assay of R3.1 Antiserum with HeLa Digested- and 
Undigested-chromatins 
Complement fixation assay of R3.1 antiserum (1/200) 
fixed with various concentrations of HeLa DNA, 
chromatin and micrococcal nuclease-digested chromatin 
before and after reconstitution with HeLa DNA. All 
chromatin preparations were measured as total protein 
content except DNA alone estimated as total DNA. 
(Antibody and antigen controls were subtracted). 
O HeLa chromatin 
Q Micrococcal nuclease-digested HeLa chromatin 
reconstituted with HeLa DNA 
Micrococcal nuclease-digested HeLa chromatin 
0 HeLa DNA alone 
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target antigen lies with the DNA itself or not, HeLa DNA alone was 
allowed to react with R3.1 antiserum. Figures 4.1.2 and 4.1.3 show asmall 
amount of, immunoreaction between R3.1 antiserum and HeLa DNA, when 
assayed by complement fixation and ELISA. This indicates that the 
target antigen is not the DNA alone but a complex of DNA and chromosomal 
proteins. 
These data were substantiated by using the competition assay 
described in Section 3.4.5. R3.1 antiserum was absorbed either by HeLa 
chromatin or by micrococcal nuclease-digested chromatin prior to its 
application to an ELISA plate coated with HeLa chromatin. The results 
shown in Figure 4.1.4 demonstrate that a great deal of immunoreactivity 
of R3.1 antiserum (diluted 1/250) was absorbed by micrococcal 
nuclease-undigested HeLa chromatin even at a small amount of 0.625Ng of 
chromatin in 50111 of the reaction mixture. The nuclease-digested 
chromatin failed to absorb large amounts of R3.1 antiserum. These data 
are presented clearly when plotted as a percentage of the absorbed 
chromatin in relation to the freely reacted R3.1 antiserum shown in 
Figure 4.1.4b. 
In order to further characterise the protein antigens, HeLa 
chromatin and dehistonised chromatin together with cytoplasmic fractions 
were resolved on an SDS-polyacrylamide gel electrophoresis and then 
transferred onto nitrocellulose paper as described in Section 3.6.4.1. 
The antibody-antigen reaction was monitored by enzyme linked 
immunoblotting as outlined in Section 3.5.4.1 and shown in Figure 4.1.5 
(the bands are very faint on the photograph so a diagramatic 
representation is traced from the original blot). R3.1 antiserum 
(1/200) did not show any reaction with cytoplasmic fraction (lanes 7& 
10) while faint colouring was noted corresponding to 
bands of Mr 45,000 
and 43,000 on both dehistonised and chromatin 
fractions (lanes 5,8, 
6& 9). Another faint band could be seen on the 
immunoblot in 
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Figure 4.1.4a Competition ELISA of HeLa Chromatins Reaction with R3.1 
Antiserum 
Enzyme linked immunoassay of R3.1 (1/250) absorbed with 
various concentrations of micrococcal nuclease-digested 
(as described in Section 3.8.2) and undigested HeLa 
chromatins, 50xl of this mixture then allowed to react 
with HeLa chromatin (layered as lOpg/well) immobilised 
on an ELISA plate. (Antigen and antibody controls were 
subtracted). 
O Micrococcal nuclease-undigested HeLa chromatin 
A Micrococcal nuclease-digested HeLa chromatin 
The dotted line represents the average of 50pl of 
unabsorbed R3.1 (1/250) reacted with HeLa chromatin 
(layered as lOpg/well) immobilised on ELISA plate. 
Figure 4.1.4b Percentage of Competition ELISA of HeLa Chromatins 
Reaction with R3.1 Antiserum 
The amount of R3.1 (1/250) antiserum absorbed by 
micrococcal nuclease-digested and -undigested HeLa 
chromatin expressed as a percentage of free R3.1 
reaction with immobilised HeLa chromatin (10pg/well). 
Q Micrococcal nuclease-undigested chromatin 
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Figure 4.1.5 Immunoblots of HeLa Subcellular Fractions Reacted with 
R3.1 and Normal Rabbit Antisera 
Protein immunoblot of R3.1 (1/200) antiserum (Strips B 
& C) and normal rabbit serum (1/200) (Strip D) reacted 
with cytoplasmic fraction (lanes 7,10 & 13), chromatin 
(lanes 6,9, & 12) and 2M-salt extracted chromatin 
(lanes 5,8, & 11) preparations from HeLa cells 
visualised by using the immunoperoxidase method 
described in Section 3.5.4.1. Strip (C) was incubated 
with HeLa DNA as described in Section 3.6.3.5 prior to 
its reaction with R3.1 antiserum. Lanes 2,3, &4 
represent the amido black-stained proteins 
corresponding to 2M-salt extracted chromatin, chromatin 
and cytoplasmic preparations. Lane (1) is the 
molecular weight marker. Phosphorylase b 94,000; 
Bovine serum albumin 67,000; Ovalbumin 43,000; 
Carbonic anhydrase 30,000; Soybean trypsin inhibitor 
20,100; M -Lactalbumin 14,400. The proteins were run 
in a 10% Laemmli gel containing 0.5M urea. 
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lanes 5 and 6 which represent the dehistonised chromatin and 
chromatins. This band is at an approximate molecular weight of 
67,000. Increasing the concentration of the antiserum (R3.1) used, 
failed to show any increase in colour intensity on the immunoblot. 
Furthermore, normal rabbit serum (1/200) from unimmunised animal showed 
no visible immunoreaction on the blot (Strip D). 
Since the antigens in HeLa chromatin require the presence of DNA 
for its reactivity with R3.1 antiserum, and the DNA itself is too large a 
molecule to enter the high percentage polyacrylamide gel, incubating the 
blot with DNA may enhance or change the antigenic determinants on the 
blot and make them accessible to the antibody recognition. The blot was 
incubated with HeLa DNA (100pg/ml) prior to its reaction with R3.1 
antiserum as described in Section 3.6.3.5. The pattern seen after DNA 
treatment did not significantly affect the distribution of the reactive 
proteins except for the appearance of one faint band (Mr 70,000) in the 
dehistonised fraction and two faint bands at Mr 70,000 and 68,000 in the 
chromatin lane (Lane 9). The latter may be the same as the 67,000 seen 
in lanes 5 and 6. 
By inspecting the immunoblot in Figure 4.1.5, it is possible to 
categorise the proteins which reacted with R3.1 antiserum into two 
groups. The first comprises the 67,000-70,000 proteins seen in 
chromatin and the dehistonised fractions in the DNA-treated blot. The 
second group comprises the 43,000-45,000 proteins detected in the 
chromatin and dehistonised chromatin, respectively, of both the 
DNA-treated and untreated blots. This group is therefore 
immunologically detectable in all chromatin and dehistonised chromatin 
except those which were allowed to react with normal rabbit serum. 
It is interesting to see the appearance of 68,000 and 70,000 
protein bands in the DNA-treated blot (Lanes 8& 9) which indicates the 
necessity of DNA for the antibody-antigen reaction of 
these proteins. 
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It is worth mentioning that the immunoreactivity of HeLa 
chromatin with R3.1 was greatly affected by SDS-treatment. It was 
observed that this reactivity reduced drastically when chromatin 
preparation was incubated with 1% SDS in TN buffer for 90 minutes at room 
temperature then applied onto a nitrocellulose paper and allowed to react 
with R3.1 in the same way as for the electroblot. The reactivity 
decreased further upon increasing the SDS concentration until it was 
completely abolished at 10% SDS treatment. This was monitored visually 
by looking at the intensity of the substrate colour on the reacted 
chromatin. 
To determine the localisation and distribution of the antigen 
using R3.1 antiserum as first antibody, an indirect fluorescein 
isothiocyanate (FITC) staining of HeLa cells was performed (Figure 
4.1.6). The staining is seen mainly in the nuclei with more intensity 
at the periphery (perinuclear area). A cons iderable amount of staining 
could also be noted in the cytoplasm. 
Pure nuclei were also prepared as described in Section 3.1.1.1 
and then fixed on the slide and treated with R3.1 antiserum followed by 
FITC-conjugated second antibody in the same manner as the treatment of 
the cells. Again all the nuclei were stained with more intensity at the 
nuclear periphery (Figure 4.1.7). In comparable experiments using the 
same technique, Chang liver and FL cells failed to show significant 
nuclear reaction with R3.1. A small amount of cytoplasmic reaction was 
again observed (Figure 4.1.8). Moreover, normal rabbit serum used at 
the same dilution as R3.1 antiserum showed no significant reaction with 
HeLa cells (Figure 4.1.9). 
As is observed in Figure 4.1.6a, fluorescein stained cells 
showed more staining intensity on the periphery of the nuclei. This 
suggests that part of the reaction antigen may 
be associated with nuclear 
matrix or nuclear envelope. 
This observation, together with the fact 
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Figure 4.1.6 FITC-staining of HeLa Cells Reacted with R3.1 Antiserum 
(a, b. c) Immunofluorescent staining of HeLa cells 
reacted with 1/100 R3.1 antiserum (X2000). 

- 111 - 
Figure 4.1.7 FITC-staining of HeLa Nuclei Reacted with R3.1 Antiserum 
(a) Indirect immunofluorescent staining of HeLa nuclei 
reacted with R3.1 antiserum (X2000). 
(b) Phase contrast of the nuclei in (a). 
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Figure 4.1.8 FITC-staining of Human Cells Reacted with R3.1 Antiserum 
Indirect immunofluorescent staining of human cells 
allowed to react with R3.1 antiserum (X2300). 
(a) Chang liver cells 
(b) Phase contrast of (a) 
(c) FL cells 
(d) Phase contrast of (c) 
ý, ý: 
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Figure 4.1.9 FITC-staining of HeLa Cells Reacted with Normal Rabbit 
Serum 
Indirect immunofluorescent staining of normal rabbit 
serum (1/100) allowed to react with HeLa cells (X2000), 
ý, ý, ý 
BEST COPY 
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that protein bands of Mr 68,000-70,000 showed some degree of reactivity 
with R3.1 antiserum in the presence of DNA suggests that nuclear matrix 
or pore complex-lamina proteins may be the dominant antigens since these 
lie in the molecular weight range of 68,000-70,000. Therefore, the 
protein fraction from a nuclear pore complex-lamina matrix-enriched 
preparation (prepared as described in Section 3.8.7) was allowed to react 
with R3.1 antiserum (1/250). Equal amount of proteins from chromatin 
and nuclear laminar preparations layered on an ELISA plate showed 
different reactivity towards R3.1 antiserum (Figure 4.1.10). Nuclear 
lamina-matrix proteins exhibited only about half of the reactivity seen 
with a chromatin preparation tested simultaneously. It is worth noting 
that the lamina-matrix preparation involved the use of small amounts of 
micrococcal nuclease digestion. 
The specificity of R3.1 antiserum was tested with human and 
non-human chromatins (Figure 4. l. lla & b) using C'F assay. The 
antiserum showed more than 95% complement fixation at a dilution of 1/200 
when reacted with HeLa chromatin, while little (less than 10%) of the 
complement was fixed on its reaction with other human chromatins. 
Approximately 15-20% fixation was noted with Chang liver and FL cells. 
Similarly, no significant complement fixation was observed when R3.1 
antiserum was allowed to react with non-human chromatins (Figure 4. l. llb). 
In the enzyme linked immunoassay (Figure 4.1.12a & b), R3.1 
antiserum showed a reaction with HeLa chromatin relatively higher than 
its reactivity with other human and non-human chromatins. Again, Chang 
liver and FL cells showed rather high reactivity with R3.1. This 
reactivity is even higher than that detected by C'F assay. The 
difference in the reactivity between ELISA and C'F assays will be 
discussed later. 
It is worth noting that the human cell lines used for the 
microcomplement fixation and ELISA assays were from various tissues, 
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Figure 4.1.10 ELISA of R3.1 Antiserum with HeLa Lamina Preparation 
An enzyme linked immunosorbent assay comparing the 
reactivity of HeLa chromatin and HeLa nuclear-lamina- 
matrix-enriched preparation towards R3.1 (1/250) 
antiserum. (Antibody and antigen controls were 
subtracted). 
O HeLa chromatin 
0 HeLa nuclear pore complex-lamina-matrix 
preparation 
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Figure 4.1.11a C'F Assay of R3.1 Antiserum With Human Chromatin 
Complement fixation assay of various human chromatins 
(20Ng of protein) from different tissues (see Table 2a) 
fixed with different concentrations of R3.1 
antiserum. (Antibody and antigen controls were 
subtracted). 
O HeLa 





Antigen control showed between 2-3% C'F while antibody controls exhibited only 1% C'F at 1/200 dilution and a -1% C'F at 1/1600 diltuion of antibody. 
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Figure 4.1.11b C'F Assay of R3.1 Antiserum with Non-human Chromatins 
Complement fixation assay of HeLa chromatin compared 
with various non-human chromatins (20pg of protein), 
from different tissues (see Table 2b) fixed with 
different concentrations of R3.1 antiserum. (Antibody 
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Figure 4.1.12a ELISA of R3.1 Antiserum with Human Chromatins 
An enzyme linked immunosorbent assay of different 
concentrations of R3.1 antiserum reacted with 
fixed 
amounts of human chromatins (10Ng chromatin 
layered in 
each well) immobilised on an ELISA plate. (Antibody 
and antigen controls were subtracted). 
O HeLa 
  H. Ep-2 





Antigen controls were as follows: HeLa 0.149, H. Ep-2,0.18, Chang liver 0.1 6 
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Figure 4.1.12b ELISA of R3.1 Antiserum with Non-human Chromatins 
An enzyme linked immunosorbent assay of different 
concentrations of R3.1 antiserum reacted with non-human 
chromatins (10pg layered in each well) immobilised on 
an ELISA plate. The reactivity simultaneously 
compared with equal amount of HeLa chromatin. 
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while the non-human chromatins were not only from different tissues but 
also from three kinds of animals; rat, monkey and mouse (see Table 2a & 
b). 
Since FL and Chang liver cells have shown relatively higher 
immunoreactivity with R3.1 compared with other human cell lines, and in 
addition, some kind of complex association between the DNA and HeLa 
chromatin has been found necessary for the immunoreactivity with R3.1 
antiserum, it is obviously important to compare the DNA content of each 
chromatin preparation with the degree of its reactivity with R3.1 
antiserum. Table (5) shows the ratio of DNA: protein in the human 
chromatins which were subjected to reaction with R3.1. Chang liver and 
FL cells have a higher ratio of DNA: protein than HeLa chromatin, yet they 
show lower reactivity than HeLa cells. Other human chromatins (H. Ep-2 & 
K562), which have similar ratio of DNA: protein as that of HeLa cells, 
exhibited very little reactivity with R3.1. This suggests no direct 
correlation between the amount of DNA content and the immunoreactivity of 
any human chromatin with R3.1 antiserum. 
Treatment of HeLa cells with colcemid (Democolcine) resulted in 
variable immunofluorescent patterns. The differences may reflect the 
various stages of the cell cycle. This is shown in Figure 4.1.13 and 
4.1.14. The fluorescent staining was predominantly found in the whole 
cell with more intensity at the cytoplasmic boundaries with nuclei 
(Figure 4.1.13b). A number of cells showed batches of staining 
distributed either evenly in coarse speckled-like staining (Figure 
4.1.13d & e, top) or unevenly in granular pattern (Figure 4.1.13a, centre 
& top right). The FITC staining indicates the presence of the HeLa 
antigen(s) during the interphase as well as mitosis. When mitotic cells 
were cytocentrifuged then fixed and allowed to react with R3.1 (1/100) 
antiserum, no defined FITC-stained chromosomal structures were identified 
(Figure 4.1.14). 
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ITable 5: The ratio of DNA: protein of chromatin preparations from human 
cell lines. The protein content was measured by Bradford's 
method and the DNA estimated by Burton's procedure. 
K562 1: 1.9 
HeLa 1: 1.8 
H. Ep-2 1; 1.8 
Chang liver 1: 1.5 
FL 1; 1.4. 
KB lsl. 4 
HT1080 1 j, l. 4 
2M salt extracted chromatir 1: 0.214 
214 salt/5M urea extracted chromatic 1: 0.097 
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Figure 4.1.13 FITC-staining of HeLa Mitotic Cells Reacted with R3.1 
Antiserum 
Indirect immunofluorescent staining of HeLa cells on 
cover slips treated with colcimid for 18 hours, fixed 
and allowed to react with R3.1 antiserum (1/200). 
a, b, d fluorescent staining (X2000) 
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Figure 4.1.14 FITC-staining of Mitotic HeLa Cells Cytocentrifuged and 
Reacted with R3.1 Antiserum 
Indirect immunofluorescent staining of HeLa cells grown 
in culture and treated with colcemid for 5h before 
harvesting. The mitotic cells were cytocentrifuged on 
slides, fixed then allowed to react with R3.1 (1/100) 
antiserum. 
(a, c) fluorescent staining (X500 & X2000 
respectively) 
(b) phase contrast of a (X500) 
b 
wiv 
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Discussion 
Immunological methods have long been used for the 
characterisation and detection of nuclear components. The antisera 
against these components were generally raised in rabbits. Different 
rabbits respond variably to any given antigen complex. Antisera to HeLa 
dehistonised nuclear preparations were found by immunocytochemical 
methods to localise the antigen (or antigen complex) specifically in the 
nuclei (Campbell et al., 1979; Briggs et al., 1979) or nuclear matrix 
(Wojtkowiak et al., 1982). Although in these preparations the antigen 
complex was prepared in a similar way using 2M salt-5M urea extraction, a 
different pattern of reactivity was observed. The reported antisera 
obtained against the above 2M salt-5M urea extracted chromatin were 
raised in white New Zealand rabbits. It is possible that different 
rabbits may give a different response to this kind of antigen complex. 
The antiserum R3.1 was raised in a Half Lop rabbit. 
The specificity of antisera raised against 2M salt-5M urea 
extracted fraction has been tested with a number of cell lines (Campbell 
et al., 1979; Wojtkowiak et al., 1982), but there has been no previous 
attempt to examine a wider range of tissue-culture established human and 
non-human cells. In this attempt R3.1 antiserum was allowed to react by 
C'F and ELISA with human cell lines derived from different tissues 
(blood, liver, amnion, mouth, skin and larynx). These cells are of 
epithelial and non-epithelial origin (Table 2a). 
In the previous attempts, microcomplement fixation was the only 
sensitive technique used to examine the specificity of antisera. 
Examining the specificity pattern of R3.1 antiserum obtained by C'F assay 
(Figure 4.1.11) implies that R3.1 is cell specific. However, the ELISA 
technique shows a considerably different reactivity (Figure 4.1.12). 
Although in the latter technique (ELISA), R3.1 antiserum showed a high 
reactivity with HeLa chromatin, other 
human epithelial (Chang liver & FL) 
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cell lines also exhibited a great deal of immunoreactivity. Therefore, 
the use of two sensitive techniques which work by two different 
mechanisms (the microcomplement fixation & ELISA), simultaneously, gives 
wider scope for looking at the specificity of a given antiserum. 
This difference between C'F assay and ELISA has several possible 
explanations: 
1. The plate binding capability of the antigens may vary. ELISA 
is a very sensitive technique which depends on the binding of the 
antigens to a solid phase (the ELISA plate). Since there may be a 
differential capacity of certain proteins to bind to the plate and 
because ELISA involves several washings which might affect the low 
affinity binding proteins, an enrichment and increase in the binding of a 
given component is probable. Moreover, out of the 10jg of chromatin 
layered per well, an unknown amount of antigen actually binds to the 
plate (see Figure 4.1.1). 
2. Because of the high sensitivity of ELISA, minor antigens, which 
are common to certain types of tissue culture cells (HeLa, Chang liver & 
FL epithelial cell lines grown in culture for many years), may be 
detected, while these antigens are possibly missed by the C'F assay. 
Added to this is the polyclonality of the antiserum (R3.1) in which 
antibodies of different abundance and affinity may alter the apparent 
specificity at various dilutions of antibody and antigen in the two 
assays. 
3. A third possible difference is that the ELISA involves detecting 
the first antibody by an anti-IgG second antibody, thus the ELISA 
preferentially selects IgG class of antibodies. 
Earlier reports have indicated that the immunogenic components 
of HeLa dehistonised chromatin reside in the high salt-resistant residual 
fraction (Campbell et al., 1979). Although only a small amount of 
protein is tightly bound to the DNA, the immunoreactivity tested by C'F 
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assay was found to be associated with the residual protein fraction in 
complex formation with human (homologous) DNA (Dunn et al., 1980). This 
immunoreactivity was reported to be sensitive to micrococcal nuclease 
digestion (Campbell et al., 1979; Briggs et al., 1979; Dunn et al., 
1980). 
Using R3.1 antiserum, it is again possible to demonstrate that a 
great deal of HeLa chromatin antigenicity is susceptible to micrococcal 
nuclease digestion (Figures 4.1.2-4.1.4). Such antigenicity that can 
only be assayed in the presence of two discrete components (DNA & 
protein) is difficult to analyse for the role played by each separate 
component. Massive amounts of micrococcal nuclease (7500U/0.3mg DNA/ml) 
were used for the digestion which drastically reduced the 
immunoreactivity of chromatin with R3.1 antiserum. About 65-85% of the 
activity, as monitored by ELISA and C'F assays respectively, was lost 
(Figures 4.1.2 & 4.1.3). This high loss of immunoreactivity was 
restored by the addition of HeLa DNA to the digested chromatin. 
The earlier reports using antiserum raised in white New Zealand 
rabbit suggested that only when a large amount of micrococcal nuclease 
(above 150U/3pg DNA/0.5m1) was used, a considerable degree of 
immunoreactivity of HeLa chromatin was lost. This was monitored by C'F 
assay (Campbell et al., 1979). It is possible that the antigen complex 
which reacts with R3.1 antiserum is different in being highly susceptible 
to nuclease digestion. Figure 4.1.10 shows that HeLa nuclear lamina- 
matrix-enriched preparation exhibited only half the activity of the same 
amount of chromatin preparation. This is believed to be largely due to 
the use of micrococcal nuclease digestion during the course of the matrix 
preparation (Section 3.8.7), even though that very small amount of 
nuclease was involved (for a limited period of time). The amount of 
micrococcal nuclease used for the lamina preparation was estimated to be 
approximately 10U/0.3mg DNA/ml. 
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It is possible that other reasons have contributed collectively 
to this reduction in immunoreactivity shown in Figure 4.1.10. Among 
these possibilities are the following: 
1. The use of a high concentration of 2-mercaptoethanol to prevent 
disulfide bridge formation might have reduced the possibility of complex 
formation (between DNA & protein) and/or may have caused the loss of 
important proteins essential for the complex component which is in turn 
necessary for the antigen immunoreactivity. Supporting this idea is the 
recent finding of Lebkowski and Laemmli (1982) that in the dehistonised 
chromatin preparation, the addition of 2-mercaptoethanol to the lysis 
mixture leads to a partial unfolding of the DNA and a selective loss of 
proteins. 
2. Additionally, that the preparation was subjected to a very high 
salt (3M NaCl) extraction procedure which possibly solubilised some 
important component(s) of the complex antigen. 
Lebkowski and Laemmli (1982) described two forms of 
histone-depleted HeLa nuclear proteins. Type I protein structure which 
was obtained by 2M NaCl extraction, is represented by the three nuclear 
laminar proteins of Mr 60,000-70,000 and high molecular weight residual 
species. Histone extraction in the presence of 2-mercaptoethanol 
produced type II structure which comprises almost exclusively the major 
laminar proteins (Mr 60,000; 68,000 & 70,000) and two minor proteins of 
Mr 64,000 & 200,000. A laminar protein enriched preparation was also 
obtained by McKeon et al. (1983), using a slightly different approach. 
Wojtkowiak et al. (1982) have raised antisera against 2M salt-5M 
urea-extracted chromatin fraction from HeLa cells. These sera showed a 
wide range of cross reactivity not only with other human malignant cell 
preparations in the immunoblot, but with a number of protein bands in the 
HeLa chromatin fraction. The antisera also reacted with many bands in 
the nuclear matrix preparation and many of these proteins were found to 
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be common to other HeLa subcellular fractions including nucleoli and RNP 
particles. Detke & Keller (1982) have presented data which suggest that 
the major chromosome scaffold proteins are also the major proteins of the 
nucleoskeleton. However, no similarity between the reactive protein 
bands shown by Wojtkowiak et al. (1982) and the major nucleoskeletal 
proteins has been noted. Moreover, although these antisera were raised 
against HeLa antigen preparation similar to that reported by Campbell et 
al. (1979) and Briggs et al. (1979), no DNA-dependent immunoreactivity 
was reported. 
On the other hand, R3.1 antiserum was elicited against the same 
dehistonised chromatin fraction (extracted by 2M salt-5M urea) and again 
its immunoreactivity showed great dependence on the presence of 
homologous DNA complex formation (Figures 4.1.2 & 4.1.3). Unlike the 
antisera reported by Wojtkowiak et al. (1982), R3.1 antiserum showed very 
slight reactivity with proteins on the immunoblot (Figure 4.1.5). Using 
the sensitive immunoblot technique reported by Towbin et al. (1979), R3.1 
antiserum reacted with only two protein bands (Mr 43,000 & 45,000) in the 
chromatin and dehistonised chromatin fractions (Figure 4.1.5). Since it 
had been shown that the chromatin antigen which reacted with R3.1 
requires complex formation between the DNA and protein(s) (Figures 4.1.2 
& 4.1.3), HeLa DNA was added to the blot following the method of Bowen et 
al. (1980) which was reported to allow considerable DNA binding to the 
proteins on the blot. The DNA-treated electroblot was then prepared to 
react with R3.1 antiserum. No major immunoreactivity change was 
observed except that a protein group of Mr 68,000-70,000 showed marginal 
reactivity with the antiserum. The failure of additional DNA to produce 
a major change in the immunoreaction pattern may be because the ability 
of the DNA to bind to the blot is limited, and not enough is bound to 
make the necessary conformational alterations on the antigen to make it 
accessible to antibody reaction. Since 
it has been observed (see 
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results section) that SDS treatment of chromatin greatly reduces its 
immunoreactivity with R3.1 antiserum, another reason why the addition of 
DNA did not produce a significant change on the protein activity may be 
due to an irreversible denaturation of the target antigen in the 
SDS-polyacrylamide gel, so that even after the limited reconstitution 
with DNA on the blot no extensive renaturation occurred. The third 
possibility is that the proteins on the blot are restricted by the nature 
of their binding to the nitrocellulose paper which may not permit an 
adequate reconstitution with DNA. 
There are other points which could also be considered before 
drawing any conclusion regarding the immunoreactivity of R3.1 on the 
electroblot. 
1. The use of 3% stacking gel and the addition of urea to the gel 
mixture enhances the protein resolution. This additional modification 
may possibly trap large molecules of DNA on the top of the gel. It is 
also possible that some protein molecules, tightly bound to DNA are 
trapped with it. This is unlikely since the stained gel and the 
amido-black-stained electroblot showed no protein staining, at the top of 
both the gel and the blot. 
2. It is obvious that large molecules of DNA are unable to enter 
the high percentage gel. DNA in the concentration of 100pg/ml was added 
to the blot before its reactivation with R3.1 in an attempt to enhance 
the antigen immunoreaction. This amount of DNA is not the limiting step 
for its binding ability, since a lower amount of DNA (10ig/ml) gave a 
comparatively similar pattern of immunoreactivity. The amount of DNA 
added to the blot is far more (approximately 10-15 times) than the 
original DNA content in the chromatin or dehistonised chromatin loaded on 
the polyacrylamide gel. 
Consequently, it is possible to conclude that proteins 68,000 
and 70,000 are part of the HeLa immunogen complex which requires DNA 
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binding for its immunoreactivity with R3.1 antiserum. Based on the 
immunofluorescent staining (Figure 4.1.6) and the results in Figure 
4.1.10, which show a considerable amount of reactivity lying within the 
nuclear lamina-enriched HeLa preparation (predominantly comprises the 
60,000; 68,000 & 70,000 proteins as reported by McKeon et al., 1983), it 
may be suggested that part of the antigen complex is associated with 
nuclear lamina proteins or proteins which constitute a component of the 
nuclear membrane. The former possibility (i. e. association with lamina 
proteins) is more likely. Supporting evidence for this is the different 
distribution of fluorescent reactivity, after treatment with colcemid, 
which indicates the presence of the antigen at various stages of the cell 
cycle (Figures 4.1.6, & 4.1.13 & 4.1.14). This could be correlated with 
Detke & Keller's (1982) report that the lamina proteins are dispersed 
throughout the cell cycle. 
The high titre of immunoreactivity of R3.1 antiserum towards 
HeLa chromatin (Figures 4.1.1,4.1.11 & 4.1.12) contrasts strongly with 
the poor reaction seen on the immunoblot (although the technique is very 
sensitive) and it is important to clarify this discrepancy. It is 
likely that the major antigenic reactivity can not be visualised on the 
immunoblot. This speculation can lead to a more feasible conclusion. 
The major antigen complex which is reactive with R3.1 antiserum may be a 
large complex of delicately (and maybe specifically) associated DNA with 
protein. It is also possible that more than one protein is 
participating in this complex immunoreactivity, and that upon separating 
the protein components by electrophoresis, no significant restoration of 
activity on the immunoblot, even after the addition of DNA, could be 
achieved. It is likely that the major immunoreactivity of this complex 
is highly dependent on this delicate and balanced association between the 
two discrete components (DNA & protein). The immunogen complex is 
susceptible to disorganisation by the effect of SDS treatment, 
electrophoresis and DNA digestion. 
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4.2 Results Obtained Using R2.1 Antiserum 
R2.1 antiserum was raised in a white English rabbit immunised 
with 2M salt-extracted HeLa chromatin given as two (150pg DNA) 
subcutaneous injections ten days apart and one intravenous booster six 
days before bleeding the animal. 
The antiserum showed a high titre on reaction with HeLa 
chromatin. The immunoreaction was demonstrated by C'F assay (Figure 
4.2.1) and ELISA (Figure 4.2.2). A dilution as high as 1/1200-1/1600 
was still enough to show a considerable amount of immunoreactivity with 
the HeLa antigen. 
When R2.1 antiserum was allowed to react with other chromatins 
of human and non-human origin, different patterns of reactivity were 
observed. In C'F assay, two human epithelial cell lines, KB and Chang 
liver chromatins showed little C'F activity (20%) when reacted with R2.1 
antiserum at a dilution of 1/300 (Figure 4.2.1a). Similar results were 
found by ELISA, where KB and Chang liver chromatins showed just below 20% 
of the activity of HeLa chromatin at an antiserum dilution of 1/200-1/400 
(Figure 4.2.2a). However, a non-epithelial human cell line (K562) 
showed high reactivity with R2.1 at serum concentration of 1/200-1/300 in. 
both the C'F and ELISA techniques. 
Other human chromatins from cell lines such as the laryngeal 
carcinoma (H. Ep-2) and the fibrosacroma (HT1080) also exhibited little 
(30%) immunoreactivity in comparison with HeLa chromatin, when tested by 
ELISA (Figure 4.2.2a). 
In contrast to the human chromatins, chromatins from non-human 
cell lines (BSC-1, L929 & NS1) showed no significant immunoreactivity 
(less than 10%) in comparison to HeLa activity in both the C'F and ELISA 
techniques (Figures 4.2.1b & 4.2.2b). These cell lines were green 
African monkey kidney, mouse fibroblast and mouse myeloma respectively. 
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Figure 4.2.1a C'F Assay of R2.1 with Human Chromatins 
Complement fixation assay of various human chromatins 
(20Ng of protein) fixed with different concentrations of 




p Chang liver 
KB 
Antibody control at 1/300 dilution showed a 5% C'F while it was only 1% at 1/1200 dilution. Antigen controls were as follows: 
0% C'F : HeLa, I562 
1% C'F : Chang liver 








antiserum dilution(X 10 
-2) 
X724 1712 1t /s 73 
- 133 - 
Figure 4.2.1b C'F Assay of R2.1 with Non-human Chromatins 
Complement fixation assay of HeLa chromatin compared with 
various non-human chromatins (20pg of protein) fixed with 
different concentrations of R2.1 antiserum. Antibody and 





Antibody control at 1/300 dilution showed a 57, C'F while it was only 1% at 
1/1200 dilution. Antigen controls were as follows: 
0% : HeLa, NS1 








antiserum dilution( x 10-2) 
X124 1712 14r6 1/3 
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Figure 4.2.2a ELISA of R2.1 with Human Chromatin 
Enzyme linked immunoassay of different concentrations of 
R2.1 antiserum reacted with human chromatins (10pg of 
protein layered in each well) immobilised on an ELISA 





Q Chang liver 
  H. Ep-2 
Antibody control was highest at 1/200 dilution (0.08 A492 unit) while 
antigens controls were as follows: 
HeLa 0.126 A429 unit 
BT1080 . 0.102 A492 unit 
KB . 0.101 A492 unit 
K562 0.105 A429 unit 
Chang liver : 0.107 A492 unit 








antiserum dilution ( x10 
2) 
1 11 /16 8 /4 / 2 
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Figure 4.2.2b ELISA of R2.1 with Non-human Chromatins 
Enzyme linked immunosorbent assay of different 
concentrations of R2.1 antiserum reacted with HeLa and 
non-human chromatins (10jig of protein layered in each 
well) immobilised on an ELISA plate. Antibody and 





Antigen controls were found to be: 
HeLa 1 0.126 A492 unit 
L929 : 0.111 A492 unit 
BSC-1 : 0.130 A492 unit 








antiserum dilution(x10-2 ) 
2 
I 16 118 114 
1z 
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To demonstrate whether R2.1 reactivity with HeLa chromatin is . 
dependent on DNA: protein complex formation or not, the chromatin was 
digested with large amount of micrococcal nuclease (2500U/O. lmg/ml). 
The nuclease digested chromatin was then allowed to react with R2.1 
antiserum using the ELISA. About 70% of the chromatin immunoreactivity 
with R2.1 was retained after nuclease digestion (Figure 4.2.3). The 
lost immunoreactivity was almost restored on reconstituting the digested 
chromatin with HeLa DNA alone (Section 3.8.2). The HeLa DNA alone 
exhibited very low reaction (10%) compared with the chromatin reactivity 
(Figure 4.2.3). This suggests that approximately a third of HeLa 
chromatin reactivity with R2.1 antiserum requires the presence of HeLa 
DNA. This part of the immunoreactivity does not lie within the DNA 
alone. 
In order to determine the protein antigen(s) of HeLa chromatin 
and dehistonised chromatin, these fractions were run on an SDS-gel and 
then transferred onto nitrocellulose paper and allowed to react with R2.1 
antiserum (1/250) using the immunoperoxidase method described in Section 
3.5.4.1. Figure 4.2.4 shows a typical result. Both the chromatin 
fraction and the 2M salt-extracted chromatin (lanes 6& 7) showed an 
intense reaction corresponding to a range of approximate molecular 
weights of 42,000-52,000. 
In an attempt to find out whether preincubating the protein blot 
with HeLa DNA has any effect on the pattern of the immunologically 
reactive proteins or not, one strip of protein-containing nitrocellulose 
paper was incubated with DNA as described in Section 3.6.3.5 then allowed 
to react with R2.1 antiserum. Chromatin proteins (lanes 8& 10) show 
the same high colour intensity indicating that the reactive proteins are 
of molecular weights 42,000-52,000. Moreover, the intense and thick 
band of the 2M salt-extracted fraction (lane 9) extends further to 
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Figure 4.2.3 ELISA of R2.1 with Nuclease-digested and -undigested 
HeLa Chromatins 
Enzyme linked immunoassay of R2.1 antiserum (1/250) 
allowed to react with different concentrations of HeLa 
antigen immobilised on an ELISA plate. Antibody and 
antigen controls were subtracted. (Chromatin measured as 
total protein content and HeLa DNA estimated as total DNA 
content). 
O Undigested HeLa chromatin 
p Micrococcal nuclease-digested HeLa chromatin 
reconstituted with HeLa DNA 
D Micrococcal nuclease-digested HeLa chromatin 
D HeLa DNA alone 
The average antibody control was 0.1 while antigen controls varied slightly 
witl'the amount of antigen plated and the highest was 
found at about 









jig of protein or DNA 
0.28 0.56 1.125 2.25 
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Figure 4.2.4 Protein Blot of HeLa Chromatin Reacted with R2.1 and 
Normal Rabbit Sera 
Protein immunoblot of R2.1 antiserum (strips C and D) and 
normal rabbit serum (strip A) reacted, at a dilution of 
1/250, with chromatin (lanes 1,6,8 and 10) and 2M 
salt-extracted chromatin (lanes 2,7 and 9) preparations 
from HeLa cells visualised by using the immunoperoxidase 
method. Lanes 3 and 5 are the amido-black stained 
proteins corresponding to chromatin and dehistonised 
chromatin respectively. Lane 4 is the molecular weight 
marker (from top: phosphorylase b 94,000; bovine serum 
albumin 67,000; ovalbumin 43,000; carbonic anhydrase 
30,000; soybean trypsin inhibitor 20,100; OC-lactalbumin 
14,400). The proteins were analysed in a 10% Laemmli 
polyacrylamide gel containing 0.5M urea. Strip D has 
been incubated with HeLa DNA prior to its reaction with 
R2.1. 
Although the core histone 'proteins were well separated (lane 3), Hl histone 
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encompass a range of 40,000-52,000 of molecular weight. In addition, a 
faint and again unresolved thick band corresponding to a molecular weight 
range of 52,000-64,000 was visible in both chromatin and dehistonised 
chromatin fractions only on pretreating the blot with DNA prior to the 
antibody reaction. Another, very faint but single, protein bandscan be 
seen at approximate molecular weights of 80,000 and above 100,000 in the 
DNA treated blot (arrows). 
Normal rabbit serum (1/250) again failed to show any reactivity 
with HeLa chromatin and dehistonised chromatin. 
Examination of the amido-black stained blot shows that both 
chromatin (lane 3) and dehistonised chromatin (lane 5) have one 
detectable band at the range of Mr 43,000-45,000. No other band at the 
range of Mr 40,000-52,000 could be seen. This may indicate the presence 
of amido-black-undetected proteins above and below the 43,000-45,000 
protein band(s). While these proteins are not detectable by amido-black 
staining, they are readily observed by immunoblotting. This exemplifies 
the usefulness and efficiency of the sensitive immunoblotting technique. 
Indirect immunofluorescence was employed to determine the 
subcellular localisation of the HeLa antigen. HeLa cells were grown on 
coverslips, washed, lysed, fixed and allowed to react with R2.1 antiserum 
(1/100) then FITC-conjugated second antibody. The immunofluorescent 
stained-cells were inspected under the fluorescent microscope. Figure 
4.2.5 demonstrates that the immunoreactivity is distributed in both 
nuclei and cytoplasm. The fluorescent staining is more intense in 
nuclei with negatively stained nucleoli (Figure 4.2.5a-e). Filamentous 
structures extending from the cytoplasmic periphery (Figure 4.2.5f & g) 
could also be seen using high magnification. 
In order to examine whether the cytoplasmic staining was of the 
cytokeratin type or not, the FITC 
technique was employed with the aim of 
preserving the structure of the 
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Figure 4.2.5 FITC-staining of HeLa Cells Reacted with R2.1 
_ ý:,; ý. 
Indirect immunofluorescent staining of HeLa cells reacted 
with R2.1 (1/100) antiserum. The cells were grown on 
coverslips and treated as described in section 3.7.4. 
(a) X310 
(b & C) X500 
(d & e) X2000 
(f & g) X2000 with reference to filamentous structures 
ý: 
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described in section 3.7.3 and the fluorescent staining is shown in 
Figure 4.2.6. No distinct filamentous structures were identified 
although predominant cytoplasmic staining was noted. The intermediate 
filaments of HeLa cells are largely of the prekeratin and vimentin type 
and these are both of molecular weights higher than 52,000. Since no 
strong immunoreactivity of R2.1 antiserum with proteins higher than Mr 
52,000 in the chromatin and dehistonised chromatin fractions was detected 
(Figure 4.2.4), it is likely that the antiserum is either not directed 
primarily against this type of protein, or that the prekerat'in and 
vimentin groups of cytoplasmic location are probably not contaminating 
the chromatin preparations. 
To clarify this finding, a cytokeratin preparation from whole 
HeLa cells was run on a gel, blotted onto nitrocellulose paper, and 
allowed to react with R2.1 antiserum, by the immunoperoxidase method 
(Figure 4.2.7). In addition to the thick band of Mr 42,000-52,000 (lane 
2), another strongly reactive broad band at approximate range of 
molecular weight of 54,000-61,000 was observed. Another group of 
proteins in the cytokeratin preparation (lane 2) showed a strong 
immunoreactivity with R2.1 antiserum at Mr 20,500-24,000. These two 
groups of proteins were not present in the nuclei and 2M salt-extracted 
chromatin preparations (lane 3& 4). The cytokeratin as well as the 
nuclei preparation (lane 2& 3) both exhibited another immunoreactivity 
at approximate Mr of 15,000-16,000, which was absent in the 2M 
salt-extracted chromatin (lane 4). 
Lane (3) in Figure 4.2.7 represents nuclei prepared by the 
Chauveau method and allowed to react with R2.1 (1/250) antiserum in the 
immunoblot. A reaction similar to that of the dehistonised chromatin 
(lane 4) was observed while there was no immunoreactivity with proteins 
corresponding to molecular weight ranges of 54,000-61,000 and 
20,500-24,000. This suggests that there were no reactive proteins in 
- 142 - 
Figure 4.2.6 FITC-staining of HeLa Keratin Structures Reacted 
with R2.1 
(a) An indirect immunofluorescent staining of HeLa cells 
prepared on coverslips as described in section 3.7.3 
preserving the cytokeratins then allowed to react with 
R2.1 antiserum (1/150). (X2000) 
(b) Phase contrast of cells in a (X2000) 
r 
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Figure 4.2.7 Immunoblot of R2.1 Reacted with HeLa Subfractions 
Compared with Human and Non-human Dehistonised 
Chromatins 
A protein immunoblot (section 3.5.4.1) of R2.1 antiserum 
reacted with 2M salt-extracted chromatin preparations 
(lanes 4-12) from different human and non-human cell 
lines, as well as with HeLa keratin preparations (lane 2) 
(section 3.8.6) and HeLa nuclei (lane 3) (section 
3.1.1.1). Lane (1) is a blot of protein marker stained 
with amido-black. The protein preparations were run on a 
10% Laemmli gel plus 0.5M urea. 
Lanes 1: protein marker (from top: phosphorylase b 94,000; 
bovine serum albumin 67,000; ovalbumin 43,000; 
carbonic anhydrase 30,000; soybean trypsin 
inhibitor 20,100; oC-lactalbumin 14,400). 
2: HeLa keratin preparation 
3: HeLa nuclei preparation 
4 HeLa 5 K562 
6 FL 7 KB 
8: Chang liver 9 HT1080 
10 : BSC-1 11 CHO 
12 : BHK-21 
10 11 12 
, /ý 
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these two ranges of molecular weights, present in the preparation of 
nuclei. 
Whether the cytoplasmic immunofluorescent staining seen in 
Figures 4.2.5 and 4.2.6 is due to naturally occurring anti-intermediate 
filament antibodies in the rabbit antiserum or to contaminants in 
immunising nuclear proteins, remains to be established. However, it is 
possible that some of these protein antigens are nuclear but because they 
are synthesised in the cytoplasm, and therefore have been localised there 
by immunofluorescence. Furthermore, it is also possible that one (or 
more) of the proteins in the range of Mr 42,000-52,000 is genuinely 
nuclear but masked by the overlapping of other reactive proteins (of 
cytoplasmic localisation) which are of similar or approximately similar 
molecular weights. 
An efficient method of resolving the immunoreactive bands at 
42,000-52,000 is by the use of highly purified radiolabelled antibody as 
shown in Figure 4.2.8. Three highly resolved and sharp bands of 
molecular weights corresponding to approximately 54,000,51,000 and 
45,000 were clearly observed on the autoradiogram, in the lane which 
represents the keratin preparation (lane 1). Interestingly, only one 
single and sharp band at Mr 51,000 could be seen in the nuclear 
preparation obtained by the method of Chauveau method (lane 2), while in 
the lane representing the 2M salt-extracted chromatin (lane 3), three 
bands of approximate molecular weights of 52,000,49,000 and 43,000 were 
observed. This may suggest that one protein (51,000) at least could be 
assigned to the nuclear fraction. The other two proteins in the 
dehistonised fraction (Mr 49,000 & 43,000) may be present in too small 
quantities in nuclear preparations, to be detected on the immunoblot. 
The relative amount of these two proteins may be enriched in the 
dehistonised chromatin preparation. The molecular weights of these 
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Figure 4.2.8 Autoradiography of R2.1 Reacted with HeLa 
Subfractions 
An autoradiogram of a protein immunoblot of R2.1 antiserum 
(1/300) described in section 3.5.4.2 reacted with HeLa 
keratin preparation (lane 1), HeLa nuclei prepared by 
Chauveau method (lane 2) and 2M salt-extracted chromatin 
(lane 3). The second antibody (affinity purified 
anti-rabbit IgG) was labelled by 
125 
I as described in 
methods section. 
Mrx10 3 Mrx10 
3 
54- 51 
451 5- i149 
-43 
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bands were estimated by running a marker protein standard, simultaneously 
on the same gel. The blot corresponding to the protein marker was 
stained with amido-black, then aligned with the negative of the 
autoradiogram to indicate the approximate molecular weight of the 
reactive proteins. 
It is suggested by Lewis and Laemmli (1982) that isolation of 
the nuclei in a buffer containing polyamines (spermine and spermidine) 
and digitonin with subsequent sedimentation of nuclear pellet through 
sucrose gradients results in elimination or reduction of contamination by 
intermediate filaments. The total chromatin obtained from this method 
and the Chauveau method of preparation was electrophoresed on a long 
polyacrylamide gel and transferred onto a nitrocellulose paper. The 
blot was then allowed to react with R2.1 antiserum diluted 400 times with 
TN-GS-BSA buffer. The use of a more dilute antiserum should minimise 
the reaction of non-specific or less abundant antibodies thus reducing 
interference. Figure 4.2.9 shows little difference between the two 
preparative methods (lanes 5& 6). Moreover, it can be seen that only 
one band is visible at a molecular weight of 51,000 in lane (6) which 
contains the chromatin obtained by the Chauveau method, while lane (5) 
showed a broader reaction at approximately the same molecular weight. 
Chromatin prepared by the routine procedure (section 3.1.2) demonstrated 
an immunoreactivity at approximate molecular weight of 50,000-51,000 
(lane 3). Again, the 2M salt-extracted chromatin (lane 2) showed a 
strong, broad and unresolved band at a range of Mr 42,000-52,000 which 
may be due to the enrichment of the other reactive proteins in this kind 
of preparation. It is worth noting that the cytoplasmic fraction 
exhibited no detectable immunoreactivity with R2.1 (1/400) antiserum 
(lane 4). 
The results shown in Figure 4.2.8 (lane 2) in conjunction with 
those presented in Figure 4.2.9 (lanes 3& 6) confirm that one major 
nuclear protein is immunoreactive in these subcellular fractions. It is 
- 147 - 
Figure 4.2.9 Immunoblot of R2.1 Reacted with HeLa Subfractions 
Protein immunoblot of R2.1 antiserum reacted with 
different subcellular preparations from HeLa cells. 
Lane 1: Amido-black-stained protein marker 
2: 2M salt-extracted chromatin 
3: Chromatin preparation 
4: Cytoplasmic fraction 
5. Nuclei prepared by the polyamine method (section 
3.1.1.2) 
6 Nuclei prepared by the Chauveau method 
m 
-00 
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also possible to suggest that proteins of approximate molecular weights 
of 42,000-43,000 and 49,000 usually present in the dehistonised chromatin 
preparation may be minor components in the total chromatin fraction and 
become enriched and detectable in the 2M salt-extracted chromatin. 
However, the possibility that the 43,000 and 49,000 bands are genuinely 
cytoplasmic proteins, perhaps of the cytokeratin type contaminating the 
chromatin preparations, can not be ruled out. 
Mitotic HeLa cells fixed on coverslips reacted with R2.1 
antiserum. Although the intensity of FITC staining in these cells is 
not as bright as in interphase (Figure 4.2.5), it is clear that all the 
cells have shown fluorescent immunoreaction (Figure 4.2.10a, c& e). 
Examination of the swollen mitotic cells revealed unidentified 
speckled-structures scattered throughout the cell (Figure 4.2.10g). 
Although the mitotic cells were cytocentrifuged according to the method 
of Stenman et al. (1975), before reaction with the antibody, in an 
attempt to spread and detect the chromosomes, the fluorescent staining 
has not revealed clear metaphase chromosomal structures (Figure 
4.2.10g). However, this does not rule out the presence of chromosomal 
decoration because the antiserum (R2.1) is polyclonal and may have 
reacted with other components which hinder the clear identification of 
chromosomal staining. 
Figure 4.2.7 shows that other human dehistonised chromatins give 
different pattern of immunoreactivity with R2.1 antiserum, though there 
are some similarities. It is interesting to note that the K562 cell 
line which is a myelogenous leukemia line, despite exhibiting a high 
reactivity with R2.1 in both C'F and ELISA techniques, shows only one 
major band at Mr 49,000 (lane 5). The FL cell line which is of an 
epithelial origin exhibited a broad and unresolved reactive band at Mr 
41,000-49,000 (lane 6). KB chromatin (lane 7) reacted less vigorously 
showing two faint bands corresponding to molecular weights of 45,000 and 
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Figure 4.2.10 FITC-stained Mitotic HeLa Cells Reacted with R2.1 
An indirect immunofluorescent staining of HeLa cells 
swollen in hypotonic solution and spread and fixed on 
slides by cytocentrifugation then allowed to react with 
R2.1 (1/100) antiserum. 
(a, c & e) : FITC staining (X500) 
(b, d & f) Phase contrast of cells in a, c and e 
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48,000. On the other hand, Chang liver, which showed very little 
activity in C'F and ELISA, its dehistonised chromatin demonstrated a 
strong immunoreaction with R2.1 antiserum at Mr 42,000,45,000 and 49,000 
although some overlapping was also noted at the same range of molecular 
weight. Weak immunoreaction at Mr 51,000 and 59,000 was also observed 
in the immunoblot (lane 8). The fibrosarcoma cell line, HT1080, showed 
clear reactive protein bands at Mr 42,000,44,000 and 49,000 (lane 9). 
Of the non-human chromatins, only the green African monkey 
kidney cell line (BSC-1) showed a clear immunoreaction at 49,000 (lane 
10), while both hamster cell lines (CHO & BHK-21) exhibited a weaker 
reaction corresponding to proteins at molecular weights of 59,000 and 
64,000 (lanes 11 & 12). 
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When the isolated nuclei of HeLa cells were extracted with 2M 
salt-buffer, a group of proteins believed to have high affinity to DNA 
could be sedimented through 1M sucrose bed. This 2M salt-extracted 
chromatin was strongly antigenic. and the resulting polyclonal antiserum 
(R2.1) was used to determine and characterise the immunologically 
reactive groups in HeLa chromatin as well as in other human and non-human 
cell lines, using different techniques (C'F, ELISA, immunoblotting and 
immunofluorescence). The amount of protein remaining after 2M 
salt-extraction is greater than the residual protein left behind in 2M 
salt-5M urea-extraction. Adding to this is the irreversible 
denaturation of some nuclear components (such as some enzymes) which 
could be avoided or considered less likely by excluding the urea from the 
extraction buffer. 
Both C'F assay and ELISA (Figures 4.2.1 & 4.2.2) demonstrated 
very small immunoreactivity between R2.1 and non-human chromatins. On 
the other hand, different reactivity patterns with respect to human 
chromatins was observed. Human epithelial cells (Chang liver, KB and 
H. Ep-2) showed between 20-30% of the reactivity of HeLa chromatin at an 
antiserum dilution of over 1/200. Exceptionally higher reactivity was 
exhibited by human blood cell line (K562) in C'F assay (more than 80% 
C'F) as well as ELISA (approximately 40% of HeLa chromatin reactivity). 
Unlike the immunoreactivity of the antigen-complex seen with 
R3.1 antiserum and those reported by Campbell et al. (1979) which were 




immunoreaction of R2.1 with HeLa chromatin was lost extensive micrococcal 
nuclease digestion (Figure 4.2.3). The lost immunoreactivity was again 
almost restored on reconstituting the digested chromatin with HeLa DNA, 
while the DNA alone failed to exhibit any significant reaction with R2.1 
antiserum. 
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The need for DNA association (for part of the antigen) was once 
again demonstrated when a group of immunologically reactive proteins 
showed a faint reaction after treating the immunoblot with HeLa DNA prior 
to its reactivity with R2.1 antiserum. These reactive groups were seen 
in both chromatin and dehistonised chromatin fractions (Figure 4.2.4). 
The first group which was not clearly resolved on the blot occupy a range 
of molecular weights of 52,000-64,000. The other DNA-dependent reactive 
groups could be seen (arrows) at higher molecular weights (approximately 
Mr 80,000 & 100,000). A third and again unresolved group which showed 
clearly strong reaction with R2.1 antiserum after treating the blot with 
HeLa DNA was also observed at a range of Mr 40,000-42,000, overlapping 
the other group (42,000-52,000) which did not require DNA-association for 
its immunoreaction. 
There is a great difference in the intensity of reaction between 
the HeLa interphase and metaphase cells as viewed by FITC staining 
(Figure 4.2.5 & 4.2.10). This difference could be attributed to the 
absence (or decrease) of some components of the reactive antigen(s) 
during mitosis. The pattern seen in mitotic cells did not show any 
distinct FITC-stained chromosomal structures. This may be due to the 
overlapping of chromosomal and non-chromosomal reactions. 
It is obviously relevant to determine whether all the reactive 
groups seen on the immunoblot are nuclear, or cytoplasmic. The risk of 
cytoplasmic contamination stems mainly from a group of proteins 
(collectively called cytokeratins and specifically termed intermediate 
filaments - I. F. ) which resist solubilisation by non-ionic detergents 
(such as triton X-100) and by low or high salt-extraction (reviewed 
recently by Moll et al. 1982 & Lazarides 1982). 
Although Franke et al. (1979) have reported the presence of only 
four major intermediate filament protein bands in HeLa cells of Mr 
54,000,52,000,48,000 and 46,000, recent reports have demonstrated 
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another two immunologically reactive protein groups at Mr 43,000 and 
50,000 (Bravo et al, 1983) and at 58,000 and 65,000-67,000 (Tseng et al. 
1982). 
Figure 4.2.7 (lane 2) shows a cytokeratin preparation from HeLa 
cells reacting with four groups of proteins on the immunoblot. 
Comparing these immunologically reactive groups with that of the 
dehistonised chromatin (lane 4), it is possible to detect that only one 
group (42,000-52,000) is common to both preparations, while the other 
three groups, (54,000-61,000,20,500-24,000 & 15,000-16,000) are confined 
to the keratin preparation. The chromatin preparation (Figure 4.2.4) 
exhibited a reaction pattern exactly similar to the dehistonised fraction 
(lanes 6& 7). Unlike the keratin preparation (Figure 4.2.7, lane 2), 
no other reactive group (other than the 42,000-52,000 group) could be 
seen in either of these two preparations (chromatin and dehistonised 
chromatin; Figure 4.2.4, lanes 6& 7) nor in the nuclear fraction 
(except the Mr 15,000-16,000 group) seen in Figure 4.2.7, lane (3). 
It is important to emphasise that HeLa intermediate filaments 
have been shown to be distinct (Franke et al. 1979; Moll et al. 1982). 
It is also noteworthy that antisera and monoclonal antibodies produced by 
immunising the animals with dehistonised chromatin fraction have also 
exhibited specific reactivity with intermediate filament class of 
proteins (Schmidt et al. 1981; Turner, 1981). 
The major cytokeratin proteins in HeLa cells (vimentin and 
phosphovimentin) are of Mr 54,000-55,000, and another two cytokeratins of 
Mr 52,000 and 58,000 have been identified (Bravo & Celis, 1982). 
Consequently, some of the reactive proteins (which reacted with R2.1) in 
this region of the keratin preparation (Figures 4.2.7, lane 2&4.2.8 
lane 1) may be assigned to cytoplasmic-reactive groups including 
intermediate filaments. This could also be correlated with some of the 
cytoplasmic reaction seen by immunofluorescent staining (Figure 4,2,5 & 
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4.2.6). Since there are no distinctly defined filaments or meshwork 
arrays or fibrils, it is difficult to speculate whether these fibrous 
structures are of the intermediate filament type or of actin (Mr 
43,000). Hindering this identification is the possibility of a mixture 
of a number of cytoplasmically reactive groups, present together, which 
mask the presence of a defined filamentous organisation. 
The relative intensity of the reactive group in the dehistonised 
chromatin fractions, shown in Figure 4.2.7, implies that the HeLa 
fraction (lane 4) has approximately the same immunoreactivity as that of 
Chang liver chromatin (lane 8). This is in contrast to the results 
shown in Figure 4.2.2a where HeLa chromatin demonstrated very high 
immunoreaction with R2.1 antiserum, in comparison with Chang liver 
chromatin. The latter demonstrated only 20% of HeLa chromatin 
immunoreactivity. This could be explained as follows: 
1) Some of these reactive groups are of intermediate filament 
(I. F. ) contaminants which are common to both cell lines. Their 
contribution (I. F. ) to the immunoreactivity of HeLa chromatin is probably 
equivalent to the observed 20% exhibited by Chang liver chromatin. 
2) Much of the specific HeLa antigen immunoreaction is associated 
with a) DNA-complex formation. Evidence supporting this possibility is 
that part (at least 30%) of the HeLa antigen requires DNA-association to 
exert its immunoreaction with R2.1 antiserum (Figure 4.2.3), and b) 
chromatin components of a complex of components which are more abundant 
in HeLa chromatin than in Chang liver. Upon 2M salt extraction of both 
chromatins, enrichment of the nonspecific components has taken place in 
both dehistonised fractions (HeLa & Chang liver). These components may 
be common to many epithelial and related cell lines (HeLa, Chang liver, 
FL and HT1080). This would result in overlapping between the 
chromatin-associated reactive proteins and the cytoplasmic contaminants 
in a broad reactive band, and indicate that the dehistonised fraction of 
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HeLa chromatin exercises a similar reactivity pattern with those of other 
epithelial cell lines on the blot. 
Amongst the reactive group of Mr 42,000-52,000 in HeLa chromatin 
preparations, at least one band (Mr 51,000) is genuinely a nuclear 
protein (Figures 4.2.8 lane 2&4.2.9 lane 3& 6). The rest of the 
reactive proteins in this region are either cytoplasmic contaminants or a 
result of overlapping between nuclear and non-nuclear bands. The 
FITC-staining of whole HeLa cells (Figure 4.2.5) indicates that the 
predominant immunofluoresence is concentrated in the nuclei. This 
implies that the majority of the reactive antigens are of nuclear 
localisation. Further support to this idea is the DNA-requirement for 
part (30%) of the HeLa chromatin reactivity demonstrated in Figures 4.2.3 
and 4.2.4, and also by the observation in Figures 4.2.8 and 4.2.9 which 
shows that the Mr 51,000 protein is nuclear associated. Thus the 
nuclear antigen visualised by FITC-staining is very probably from two or 
more sources: - 
1) Nuclear protein(s) represented mainly by Mr 51,000 which do not 
require complex formation with DNA for immunoreactivity. The presence 
of other reactive nuclear protein(s) of this class in the region of 
42,000-52,000 is highly possible (Figure 4.2.8 lane 3). 
2) Nuclear antigens which require the presence of DNA-complex 
formation for immunoreactivity. These antigens are represented by 
(a) strongly reactive proteins, Mr 40,000-42,000 (Figure 4.2.4 lane 9). 
(b) very weakly reactive bands at Mr 80,000 and above 100,000. 
(c) intermediately reactive protein bands at Mr 52,000-64,000. 
The last finding is in agreement with the report of Lebkowski 
and Laemmli (1982) in which it is emphasised that major DNA-binding 
proteins, in 2M salt-extracted HeLa chromatin, are of molecular weights 
of 60,000-70,000 and include bands at Mr 60,000,68,000 and 70,000 and a 
minor protein at Mr 64,000. 
- 156 - 
In summary it can be suggested that R2.1 antiserum, which has 
been raised in a rabbit against 2M salt-extracted chromatin, reacts with 
two different groups of proteins in HeLa cells. 
1. Nuclear proteins: This group is of two types: 
(a) Nuclear proteins whose immunoreactivity necessitates 
DNA-binding in order to dictate the required antigenic determinants 
presentation for R2.1 reaction. Some of these proteins, are possibly 
the type of nuclear laminar proteins (Mr 60,000-70,000) described by 
Lebkowski and Laemmli (1982). 
(b) Nuclear proteins which react with R2.1 antiserum 
regardless of the presence of DNA-binding. 
2. The second group is that of cytoplasmic localisation. This 
group again could be divided into two subgroups. 
(a) Those of cytoplasmic contaminants represented mainly by 
the cytokeratins or other filamentous-forming proteins. 
(b) Those of nuclear origin but reacted in the cytoplasm 
because they are synthesised there. 
It is also interesting to note that Adolph (1980a) has reported 
that a cluster of the scaffold proteins in HeLa cells is of the 
approximate molecular weight range of 50,000-55,000. Although this 
report has been contradicted recently by Lebkowski and Laemmli (1982) who 
suggested that these proteins represent intermediate filaments 
contamination, Figures 4.2.4,4.2.8 and 4.2.9 indicated that a protein of 
Mr 51,000 is amongst the residual nuclear scaffold components. In 
addition, DNA-binding proteins (Figure 4.2.4) are also among the residual 
proteins and could be immunologically localised at a molecular weight 
range of 52,000-64,000. This is also in agreement with Adolph's 
previous report (Adolph, 1980a) as well as with the suggestion of 
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Lebkowski and Laemmli (1982), since the DNA-binding proteins recognised 
by R2.1 reaction accommodate parts of the two groups of proteins 
(50,000-55,000 and 60,000-70,000) reported by Adolph (1980a)and Lebkowski 
& Laemmli (1982) respectively. 
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4.3 Results and Discussion of Monoclonal HNo-G7 
HNo-G7 is a monoclonal antibody resulting from the fusion of 
spleen cells from a BALB/c mouse immunised with dehistonised HeLa 
chromatin and X63-Ag8-653 (653) plasmacytoma cells. The fusion schedule 
is outlined in Figure 4.3.1a. The murine hybridoma cell line was cloned 
four times by limited dilution at 0.5-1 cell/well and has been 
established in culture for more than 18 months without loss of 
secretion. The established clone can be frozen and recovered from 
liquid nitrogen and when grown to exhaustion secretes 30pg IgM/106 
cells/day as estimated by ELISA with reference to controls of standard 
mouse IgM. Recloning shows no revertant colonies and the line is now 
assumed to be stable. 
The hybridoma line which produces the cells is shown in Figure 
4.3.1b forming a colony. 
HNo-G7 was shown to be from an IgM-secreting hybridoma both by 
ELISA assays utilising class-specific antisera and internal 
radio-labelling (Fig. 4.3.2). 
The reaction of the monoclonal antibody and its unknown antigen 
was initially investigated with respect to the pH of the ELISA assay 
since other monoclonal antibodies have been shown to have very precise 
assay requirements in this respect and these would clearly affect 
subsequent characterisation (Fraser et al., 1982; Mossman et al., 
1980). Figure 4.3.3 shows that the pH does not have a substantial 
effect on the assay of the monoclonal antibody with immobilised HeLa 
chromatin at pH7-11. Figure 4.3.4 demonstrates that, although the 
binding to the plate differs at various pH values, it is at saturation at 
the usual concentrations of antigen employed (l0pg/well). The 
difference at low antigen concentration could also be attributed to the 
buffer system used for immobilising the antigen, but this again has no 
significant effect on the course of this study since carbonate is the 
routinely used buffer. ' 
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Figure 4.3.1a Fusion Schedule 
Step Day Operation 
1 -28 Injection with 100 P9 DNA of dehistonised 
chromatin prepared by 2M salt - 5M urea 
extraction (see section 3.2.2) in complete 
Freund's adjuvant, intraperitoneally. 
2 -18 Injection with 100rg DNA of dehistonised 
chromatin as above. 
3 -5 Injection of 100pg dehistonised chromatin 
in saline, intraperitoneally. 
40 Fusion (see section 3.3.5). 
5 14-18 Assay. Positive clones selected subcloned 
at 0.5-1 cell/well. 
6 30-34 Clones assayed. Positives selected and 
subcloned at 0.5-1 cell/well. 
7 Steps 5&6 repeated twice. 
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Figure 4.3.1b Hybridoma Colony of HNo-G7 
HNo-G7 Hybridoma colony visualised under Light Microscope 
(X125) 
Oil: 
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Fiqure 4.3.2 Immunoglobulin Secretion of HNo-G7 
Immunoprecipitate of secreted immunoglobulin (internally 
labelled with [35S]-methionine) from the P3-X63-Ag8(IgG 
secreting) myeloma cell line (lane 1) and HNo-G7 
Hybridoma (lane 2) analysed on a 10% SDS-PAGE. The 
proceduresof radiolabelling and immu noprecipitation are 
described in section 3.5.2. The gel mixture is of a 
ratio of 0.8: 30 (bisacrylamide: acrylamide) 
3 
MrxIÖ 
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51 - 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Figure 4.3.3 pH Effect on HNo-G7 Immunoreactivity 
The effect of pH on the immunoreactivity of HNo-G7 with 
HeLa chromatin as tested by ELISA (Procedure is described 
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Figure 4.3.4 Effect of Ag- Coating Buffer 
ELISA of HNo-G7 antibody reacted with various amounts of 
HeLa chromatin, suspended and immobilised in the ELISA 
plate using different coating buffers. 
O In carbonate buffer pH9.5 
A In PBS pH7.3 
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The "Chequerboard" ELISA of the monoclonal antibody with the 
antigen (Fig. 4.3.5. a) is performed to give an indication of the 
dilutions of culture supernatant which may be used for assay of both 
antibody and antigen. While visual inspection of the plate gives a 
clear indication of the results, the data are also read by "Titretek 
Multiskan Spectrophotometer" to give a more detailed analysis and 
laboratory record. Figure 4.3.5b shows selective reading from the above 
"Chequerboard". It is clear that at excess antibody (diluted up to 
1/64) there is only small difference (less than 0.2 A492 units) between 
the reactivity of HNo-G7 with various concentrations of HeLa chromatin 
above 2.5pg/well. This again indicates that a near saturation of 
antigen binding is reached when more than 2.5pg/well of chromatin is 
layered on the ELISA plate. 
The specificity of HNo-G7 was then tested by its reaction with 
other human chromatins in comparison to HeLa chromatin. Figure 4.3.6 
shows the reaction in comparison to two other established human 
epithelial cell lines (H. Ep-2 & Chang liver) and a fibrosarcoma line, 
HT1080. It is clear that either the same antigen or the same 
determinant is present in the other epithelial cell lines but that there 
is no detectable antigenic activity in the fibrosarcoma cell line. It 
is also clear that the antigenic determinant is not present on purified 
human DNA. 
The quantitative difference between the various types of chromatin 
could reflect differential binding of the antigen to the ELISA plate. 
Consequently, a competition assay as described in section 3.4.5 was also 
employed to examine this phenomenon. HeLa and other human chromatins at 
different concentrations were incubated at 4°C for 18-24 hours with a 
fixed amount of HNo-G7 culture supernatant diluted 1/20 to absorb the 
antibody. The mixture was centrifuged briefly and 50pl of a supernatant 
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Figure 4.3.5a A Chequerboard ELISA of HNo-G7 with HeLa Chromatin 
ELISA of different dilutions (1-1/64) of HNo-G7 antibody 
(lanes B-"H) with various concentrations (40pg-0.08pg) of 
HeLa chromatin (lanes 3-. 12) on an ELISA plate. Wells 
numbered A3-A12 represent the antigen control of various 
amounts of HeLa chromatin, while antibody controls of 
different dilutions are represented by wells numbered 
2B-2H. Well number A2 was not treated intially with 
either antigen or HNo-G7 but at the final stage of the 
procedure was incubated with anti-mouse-IgG-peroxidase- 
conjugated antiserum. 
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Figure 4.3.5. b ELISA of HNo-G7 with HeLa Chromatin 
ELISA of different dilutions of HNo-G7 antibody with 
various concentrations of HeLa chromatin selected from 
the "chequerboard" test in Figure 4.3.5a. Antibody and 
antigen controls were subtracted. 
O HNo-G7 antibody diluted 1/16 
HNo-G7 diluted 1/32 
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Figure 4.3.6 ELISA of HNo-G7 with Human Chromatins 
Enzyme linked immunosorbent assay of HNo-G7 (1/20) 
antibody reacted with different concentrations of various 
human chromatins. Antibody and antigen controls were 
subtracted. All chromatins measured as total protein 
content and DNA estimated as total DNA content. 
O HeLa chromatin 
El Chang liver 
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from each sample was then added to a fixed amount of HeLa chromatin 
immobilised on an ELISA plate. The results are shown in Figure 
4.3.7a. Much of the reactive antibody was absorbed by the HeLa 
chromatin while H. Ep-2 and Chang liver chromatins exhibited lower 
absorption profiles. The data are shown with greater clarification, 
replotted as a percentage in Figure 4.3.7b. It can be seen that HeLa 
chromatin at a concentration of 20pg/50pl of antibody (1/20) was able to 
bind almost 80% of the reactive antibody while H. Ep-2 and Chang liver 
chromatins were only able to bind 35% and 25% at the same 
concentrations. The data thus appear to indicate that the antigenic 
determinant is either present at lower concentrations or less accessible 
in the chromatins of the two other epithelial cell lines. 
The HNo-G7 monoclonal antibody reacted variably with subcelluar 
preparations from HeLa cells (Fig. 4.3.8). Chromatin, cytoplasmic, 
nucleolar and 2M salt soluble extracts of chromatin were allowed to react 
with the monoclonal antibody on ELISA, using fixed amounts of each 
preparation (10ig protein/well) bound to the plate. The chromatin 
preparation again demonstrated high reactivity with HNo-G7 and 
considerable but lesser activity was also present in cytoplasmic and " 
nucleolar preparations. The 2M salt-soluble chromatin, which had been 
extensively dialysed against PBS buffer, failed to show any activity. 
As this preparation contains large amounts of histones these results 
indicate that the antigen is unlikely to be a histone. 
In order to confirm that the qualitative difference between the 
different subcellular fractions does not reflect differential binding of 
the proteins to the ELISA plate, a competition assay was performed in a 
manner similar to the assay used for Figure 4.3.7a and b. The results 
are shown in Figures 4.3.9a and b. It can be seen that HeLa chromatin 
competed very effectively against itself as would be expected with 80% of 
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Figure 4.3.7a Competition ELISA of HNo-G7 with Human Chromatins 
Enzyme linked immunoassay of HNo-G7 (1/20) absorbed with 
various concentration of human chromatins. The 
supernatants (50pl) after this incubation were allowed to 
react with constant amount of HeLa chromatin immobilised 
on an ELISA plate (section 3.4.5). 
O HeLa 
  H. Ep-2 







(pg/50p1) of various chromatins competed with 
HeLa Chromatin for the binding of HNo-G7 
2.5 5 10 20 
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Figure 4.3.7b Percentage of Absorbed HNo-G7 Used in Competition ELISA 
of-Human Chromatins 
The amount of the remaining reactive antibody (HNo-G7), 
after absorption with the chromatins described in 4.3.7a, 
expressed in percentage of total free HNo-G7 reacted with 
the immobilised HeLa chromatin. 
O HeLa 
0 Chang liver 








(fig/50p1) of the competed Chromatins described 
in Figure 4.3.7a 
LV 
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Figure 4.3.8 ELISA of HNo-G7 with HeLa Subfractions 
Enzyme linked immunoassay of different concentrations of 
the HNo-G7 antibody reacted with fixed amount of HeLa 
P, Ote1ý, 
cell subcellular fractions (10)tg/well) immobilised on an 
ELISA plate. Antibody and antigen controls were 
subtracted. 
O HeLa chromatin 
13 Cytoplasmic preparation 
Nucleolar preparation 
0 2M salt-soluble chromatin (Histones) 
(the soluble protein was dialysed against PBS and 
the precipitate resuspended in the coating buffer 
as for the other preparations). 
Antibody control waß 0.05 A492 unit and the antigens controls were as 
follows: 
HeLa chromatin : 0.14 A492 unit 
Cytoplasmic preparation : 0.16 A492 unit 







'164 '132 1/16 1/8 
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Figure 4.3.9a Competition ELISA of HNo-G7 with HeLa Subfractions 
Enzyme linked immunoassay of HNo-G7 (1/20) absorbed by 
various concentrations of HeLa subcellular fractions. 
The supernatant of the mixture was allowed to react with 
HeLa chromatin immobilised (10Ng/well) on an ELISA 
plate. Antibody and antigen controls were subtracted. 
O HeLa chromatin 
Q Cytoplasmic fraction 
1 Nucleolar preparation 








()jg/50N1) of protein competed with HeLa chromatin 
for the HNo-G7 antibody binding sites 
2.5 5 10 20 
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Figure 4.3.9b Percentage of Absorbed HNo-G7 Used in Competition ELISA 
of HeLa Subfractions 
The amount of HNo-G7 antibody absorbed by different 
concentrations of HeLa cell subcellular fractions 
expressed as a percentage of free HNo-G7 reacted with 
immobilised HeLa chromatin on an ELISA plate. 
O Chromatin 
D Cytoplasmic preparation 
Nucleolar fraction 








(Ng/50j1) of protein competed with HeLa chromatin 
described in Figure 4.3.9a 
2.5 5 10 20 
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the antibody being absorbed at a concentration of 20pg of protein per 
501i1 of HNo-G7 (1/20). Both cytoplasmic and nucleolar preparations were 
able to absorb 33% of the HNo-G7 immunoactivity at the same protein 
concentration. 
The antigen was further characterised by treatment with a variety 
of enzymes before reaction with the monoclonal antibody. Figure 4.3.10 
shows that antigenic activity was unimpaired by treatment with excess of 
either DNAase I or RNAase A, indicating that the antigen itself is 
unlikely to be DNA or RNA and that it has no apparent conformational 
dependence on DNA or RNA for activity. Trypsin treatment, on the other 
hand, totally abolished the immunoreactivity indicating that the antigen 
is likely to be a protein or an epitope dependent on intact protein for 
its reaction with antigen. 
The subcellular localisation of the antigen was further 
investigated by immunofluorescent staining of HeLa cells grown and fixed 
on coverslips. The cells were allowed to react with the monoclonal 
antibody followed by FITC conjugated rabbit anti-mouse IgG. The 
immunofluorescence is clearly concentrated in the nucleoli (Fig. 4.3.11) 
and some less intense staining is also evident in the cytoplasm and at 
the nuclear boundary (4.3.11). The cytoplasmic staining was less 
intense than the nucleolar one, and this is shown more clearly at high 
magnification (Fig. 4.3.11b & c). A control sample (in which tissue 
culture medium replaced the monoclonal antibody) showed very little 
staining (Fig. 4.3.12). 
In order to investigate whether the antigen was present in 
metaphase chromosomes, and in particular on those with nucleolar 
organiser regions, a metaphase chromosome spread was prepared as 
described in sections 3.7.7 and 3.7.8 and reacted with the monoclonal 
antibody in the same manner as the interphase cells. The chromosomes 
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Figure 4.3.10 ELISA of HNo-G7 with Enzymes-Treated HeLa Chromatin 
Enzyme immunoassay of monoclonal antibody (HNo-G7) 
reacted with different concentrations of HeLa chromatin 
and enzyme-treated chromatin. The enzyme concentrations 
were in excess as described in section 3.4.6. Antibody 
and antigen controls were subtracted. 
O HeLa chromatin untreated 
Q DNAase I-treated (5001ig/ml) chromatin 
1 RNAase A-treated (200rg/ml) chromatin 
0 Trypsin-treated HeLa (200jg/ml) chromatin 
No attempt was made to estimate the extent of digestion of DNA or 
RNA. However the nucleases were used in amounts which were in 
substantial excess (as judged by specific activity) to these required 







pg of chromatin 
2.5 5 10 20 
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Figure 4.3.11 FITC-staining of HeLa Cells Reacted with HNo-G7 and 653 
Culture Supernatants 
Indirect immunofluorescent staining of HeLa cells reacted 
with HNo-G7 antibody (1/10). 
a) Low magnification (X500) 
b& c) High magnification (X2000) 
d) Black and white photograph 
1. FITC stained cells (X375) 
2. Phase contrast of 1 (X375) 
3. FITC stained cells (X500) 
4. FITC stained cells (X2000) 
5. FITC-control of HeLa cells reacted with 
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Figure 4.3.12 FITC-control of HeLa Cells Reacted with RPMI-FCS 
Indirect immunofluorescent staining of HeLa cells treated 
with RPMI-FCS instead of the first antibody (HNo-G7) 
followed by anti-mouse IgG- FITC-conjugated second 
antibody (X500). 
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were also separately stained with Giemsa to ensure that the quality of 
the spread was adequate (Fig. 4.3.13). No fluorescence was detected in 
these preparations with the monoclonal antibody indicating that either 
the antigen is not present in detectable quantity or it is not accessible 
in metaphase chromosomes. 
In view of the fact that neither DNA nor RNA were required for 
antigenic activity, experiments designed to further characterise the 
protein component of the antigen by immunoblotting were then 
undertaken. Immunoblotting of a monoclonal antibody presents particular 
technical problems as it is likely that only a single epitope will be 
present on each molecule of the antigenic protein and the signal is 
therefore likely to be extremely weak in comparison to that from a 
polyclonal antiserum. It is therefore important to have as high a 
concentration of specific protein antigen as possible on the 
nitrocellulose paper. Dehistonised chromatin was consequently chosen 
for this procedure as more of the relevant material may be loaded on the 
gel in the absence of the histones. Two different preparations of 
dehistonised chromatins were employed. The first was extracted with 2M 
salt and the second with sulfuric acid by the method of Bhorjee and 
Pederson (1973) (section 3.1.4). The result is shown in Figure 4.3.14a 
using the immunoperoxidase (section 3.5.4.1) detecting procedure. the 
monoclonal antibody used was collected from culture supernatant after 
growing the cells to exhaustion. Figure 4.3.14b also illustrates the 
reaction of monoclonal HNo-G7 with 2M salt-dehistonised chromatin 
resolved on an SDS-gel electrophoresis and blotted onto a nitrocellulose 
paper. The reaction was monitored and detected by a second antibody 
(rabbit anti-mouse IgM, H+L) followed by labelled 
125 
I-protein A. In 
both Figures 4.3.14a and 4.3.14b, a reactive antigen of approximate 
molecular weight 44,500-45,000 was observed. This reactive antigen 
could be seen in both the acid-extracted and the 2M salt-extracted 
- 179 - 
Figure 4.3.13 Giemsa Staining of HeLa Metaphase Chromosomes 
HeLa chromosome spread stained with Giemsa staining as 
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Figure 4.3.14a Immunoblot of HNo-G7 Reacted with HeLa Dehistonised 
PAL. ----i: -- 
Protein immunoblot of the HNo-G7 antibody reacted with 
nonhistone chromosomal fraction prepared by sulfuric acid 
extraction (lane c) or 2M salt-extraction of the HeLa 
chromatin (lane d), resolved on a 10% Laemmli gel. 
Detection of antibody reaction was by the 
immunoperoxidase method (section 3.5.4.1). Lane (a) 
represents the amido black-stained acid extracted - 
nonhistone proteins and lane (b) is the molecular weight 
protein marker (from top: phosphorylase-b, 94,000; 
bovine serum albumin, 67,000; ovalbumin, 43,000; 









Figure 4.3.14b Autoradiograph of HNo-G7 Reacted with HeLa Dehistonised 
Chromatins 
Protein immunoblot of HNo-G7 antibody (concentrated X3 by 
PEG 6,000) reacted with 2M salt-extracted nonhistone 
chromosomal protein fraction (from HeLa cells), resolved 
on 8.5% Laemmli gel and blotted onto nitrocellulose 
paper. The reaction was detected by the protein A 
method as described in section 3.5.4.3. 
Lane (1) An autoradiogram of the antibody reaction detected by 
125I-protein A. (Eight hours exposure) 
Lane (2) Amido black stained 2M salt extracted chromatin blotted 
on nitrocellulose paper. 
Lane (3) Protein marker (from top: phosphorylase b, 94,000; 
bovine serum albumin, 67,000; ovalbumin, 43,000; 
carbonic anhydrase, 30,000; trypsin inhibitor, 20,100; 
d-lactalbumin, 14,400). 
Note: Staining of the blot was by 0.1% amido black in 2% acetic acid and 
destaining by 2% hot (900C) acetic acid. This modification is 
to prevent any shrinkage of the blot (Du Bois & Rosen, 1983). 
ls-.,:. i. M-.:.. i 
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Figure 4.3.14c Autoradiograph of Control-Immunoblot 
An autoradiograph of protein immunoblot of supernatant 
(concentrated X5) from an irrelevant IgM-Secreting 
hybridoma (anti-human thyroglobulin) reacted with the 
HeLa 2M salt-extracted nonhistone chromosomal protein 
fraction resolved on 8.5% Laemmli gel and blotted onto 
nitrocellulose paper. The reaction was detected by the 
protein A method. (Exposure was for 14 hours). 
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nonhistone chromosomal protein fractions. Normal mouse serum (from an 
unimmunised animal diluted 1/200) showed no reactivity with HeLa 
dehistonised chromatin nor did the supernatant from other IgM-secreting 
mouse hybridomas (irrelevant IgM) (Figure 4.3.14C). 
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The HNo-G7 monoclonal antibody was clearly shown to be of the IgM 
class both by ELISA and internal radio-labelling. IgM producing 
hybridomas may be expected to be less predominant in a fusion from a 
hyperimmune animal since they are generally produced early in the immune 
response. The labelled antibody used in the selection assay was 
directed against IgG heavy and light chains so it may be expected to 
detect all isotypes because of its reaction with the light immunoglobulin 
chain. IgM antibodies have in general lower intrinsic affinity for the 
antigen than IgG antibodies directed to the same epitope (Rodwell et al., 
1983). However, their multivalence can lead to an experimentally high 
affinity in selection procedures. Additionally, some antigens such as 
the ABO blood grouping antigens, appear to elicit an isotype specific IgM 
response (Taussig, 1979). With a single sample, it is not possible to 
say whether the fact that HNo-G7 is an IgM reflects an isotype preference 
of the antigen, a phenomenon related to the immunisation and selection 
procedure, or chance. 
The internal radio-labelling of the monoclonal antibody provides 
information relating not only to its class but also to its monoclonal 
nature, since the hybridoma cell line clearly does not synthesise any 
other isotype. The possibility that the antibody is not monoclonal but 
is the product of two different co-existing hybridomas both secreting IgM 
cannot be totally discounted but it is highly unlikely since the 
hybridoma cell line has been subcloned repeatedly at 0.5 cell/well and 
antibody secretion and titre have remained constant over a period over 18 
months. In mixed cultures this is almost never true. Attempts to 
obtain final proof of the true monoclonal nature of the antibody by 
isoelectric focussing were abandoned because of the extreme difficulty of 
introducing such a large molecule into the gel medium. 
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The preliminary characterisation of the binding of the antigen to 
the ELISA plate and the chequerboard assay are extremely important in the 
design of any screening system for a monoclonal antibody. It is 
important to be able to bind as much chromatin as possible to the plate 
in order to detect positive fusion clones as early as possible so that 
they may be cloned before overgrowth by non-secreting cells can occur. 
However, it is also vital that the antigen is bound stably to the plate 
and is not able td leach off during washing procedures (Lehtonen & 
Viljanen, 1980) since leached antigen could react with the monoclonal 
antibody with both being removed during a subsequent wash. 
Early ELISA assays utilised high pH buffers for antigen binding 
(Engvall & Perlman, 1971). While more antigen may bind under these 
conditions, incubation with antibody is carried out at lower pH values 
and it is again vital, for the reasons described above, that antigen 
bound at high pH does not desorb during subsequent incubations at lower 
pH values. In addition, the pH dependence of the antibody - antigen 
reaction itself can affect the screening procedure strongly since some 
monoclonal antibodies exhibit very sharp pH profiles (Fraser et al., 
1982). The experiments described in Figures 4.3.3 and 4.3.4 indicate 
that pH effects are unlikely to affect either antigen binding or reaction 
with antibody under the routine assay conditions employed. 
The actual amount of antigen bound to the plate can be readily 
determined with a pure protein antigen since it is possible to radiolabel 
such an antigen and determine the percentage of radioactivity bound at 
various protein concentrations. However, with chromatin as an antigen 
this is almost impossible since the multiple components may incorporate 
label differentially and also bind differentially. However, some 
indication may be obtained from the chequerboard assay since the 
absorbance at 492nm was comparable over the range of 2.5-20pg/well at 
fixed antibody concentration (Fig. 4.3.5). Accordingly, it is possible 
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to suggest that the antigen binding onto the ELISA plate is restricted 
above a concentration of 2.5pg/well. 
Very small amounts of antigen (155ng/well) could be detected by 
the monoclonal antibody as shown by the chequerboard. This suggests 
either that the affinity of the antibody is extremely high, or that the 
protein is present in substantial amounts in chromatin. Variation of 
the antibody concentration over the dilution range of 1 to 1/32 at fixed 
antigen concentration also has minimal effect, indicating that at a 
concentration of 1/32 there is still sufficient antibody in the 
supernatants to saturate all the antigen molecules bound to the plate. 
In principle, some indication of the antigen bound to the plate 
can be obtained from the competition ELISA assay where HeLa chromatin is 
effectively competed against itself. Thus again with a simple protein 
antigen and at limiting concentrations of antibody, the amount of protein 
competitor required to abolish all antibody reactivity may be regarded as 
a rough indication of the amount of protein actually bound to the 
plate. Even in this situation such a conclusion is suspect since the 
binding of proteins to ELISA plates causes some degree of denaturation 
(Berkowitz & Webert, 1981). With chromatin as antigen, any such 
conclusions become even less valid. Firstly, some components of 
chromatin may bind more readily to the plate than others and consequently 
the comparison of competing antigen in solution with plate bound test 
antigen is not possible. The antibody is an IgM with ten potential 
binding sites in solution and it is highly unlikely that all these could 
bind to antigen on the plate for obvious steric considerations. 
Additionally, the pieces of free competing chromatin may have multiple 
copies of antigen on them further confusing the results. The 
comparatively large amounts of antigen required for self competition with 
HeLa chromatin probably reflect the fact that the antibody is being used 
in excess as indicated by the chequerboard experiment and it is not 
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possible to use the data to give a meaningful estimate of the amount of 
antigen actually bound to the plate. 
Many of the above considerations also apply to the use of 
conventional or competition ELISA, to compare different preparations of 
chromatin or subcellular fractions. However, on a comparative base of 
protein (or DNA) concentration the data from Figures 4.3.6 and 4.3.7 
appear to indicate that the antigen is present in substantially greater 
amounts in HeLa chromatin than in the chromatin of other epithelial cell 
lines and that it is not detectable in a fibrosarcoma cell line. there 
are several possible interpretations of this result. The most likely is 
that the antigen is related to the metabolic activity of the nucleoli in 
some way and as this differs with different cell lines, so the amount of 
antigen also varies on a protein or DNA basis. Another possible 
interpretation is that the antigen is more accessible in HeLa chromatin 
than the other cell lines. There may also be an effect relating to the 
number of nucleoli (at least five pairs of chromosomes carry nucleolar 
organisers (Flavell & Martini, 1982)) which may be greater in HeLa cells 
which carry a large aneuploid chromosome complement (Adams et al., 
1981). The lack of any apparent antigen in a fibrosarcoma cell line may 
indicate that the antigen has some preference for epithelial cells but 
this cannot be definitely ascertained until a wider panel of human cell 
lines has been tested. 
With a monoclonal antibody the possibility that the antigen is an 
epitope which is present on different proteins in each case (for example 
a carbohydrate residue) can not be ruled out. 
The use of conventional and competition ELISA assays to determine 
the subcellular localisation of the antigen carries even greater hazards 
of interpretation since, while competing chromatins all have similar 
physical characteristics (this is especially true comparing Chang liver 
and HeLa chromatins which are slightly different from H. Ep-2 chromatin as 
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illustrated in Figure 4.3.15), the competing antigens in subcellular 
localisation have very dissimilar physical properties. In addition, the 
preparation of the various components may result in substantial cross 
contamination. Within these limits, it is however possible to conclude 
from Figures 4.3.8 and 4.3.9 that the antigen is present in chromatin, 
nucleolus and cytoplasm and not detectable in the 2M NaCl-extracted 
fraction which contains the bulk of the histones. The comparatively 
large amount present in the cytoplasm on the protein basis is 
surprising. As the immunofluorescent staining (Fig. 4.3.11) is 
predominantly nucleolar, the comparatively small amount in the nucleoli 
is also unexpected. However, the nucleolar preparation consists mainly 
of condensed histones which compete with other proteins, including the 
antigen, on the basis of total protein estimation and it should be noted 
from Figure 4.3.9 that at high concentrations the nucleolar preparation 
competed almost as well as cytoplasm in the competition assay. 
A general correlation with immunofluorescence may be made but it 
is quantitatively different. This difference may again be attributed to 
several factors. The physical nature of the antigen in the various 
preparations may affect its ability to bind to the plate or 
differentially affect the reaction of plate bound chromatin antigen with 
competitor in solution. It is also very possible that the antigen may 
move from one cell compartment to another during the preparative 
procedure as in the case described by Davis et al. (1978) who reported a 
nucleolar antigen which was preferentially localised in the nucleoli in 
immunocytochemistry but which appeared to be able to equilibrate between 
the nucleoplasm and the cytoplasm during isolation. Additionally, 
preparation of the nucleoli by the method of Bhorjee and Pederson (1973) 
which involves sonication may result in the loss of substantial amounts 
of antigen. It is also possible that the antigen may genuinely be 
present in substantial amounts in the cytoplasm as well as the nucleoli 
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Figure 4.3.15a Protein Blot of Human Chromatins 
An amido black stained blot comparing three chromatin 
preparations from epithelial human cell lines. The blot 
stained by 0.1% amino black as described in Fig. 4.3.14b. 
Lane (1) Molecular weight marker: from top: bovine 
serum albumin, 67,000; ovalbumin, 43,000; 
carbonic anhydrase, 30,000; soybean trypsin 
inhibitor 20,100. 
Lane (2) HeLa 
Lane (3) H. EP-2 
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Figure 4.3.15b Protein Blot of HeLa Subfractions 
An amido black stained blot comparing three subcellular 
HeLa fractions with 2M salt-extracted Chang liver 
chromatin. Staining and destaining was as described in 
Fig. 4.3.14b. 
Lane (1) HeLa cytoplasmic fraction 
Lane (2) HeLa chromatin 
Lane (3) HeLa 2M salt-extracted chromatin 
Lane (4) Molecular weight marker: from top: bovine 
serum albumin, 67,000; ovalbumin, 43,000; 
carbonic anhydrase, 30,000; soybean trypsin 
inhibitor, 20,100 
Lane (5) Chang liver 2M salt-extracted chromatin 
Figure 4.3.15c Coomassie blue-stained Laemmli gel of HeLa chromatin 
fractions 
Coomassie blue-stained SDS-gel electrophoresis 
(10%) comparing 2M 
salt-5M urea extracted-chromatin 
(lane 1), chromatin preparation (lane 2), 2M 
salt extracted-chromatin 
(lane 3) and protein markers (lane 4) [from top: 
phosphorylase b 94,000, bovine serum albumin 
67,000, ovalbumin 43,000, 
carbonic anhydrase 30,000, soybean trypsin 
inhibitor 20,100 and 
a-lactalbumin 14,400) 
Note: In lane 2, although the core histones are well resolved, the 
H1 histone 
showed less intensitrthanthe core histones. 
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either because it is synthesised there or because it performs some 
cytoplasmic function. Finally, with a monoclonal antibody, the 
possibility of reaction with the'same epitope on two different proteins 
must always be considered as discussed above. 
The data shown in Figure 4.3.10 indicate that the antigen is 
neither DNA nor RNA. Since antibodies to nucleic acid antigens are not 
readily raised in BALB/c mice this is not surprising. However, a low 
level of anti-DNA antibodies is present in the sera of many animals and 
indeed humans (Winger et al., 1983) and such a possibility must obviously 
be investigated. The relatively high concentration of DNA (in 
comparison to any individual protein, see Table 5 for DNA : total protein 
ratio) in the chromatin used for screening also makes it possible that a 
low affinity antibody to DNA could have been selected. An antibody to 
RNA was probably less likely but such monoclonal antibodies have been 
produced (Eilat et al., 1980,1982). Antibodies to DNA are readily 
generated from other strains of mice (Lee et al., 1981; Jacobs & Tron, 
1982; Lerner et al., 1981; Kioke et al., 1982) but have not been 
reported with BALB/C strain. 
The fact that DNA and RNA are not required for antigenic activity 
also indicates that the antigen does not require nucleic acids to 
maintain its antigenic configuration and in this respect it differs from 
the HeLa antiserum described by Dunn et al. (1980) which requires human 
DNA for activity. 
Figure 4.3.10 also shows that proteolysis destroys antigenic 
activity. While the most likely interpretation of this information is 
that the antigen is a protein, it is also possible that the epitope 
itself is a carbohydrate residue bound to a protein and removed with the 
protein fragments on proteolysis. 
The immunofluorescence pictures (Fig. 4.3.11) indicate strong 
-. J 
h 
nucleolar localisation but also some cytoplasmic presence. While the 
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most obvious explanation of these data is that the antigen has a presence 
in both parts of the cell as discussed above, it is also possible that it 
has changed its location during preparation of the cells for 
immunohistochemistry. Redistribution of cytoplasmic components to the 
nucleus has been reported in one case (Briggs et al., 1981) but the 
nuclear staining showed no specific nucleolar localisation and it seems 
unlikely that the antigen is a purely cytoplasmic protein. 
Since DNA and RNA are not necessary components for the 
immunoreactivity of HNo-G7 antibody, it is anticipated that the detection 
of the corresponding antigen on the immunoblot is more feasible. Two 
nonhistone chromosomal protein preparations were analysed on SDS-PAGE, 
blotted onto a nitrocellulose paper then allowed to react with the 
antibody using the immunoperoxidase method (Fig. 4.3.14a lanes c& d). 
An antigen of approximate molecular weight of 44,500-45,000 was 
detected. However, the intensity of the reactive band was not strong. 
This could be explained either by the possibility that a limited amount 
of antibody was available in the tissue culture supernatant or by the 
likelihood that the amount of antigen on the blot was not sufficient. 
There are many reports in the literature of monoclonal antibodies 
(particularly to chromatin) which do not immunoblot or which blot poorely 
(e. g. Turner, 1983). The general interpretation is that such antigens 
have epitopes which are irreversibly denatured by the preliminary 
electrophoresis. However, others like Yurchenko et al. (1982) have 
blotted a variety of protein epitopes successfully. Work in our own 
laboratory has clearly shown that many sera blot non-specifically with 
proteins such as molecular weight marker proteins (Campbell et al., 
personal communication), and the general area of immunoblotting is very 
much less well defined than indicated in elementary laboratory 
textbooks. Accordingly, a sandwich blot utilising Protein A was used to 
identify the antigen more clearly. This blot is based on the known 
. ý. Jýý 
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ability of Protein A to bind strongly to rabbit IgG but not to many mouse 
monoclonal antibodies and certainly not to mouse IgM monoclonal 
antibodies. The limited reaction of the mouse specific IgM is amplified 
with unlabelled rabbit anti-mouse IgM (H+L) antibodies and the final 
complex is decorated with high specific activity 
125 
1 labelled Protein 
A. Background staining is reduced by the use of 0.5% Tween 20, which 
cannot be used successfully with enzyme immunoblots because of the 
substantial reduction in enzyme activity induced by the bound 
detergent. This blotting system, which is a modification of the 
process of Batteiger et al. (1982) has a high signal to noise ratio in 
comparison to other available techniques. In practice, this technique 
also indicated that the antigen was a protein in the molecular weight 
range 45,000 (Fig. 4.3.14b). 
The antigenic determinant recognised by HNo-G7 is therefore a 
protein (possibly with carbohydrate epitopes) which has a molecular 
weight in the region of 45,000, localised by immunohistochemical 
techniques primarily in the nucleoli but also present in the cytoplasm, 
and not dependent on nucleic acids for its immunoreactivity. It is 
present in smaller amounts or with lower availability in other human 
epithelial cells but is not apparently available/present in fibrosarcoma 
cells. A comparison with other published nucleolar antigens is 
obviously necessary and this is given in Table 6. 
The antigens described in Table 6 fall into four separate 
categories as indicated. The first group of reported "nucleolar 
specific" antisera are polyclonal (Busch et al., 1979). In view of the 
potential heterogeneity of such antigens (Section 4.1 and Section 4.2) it 
is difficult to make a detailed comparison of HNo-G7 with these antisera 
as they may vary with rabbit, titre and bleed. However, the claims of 
Busch et al. (1979) that their antiserum specifically detects the 
nucleoli of all human malignant tumour cells tested indicate that such 
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Table 6 Nucleolar Antigens 
Molecular Specificity of 
Reference weight Antigen Source 
1) Busch et al. (1979) 54,000 (Human Tumour (Rabbit 
Chan et al. ( 1980) ( Nucleoli (Polyclonal 
2) Davis et al. (1978) Various (Tissue specific (Rabbit 
Marachi et al. (1979) (Related to (Polyclonal 
Satoh & Busch (1983) (Metabolic (& 
Ler-º\. w oJ: L. ( 19gß) (Activity (Autoimmune 
mouse 
monoclonal 
3) Reddy et al. (1983) Various (Limited Tissue (Human 
Bernstein et al. (1982) (or Species (Polyclonal 
(Specificity 
4) This work 45,000 (Human Epithelial (Mouse 
(Tissue Culture (Monoclonal 
(Cells with Apparent 
(Preference for HeLa 
.. ý. J 
h' 
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antibodies may have possible diagnostic applications. Monoclonal 
antibody HNo-G7 clearly recognises a different antigenic determinant from 
such sera since molecular weight determination indicates that their major 
antigen is substantially larger than that of HNo-G7 (Chan et al., 
1980). In addition, the antigen is extracted by low salt (Busch et al., 
1979) and this makes it less likely to co-purify with the high salt 
associated HNo-G7 antigen. 
The second group of nucleolar antigens are not necessarily tumour 
specific but are reported to exhibit some degree of tissue specificity or 
correlation with growth and metabolic activity (Davis et al., 1978; 
Marashi et al., 1979; Satoh & Busch, 1983). These have all been 
detected with polyclonal sera and are subject to the reservations 
outlined above. The limited characterisation of the antigens in this 
group makes them difficult to compare with the HNo-G7 antigen but there 
appears to be little similarity. 
The third group of antigens which may be considered as "nucleolar" 
come from polyclonal human sources, usually from patients with systemic 
rheumatic diseases involving autoantigens such as progressive systemic 
sclerosis (Bernstein et al., 1982) and scleroderma (Reddy et al., 
1983). Other examples from this group include "cyclin" which may be 
identical to "proliferating cell nuclear antigen" (Mathews et al., 1984), 
and others reviewed by Tan (1982). Where molecular weights have been 
determined, none correlate with the HNo-G7 antigen. Additional 
complications arise not only from the polyclonality of the serum but also 
from the autoimmune nature of the response. Such antisera may detect 
antigens not amenable to conventional immunisation techniques as the host 
has a specific defect which permits the synthesis of antibodies which are 
normally suppressed. HNo-G7 was raised in a BALB/c mouse with no 
autoimmunity in its genetic background. 
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The final group in Table 6 are genuine monoclonal antibodies which 
show nucleolar staining. HNo-G7 falls into this category. No other 
monoclonal antibodies which react with nucleoli have been reported to 
date. However, a preliminary report of three monoclonal antibodies to 
purified La antigen is also of interest (Smith et al., 1984). Anti-La 
antibodies precipitate distinct sets of snRNPs. The group of mouse RNAs 
associated with these RNPs are of 90-100 nucleotides long (Reviewed by 
Busch et al., 1982). The structure of human La RNAs is not yet known. 
Other monoclonal antibodies to chromosomal proteins have been 
reported. In particular, two groups have used HeLa cells for 
immunisation. Bhorjee et al. (1983) reported several monoclonals raised 
in BALB/c mice with a very similar immunising antigen to the one used to 
make HNo-G7 (2M salt-5M urea extracted chromatin). However, none of 
these antibodies showed nucleolar staining. Davis et al. (1983) 
produced monoclonal antibodies which react strongly with mitotic cells 
and weakly with interphase cells. Monoclonal antibodies directed to 
chromatin or chromosomal proteins have also been described utilising 
Drosophila (Saumweber et al., 1980; Howard et al., 1981), avian red 
blood cells (Vanderbilt & Anderson, 1982; Kane et al., 1982) and rat and 
human tissues and cell lines (Turner, 1981) as primary antigen. Many of 
these antibodies react with antigens that have interesting cell cycle 
dependence (Howard et al., 1981; Dippold et al., 1981; Risau et al., 
1982; Davis et al., 1983) but none show the dramatic nucleolar staining 
of HNo-G7 which would appear therefore to be a monoclonal antibody 
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5. General Discussion 
The class of nonhistone chromosomal proteins remain bound to DNA 
after extraction with either 2M NaCl alone or with 5M urea has proved 
exceedingly intractable to biochemical analysis. This is due partly to 
their complexity and partly to their relative insolubility in the absence 
of DNA. Their functional role remains therefore obscure but is clearly 
of general interest. Immunological approaches have considerable 
potential both in the characterisation of these proteins and the 
assessment of their distribution within the cell and among different 
types of cell. 
R3.1 antiserum was raised in a rabbit immunised with HeLa 
dehistonised chromatin extracted with both salt and urea. The major 
antigens in this serum are in some way structurally dependent on the 
presence of both protein and DNA (section 4.1). This requirement may 
reflect simple or complex organisation. For example, protein-protein 
interaction may be a pre-requisite for DNA binding. Two recent reports 
of this type of complex reaction support the possibility of this 
concept. Staufenbiel and Deppert (1984) have shown that a group of 
chromosonal proteins from HeLa and 3T3 cells interact both among 
themselves and also with DNA and/or other nuclear structural 
components. Werner et al. (1984) have also suggested that a form of 
protein-protein-DNA complex is required for the salt stable anchorage of 
the residual DNA. In addition, they have reported covalent linkage of 
some nuclear proteins to DNA. These proteins are highly insoluble when 
the covalent linkage is broken. It is unlikely that the antigen 
recognised by R3.1 or reported earlier in HeLa cells (Dunn et al., 1980) 
is covalently linked since most of the activity can be recovered by 
reconstitution which would not be expected to result in covalent 
linkage. However, such a possibility cannot be entirely discounted. 
ý1 ýJ 
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R. 3.1 antiserum could obviously be directed against nuclear 
lamina proteins, nuclear matrix proteins or both. Some of the abundant 
nuclear matrix and the major lamina proteins lie within the same range of 
molecular weight but can be differentiated by their structural and 
functional roles (Agutter & Birchall, 1979; Franke et al., 1981). 
Staufenbiel and Deppert (1984) have shown that the nuclear lamina is not 
solubilised during mild DNase digestion or sequential salt extraction of 
mammalian nuclei in situ. In addition, Lebkowski and Laemmli (1982) 
have demonstrated that lamina proteins exhibit considerable affinity to 
bind DNA. On these bases lamina proteins are clear potential candidates 
for R3.1 major antigens. 
The analysis of nuclear matrix proteins by Werner et al. (1984) 
showed two forms. The minor fraction was that with covalent linkage to 
DNA referred to above. The major fraction was serologically related to 
the minor one but not covalently attached to DNA or dependent on DNA for 
its immunological activity. This pattern does not reflect the behaviour 
of the major antigens to R3.1. 
It is interesting to note that Werner et al. (1984) found 
nuclear matrix proteins remaining in association with purified eukaryotic 
DNA. As R3.1 antiserum did not react with purified HeLa DNA, either the 
preparation of DNA was protein-free or the R3.1 antigens do not represent 
matrix proteins. 
There is, therefore, little evidence to suggest that the major 
R3.1 antigens are matrix proteins. It is, on the other hand, possible 
that they represent at least some lamina proteins. 
The use of only 2M NaCl and no urea to extract HeLa chromatin 
results in a different spectrum of major antigens. The nuclear 
preparation, however highly purified, is generally accompanied by 
,. JO. 
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co-sedimenting collapsed intermediate filaments of cytoplasmic origin 
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(Staufenbiel & Deppert, 1982). This class of protein is resistant to 
extraction with salt and non-ionic detergents and is likely to 
contaminate the 2M NaCl-extracted chromatin. The intermediate filaments 
are highly antigenic (reviewed by Lazarides, 1982). Therefore they may 
dominate the antiserum produced while forming only a small component of 
the immunising antigen. As intermediate filament proteins can show 
considerable cell specificity (Osborn & Weber, 1982), it is very possible 
that much of the early work which appeared to detect cell specific 
nuclear proteins was reflecting this type of antigen. The importance of 
the proof on nuclear localisation of the antigen and establishment of 
other criteria such as DNA binding is therefore considerable (Briggs et 
al., 1979; Bowen et al., 1980; Lebkowski & Laemmli, 1982). Since R2.1 
antiserum shows a strong filamentous cytoplasmic reaction, it is very 
likely that this is a result of the presence of antibodies against 
keratins in the antiserum. This is emphasised by the strong reaction of 
R2.1 with keratin preparation on the immunoblot at the range of molecular 
weight covering the intermediate filaments (54,000-61,000 & 
42,000-52,000). 
The relationship of the major antigens in R2.1 to nuclear lamina 
or matrix proteins is not clear. The immunoblotting of R2.1 antiserum 
shows no indication of the major lamina proteins of molecular weight 
68,000-70,000 although the nuclear staining shows a similar pattern to 
that of an anti-lamina monoclonal antibody recently reported by Krohne et 
al. (1984). The nuclear matrix is relatively stable under the 
conditions of antigen extraction, however, and could have been present in 
the immunising antigen (Capco et al., 1982). The matrix network in HeLa 
cells appear to remain connnected to the cytoskeleton after extraction 
with high salt buffer and can be shown by electron microscopy to be more 
dense than the cytoskeleton (Capco et al., 1982). In addition, lamina 
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proteins have also been reported to be stable under similar conditions 
(Lebkowski & Laemmli, 1982). The relatively high density of 
FITC-staining surrounding the nuclei may therefore possibly represent 
antigens present on the nuclear envelope or matrix. 
Capco et al. (1982) also showed that extraction of nuclei at 
high ionic strength buffer yielded a filamentous nuclear network well 
organised in a three-dimensional anastomosing structure where the nucleoli 
are enmeshed. The intranucleolar filaments are situated deep within the 
nucleus. In situ fractionation has shown the persistance of preserved 
nucleolar structures during high salt extraction (Staufenbiel & Deppert, 
1984). Consequently, the presence of nucleolar components in chromatin 
which has been extracted with 2M NaCl 5M urea is not surprising and the 
HNo-G7 antibody presumably detects such a component. It is interesting 
to note that the R3.1 antiserum shows no comparable antigen. The 
difference could be due to the variation in immunological response 
between rabbit and mouse but is more likely to reflect the ability of 
monoclonal antibody technology to select antibodies directed to a 
specific protein which may be a minor serum antigen. 
The main structural components of the nucleolus are though to be 
condensed ribosomal DNA, histones, RNA species and ribosomal protein 
precursors. The HNo-G7 antigen is a protein which has no obvious 
association with RNA or DNA (section 4.3). The data suggest that it is 
not a histone. It remains possible that it is a ribosomal protein or a 
precursor of such a protein. Alternatively, it may be a protein which 
plays a role in nucleolar structure or function but bears no serological 
relationship to ribosomal proteins. 
The molecular weight of the IiNo-G7 antigen is close to that of 
actin. In this context it is interesting to note the prevalence of 
ýt .Jýý 
actin in preparations of chromatin and nuclear matrix proteins (Capco et 
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al., 1982; Bravo et al., 1982; LeStourgeon et al., 1975). It seems 
unlikely, however, that HNo-G7 is reacting with actin since the 
immunofluorescence is not characteristic of anti-actin antibodies 
described by Weber et al. (1976). Another major protein which has 
recently been shown to co-focus with actin (using two-dimensional gel 
electrophoresis) in HeLa cytoskeletal, chromatin and matrix preparations 
(Capco et al., 1982) is of interest. The protein is resistant to the 
extraction conditions used in these preparations and its molecular weight 
is similar to actin. However, it is not clear, from this report (Capco 
et al., 1982), whether this protein is of nucleolar localisation or not. 
The work described in this thesis has emphasised the complexity 
not only of nuclear proteins but also of the contaminants which can 
co-purify with them. Immunological analysis is of particular value in 
such a situation, since nuclear localisation or the lack of it can be 
clearly established by immunocytochemical techniques. Such antigens can 
then be further investigated and purified by immunological means. The 
comparative simplicity of the use of a monoclonal antibody as opposed to 
conventional sera to identify nuclear antigens is also evident. 
A striking feature of current advances in recombinant DNA 
technology is that even when the entire sequence of a eukaryote gene has 
been established, in the majority of cases little can be deduced about 
the control of its differential expression in the cell. It is to be 
hoped that immunological analysis of the chromosome may help in the 
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